<?xml version="1.0"?>
<!DOCTYPE rdf:RDF [
<!ENTITY DTO "http://dto.org/DTO/" >
<!ENTITY foaf "http://xmlns.com/foaf/0.1/" >
<!ENTITY life "http://www.lifekb.org/life#" >
<!ENTITY owl "http://www.w3.org/2002/07/owl#" >
<!ENTITY obo "http://purl.obolibrary.org/obo/" >
<!ENTITY xsd "http://www.w3.org/2001/XMLSchema#" >
<!ENTITY bto "http://purl.obolibrary.org/obo/bto#" >
<!ENTITY rdfs "http://www.w3.org/2000/01/rdf-schema#" >
<!ENTITY dto "http://www.drugtargetontology.org/dto/" >
<!ENTITY rdf "http://www.w3.org/1999/02/22-rdf-syntax-ns#" >
<!ENTITY core "http://purl.obolibrary.org/obo/uberon/core#" >
<!ENTITY dc "http://purl.org/dc/elements/1.1/" >
<!ENTITY oboInOwl "http://www.geneontology.org/formats/oboInOwl#">]>
<rdf:RDF xmlns="http://www.drugtargetontology.org/dto/dto_vocabulary_ic_gene.owl#"
	xml:base="http://www.drugtargetontology.org/dto/dto_vocabulary_ic_gene.owl"
	xmlns:owl="http://www.w3.org/2002/07/owl#"
	xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#"
	xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
	xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
	xmlns:life="http://www.lifekb.org/life#"
	xmlns:core="&obo;uberon/core#"
	xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
	xmlns:bto="&obo;bto#"
	xmlns:obo="http://purl.obolibrary.org/obo/"
	xmlns:dto="http://www.drugtargetontology.org/dto/"
	xmlns:DTO="http://dto.org/DTO/"
	xmlns:foaf="http://xmlns.com/foaf/0.1/"
	xmlns:dc="http://purl.org/dc/elements/1.1/">
	<owl:Ontology rdf:about="http://www.drugtargetontology.org/dto/dto_vocabulary_ic_gene.owl">
		<owl:versionIRI rdf:resource="http://www.drugtargetontology.org/dto/dto_vocabulary_ic_gene.owl"/>
		<rdfs:label>Drug Target Ontology</rdfs:label>
		<rdfs:label>DTO</rdfs:label>
		<owl:versionInfo>1.0</owl:versionInfo>
		<dc:date>2 Nov 2017</dc:date>
		<dc:contributor>Yu Lin, Saurabh Mehta, Hande Küçük- McGinty, John Paul Turner, Dusica Vidovic, Michele Forlin, Amar Koleti, Dac-Trung Nguyen, Lars Juhl Jensen, Rajarshi Guha, Stephen L. Mathias, Oleg Ursu, Vasileios Stathias, Jianbin Duan, Nooshin Nabizadeh, Caty Chung, Christopher Mader, Ubbo Visser, Jeremy J. Yang, Cristian G. Bologa, Tudor Oprea*, Stephan C. Schürer*</dc:contributor>
		<rdfs:comment xml:lang="en">contact: Stephan Schurer:  stephan dot schurer at gmail dot com</rdfs:comment>
		<dc:description>
		Drug target ontology files Drug Target Ontology (DTO) is being developed at the University of Miami in the research group of Stephan Schürer. 
		DTO is supported by grant U54CA189205 (Illuminating the Druggable Genome Knowledge Management Center, Tudor Oprea, PI) awarded by the NCI through
		the NIH Common Fund. It is a component of the Illuminating the Druggable Genome (IDG) project (https://commonfund.nih.gov/idg). The DTO project 
		develops a novel semantic framework to formalize knowledge about drug targets with a focus on the current IDG protein families. The DTO is developed
		as a reference for drug targets with the longer-term goal to create a community standard that will facilitate the integration of diverse drug discovery
		information from numerous heterogeneous resources. The first version of the DTO consists of asserted class hierarchies of the four IDG protein families,
		GPCRs, kinases, ion channels, and nuclear hormone receptors. Protein classes are linked to tissue and disease via different levels of confidence. DTO 
		also contains drug target development classifications, a large collection of cell lines from the LINCS project and relevant cell-disease and cell-tissue
		relations. DTO is modeled in OWL2-DL to enable further classification by inference reasoning and SPARQL queries. DTO is implemented following a 
		modularization approach. DTO will serve as the organizational framework for drug targets in the IDG PHAROS User Interface Portal (https://pharos.nih.gov).
		</dc:description>
		<dc:license rdf:resource="https://creativecommons.org/licenses/by-sa/4.0/"/>
	</owl:Ontology>


    <!--
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Annotation properties
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

	<!-- http://www.drugtargetontology.org/dto/entrez_xref -->

	<owl:AnnotationProperty rdf:about="http://www.drugtargetontology.org/dto/entrez_xref"/>
	<!-- http://www.drugtargetontology.org/dto/geneSynonym -->

	<owl:AnnotationProperty rdf:about="http://www.drugtargetontology.org/dto/geneSynonym"/>
	<!-- http://www.drugtargetontology.org/dto/geneSymbol -->

	<owl:AnnotationProperty rdf:about="http://www.drugtargetontology.org/dto/geneSymbol"/>



    <!--
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Classes
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

	<!-- http://www.drugtargetontology.org/dto/DTO_01200001 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200001">
		<rdfs:label rdf:datatype="&xsd;string">HTR3A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01409932"/>
		<dto:entrez_xref>3359</dto:entrez_xref>
		<dto:geneSymbol>HTR3A</dto:geneSymbol>
		<dto:geneSynonym>HTR3</dto:geneSynonym>
		<dto:geneSynonym>5HT3R</dto:geneSynonym>
		<obo:IAO_0000115>The product of this gene belongs to the ligand-gated ion channel receptor superfamily. This gene encodes subunit A of the type 3 receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor causes fast, depolarizing responses in neurons after activation. It appears that the heteromeric combination of A and B subunits is necessary to provide the full functional features of this receptor, since either subunit alone results in receptors with very low conductance and response amplitude. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200002 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200002">
		<rdfs:label rdf:datatype="&xsd;string">HTR3B gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01409932"/>
		<dto:entrez_xref>9177</dto:entrez_xref>
		<dto:geneSymbol>HTR3B</dto:geneSymbol>
		<obo:IAO_0000115>The product of this gene belongs to the ligand-gated ion channel receptor superfamily. This gene encodes subunit B of the type 3 receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor causes fast, depolarizing responses in neurons after activation. It is not functional as a homomeric complex, but a pentaheteromeric complex with subunit A (HTR3A) displays the full functional features of this receptor. [provided by RefSeq, Aug 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200003 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200003">
		<rdfs:label rdf:datatype="&xsd;string">HTR3C gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01409932"/>
		<dto:entrez_xref>170572</dto:entrez_xref>
		<dto:geneSymbol>HTR3C</dto:geneSymbol>
		<obo:IAO_0000115>The product of this gene belongs to the ligand-gated ion channel receptor superfamily. This gene encodes subunit C of the type 3 receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor causes fast, depolarizing responses in neurons after activation. Genes encoding subunits C, D and E form a cluster on chromosome 3. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200004 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200004">
		<rdfs:label rdf:datatype="&xsd;string">HTR3D gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01409932"/>
		<dto:entrez_xref>200909</dto:entrez_xref>
		<dto:geneSymbol>HTR3D</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded this gene belongs to the ligand-gated ion channel receptor superfamily. This gene encodes subunit D of the type 3 receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a mitogen and a hormone. This hormone has been linked to neuropsychiatric disorders, including anxiety, depression, and migraine. Serotonin receptors causes fast and depolarizing responses in neurons following activation. The genes encoding subunits C, D and E of this type 3 receptor form a cluster on chromosome 3. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200005 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200005">
		<rdfs:label rdf:datatype="&xsd;string">HTR3E gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01409932"/>
		<dto:entrez_xref>285242</dto:entrez_xref>
		<dto:geneSymbol>HTR3E</dto:geneSymbol>
		<obo:IAO_0000115>This locus encodes a 5-hydroxytryptamine (serotonin) receptor subunit. The encoded protein, subunit E, may play a role in neurotransmission in myenteric neurons. Genes encoding subunits C, D and E form a cluster on chromosome 3. Alternatively spliced transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Feb 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200006 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200006">
		<rdfs:label rdf:datatype="&xsd;string">CHRNA10 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400490"/>
		<dto:entrez_xref>57053</dto:entrez_xref>
		<dto:geneSymbol>CHRNA10</dto:geneSymbol>
		<dto:geneSynonym>NACHRA10</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200007 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200007">
		<rdfs:label rdf:datatype="&xsd;string">CHRNA2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400491"/>
		<dto:entrez_xref>1135</dto:entrez_xref>
		<dto:geneSymbol>CHRNA2</dto:geneSymbol>
		<obo:IAO_0000115>Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels formed by a pentameric arrangement of alpha and beta subunits to create distinct muscle and neuronal receptors. Neuronal receptors are found throughout the peripheral and central nervous system where they are involved in fast synaptic transmission. This gene encodes an alpha subunit that is widely expressed in the brain. The proposed structure for nAChR subunits is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. Mutations in this gene cause autosomal dominant nocturnal frontal lobe epilepsy type 4. Single nucleotide polymorphisms (SNPs) in this gene have been associated with nicotine dependence. [provided by RefSeq, Nov 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200008 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200008">
		<rdfs:label rdf:datatype="&xsd;string">CHRNA3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400492"/>
		<dto:entrez_xref>1136</dto:entrez_xref>
		<dto:geneSymbol>CHRNA3</dto:geneSymbol>
		<dto:geneSynonym>NACHRA3</dto:geneSynonym>
		<obo:IAO_0000115>This locus encodes a member of the nicotinic acetylcholine receptor family of proteins. Members of this family of proteins form pentameric complexes comprised of both alpha and beta subunits. This locus encodes an alpha-type subunit, as it contains characteristic adjacent cysteine residues. The encoded protein is a ligand-gated ion channel that likely plays a role in neurotransmission. Polymorphisms in this gene have been associated with an increased risk of smoking initiation and an increased susceptibility to lung cancer. Alternatively spliced transcript variants have been described. [provided by RefSeq, Nov 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200009 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200009">
		<rdfs:label rdf:datatype="&xsd;string">CHRNA4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400493"/>
		<dto:entrez_xref>1137</dto:entrez_xref>
		<dto:geneSymbol>CHRNA4</dto:geneSymbol>
		<dto:geneSynonym>NACRA4</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a nicotinic acetylcholine receptor, which belongs to a superfamily of ligand-gated ion channels that play a role in fast signal transmission at synapses. These pentameric receptors can bind acetylcholine, which causes an extensive change in conformation that leads to the opening of an ion-conducting channel across the plasma membrane. This protein is an integral membrane receptor subunit that can interact with either nAChR beta-2 or nAChR beta-4 to form a functional receptor. Mutations in this gene cause nocturnal frontal lobe epilepsy type 1. Polymorphisms in this gene that provide protection against nicotine addiction have been described. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200010 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200010">
		<rdfs:label rdf:datatype="&xsd;string">CHRNA5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400494"/>
		<dto:entrez_xref>1138</dto:entrez_xref>
		<dto:geneSymbol>CHRNA5</dto:geneSymbol>
		<dto:geneSynonym>NACHRA5</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene is a nicotinic acetylcholine receptor subunit and a member of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. These receptors are thought to be heteropentamers composed of separate but similar subunits. Defects in this gene have been linked to susceptibility to lung cancer type 2 (LNCR2).[provided by RefSeq, Jun 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200011 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200011">
		<rdfs:label rdf:datatype="&xsd;string">CHRNA6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400495"/>
		<dto:entrez_xref>8973</dto:entrez_xref>
		<dto:geneSymbol>CHRNA6</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes an alpha subunit of neuronal nicotinic acetylcholine receptors. These receptors consist of five subunits and function as ion channels involved in neurotransmission. The encoded protein is a subunit of neuronal nicotinic acetylcholine receptors that mediate dopaminergic neurotransmission and are activated by acetylcholine and exogenous nicotine. Alternatively spliced transcript variants have been observed for this gene. Single nucleotide polymorphisms in this gene have been associated with both nicotine and alcohol dependence. [provided by RefSeq, Dec 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200012 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200012">
		<rdfs:label rdf:datatype="&xsd;string">CHRNA7 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400496"/>
		<dto:entrez_xref>1139</dto:entrez_xref>
		<dto:entrez_xref>89832</dto:entrez_xref>
		<dto:geneSymbol>CHRNA7</dto:geneSymbol>
		<dto:geneSynonym>NACHRA7</dto:geneSynonym>
		<obo:IAO_0000115>The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The family member CHRNA7, which is located on chromosome 15 in a region associated with several neuropsychiatric disorders, is partially duplicated and forms a hybrid with a novel gene from the family with sequence similarity 7 (FAM7A). Alternative splicing has been observed, and two variants exist, for this hybrid gene. The N-terminally truncated products predicted by the largest open reading frames for each variant would lack the majority of the neurotransmitter-gated ion-channel ligand binding domain but retain the transmembrane region that forms the ion channel. Although current evidence supports transcription of this hybrid gene, translation of the nicotinic acetylcholine receptor-like protein-encoding open reading frames has not been confirmed. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200013 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200013">
		<rdfs:label rdf:datatype="&xsd;string">CHRNA9 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400497"/>
		<dto:entrez_xref>55584</dto:entrez_xref>
		<dto:geneSymbol>CHRNA9</dto:geneSymbol>
		<dto:geneSynonym>NACHRA9</dto:geneSynonym>
		<obo:IAO_0000115>This gene is a member of the ligand-gated ionic channel family and nicotinic acetylcholine receptor gene superfamily. It encodes a plasma membrane protein that forms homo- or hetero-oligomeric divalent cation channels. This protein is involved in cochlea hair cell development and is also expressed in the outer hair cells (OHCs) of the adult cochlea. [provided by RefSeq, Feb 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200014 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200014">
		<rdfs:label rdf:datatype="&xsd;string">CHRNA1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400498"/>
		<dto:entrez_xref>1134</dto:entrez_xref>
		<dto:geneSymbol>CHRNA1</dto:geneSymbol>
		<dto:geneSynonym>CHNRA</dto:geneSynonym>
		<dto:geneSynonym>ACHRA</dto:geneSynonym>
		<obo:IAO_0000115>The muscle acetylcholine receptor consiststs of 5 subunits of 4 different types: 2 alpha subunits and 1 each of the beta, gamma, and delta subunits. This gene encodes an alpha subunit that plays a role in acetlycholine binding/channel gating. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Nov 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200015 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200015">
		<rdfs:label rdf:datatype="&xsd;string">CHRNB2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400499"/>
		<dto:entrez_xref>1141</dto:entrez_xref>
		<dto:geneSymbol>CHRNB2</dto:geneSymbol>
		<obo:IAO_0000115>Neuronal acetylcholine receptors are homo- or heteropentameric complexes composed of homologous alpha and beta subunits. They belong to a superfamily of ligand-gated ion channels which allow the flow of sodium and potassium across the plasma membrane in response to ligands such as acetylcholine and nicotine. This gene encodes one of several beta subunits. Mutations in this gene are associated with autosomal dominant nocturnal frontal lobe epilepsy. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200016 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200016">
		<rdfs:label rdf:datatype="&xsd;string">CHRNB3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400500"/>
		<dto:entrez_xref>1142</dto:entrez_xref>
		<dto:geneSymbol>CHRNB3</dto:geneSymbol>
		<obo:IAO_0000115>The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are (hetero)pentamers composed of homologous subunits. The subunits that make up the muscle and neuronal forms of nAChRs are encoded by separate genes and have different primary structure. There are several subtypes of neuronal nAChRs that vary based on which homologous subunits are arranged around the central channel. They are classified as alpha-subunits if, like muscle alpha-1 (MIM 100690), they have a pair of adjacent cysteines as part of the presumed acetylcholine binding site. Subunits lacking these cysteine residues are classified as beta-subunits (Groot Kormelink and Luyten, 1997 [PubMed 9009220]). Elliott et al. (1996) [PubMed 8906617] stated that the proposed structure for each subunit is a conserved N-terminal extracellular domain followed by 3 conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region.[supplied by OMIM, Apr 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200017 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200017">
		<rdfs:label rdf:datatype="&xsd;string">CHRNB4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400501"/>
		<dto:entrez_xref>1143</dto:entrez_xref>
		<dto:geneSymbol>CHRNB4</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200018 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200018">
		<rdfs:label rdf:datatype="&xsd;string">CHRNB1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400502"/>
		<dto:entrez_xref>1140</dto:entrez_xref>
		<dto:geneSymbol>CHRNB1</dto:geneSymbol>
		<dto:geneSynonym>CHRNB</dto:geneSynonym>
		<dto:geneSynonym>ACHRB</dto:geneSynonym>
		<obo:IAO_0000115>The muscle acetylcholine receptor is composed of five subunits: two alpha subunits and one beta, one gamma, and one delta subunit. This gene encodes the beta subunit of the acetylcholine receptor. The acetylcholine receptor changes conformation upon acetylcholine binding leading to the opening of an ion-conducting channel across the plasma membrane. Mutations in this gene are associated with slow-channel congenital myasthenic syndrome. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200019 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200019">
		<rdfs:label rdf:datatype="&xsd;string">CHRND gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400503"/>
		<dto:entrez_xref>1144</dto:entrez_xref>
		<dto:geneSymbol>CHRND</dto:geneSymbol>
		<dto:geneSynonym>ACHRD</dto:geneSynonym>
		<obo:IAO_0000115>The acetylcholine receptor of muscle has 5 subunits of 4 different types: 2 alpha and 1 each of beta, gamma and delta subunits. After acetylcholine binding, the receptor undergoes an extensive conformation change that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. Defects in this gene are a cause of multiple pterygium syndrome lethal type (MUPSL), congenital myasthenic syndrome slow-channel type (SCCMS), and congenital myasthenic syndrome fast-channel type (FCCMS). Several transcript variants, some protein-coding and some not, have been found for this gene. [provided by RefSeq, Feb 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200020 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200020">
		<rdfs:label rdf:datatype="&xsd;string">CHRNE gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400504"/>
		<dto:entrez_xref>1145</dto:entrez_xref>
		<dto:geneSymbol>CHRNE</dto:geneSymbol>
		<dto:geneSynonym>ACHRE</dto:geneSynonym>
		<obo:IAO_0000115>Acetylcholine receptors at mature mammalian neuromuscular junctions are pentameric protein complexes composed of four subunits in the ratio of two alpha subunits to one beta, one epsilon, and one delta subunit. The acetylcholine receptor changes subunit composition shortly after birth when the epsilon subunit replaces the gamma subunit seen in embryonic receptors. Mutations in the epsilon subunit are associated with congenital myasthenic syndrome. [provided by RefSeq, Sep 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200021 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200021">
		<rdfs:label rdf:datatype="&xsd;string">CHRNG gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400505"/>
		<dto:entrez_xref>1146</dto:entrez_xref>
		<dto:geneSymbol>CHRNG</dto:geneSymbol>
		<dto:geneSynonym>ACHRG</dto:geneSynonym>
		<obo:IAO_0000115>The mammalian muscle-type acetylcholine receptor is a transmembrane pentameric glycoprotein with two alpha subunits, one beta, one delta, and one epsilon (in adult skeletal muscle) or gamma (in fetal and denervated muscle) subunit. This gene, which encodes the gamma subunit, is expressed prior to the thirty-third week of gestation in humans. The gamma subunit of the acetylcholine receptor plays a role in neuromuscular organogenesis and ligand binding and disruption of gamma subunit expression prevents the correct localization of the receptor in cell membranes. Mutations in this gene cause Escobar syndrome and a lethal form of multiple pterygium syndrome. Muscle-type acetylcholine receptor is the major antigen in the autoimmune disease myasthenia gravis.[provided by RefSeq, Sep 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200022 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200022">
		<rdfs:label rdf:datatype="&xsd;string">ANO1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400329"/>
		<dto:entrez_xref>55107</dto:entrez_xref>
		<dto:geneSymbol>ANO1</dto:geneSymbol>
		<dto:geneSynonym>ORAOV2</dto:geneSynonym>
		<dto:geneSynonym>TAOS2</dto:geneSynonym>
		<dto:geneSynonym>DOG1</dto:geneSynonym>
		<dto:geneSynonym>TMEM16A</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200023 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200023">
		<rdfs:label rdf:datatype="&xsd;string">ANO2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400329"/>
		<dto:entrez_xref>57101</dto:entrez_xref>
		<dto:geneSymbol>ANO2</dto:geneSymbol>
		<dto:geneSynonym>TMEM16B</dto:geneSynonym>
		<dto:geneSynonym>C12orf3</dto:geneSynonym>
		<obo:IAO_0000115>ANO2 belongs to a family of calcium-activated chloride channels (CaCCs) (reviewed by Hartzell et al., 2009 [PubMed 19015192]).[supplied by OMIM, Jan 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200024 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200024">
		<rdfs:label rdf:datatype="&xsd;string">ANO6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400329"/>
		<dto:entrez_xref>196527</dto:entrez_xref>
		<dto:geneSymbol>ANO6</dto:geneSymbol>
		<dto:geneSynonym>TMEM16F</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a multi-pass transmembrane protein that belongs to the anoctamin family. This protein is an essential component for the calcium-dependent exposure of phosphatidylserine on the cell surface. The scrambling of phospholipid occurs in various biological systems, such as when blood platelets are activated, they expose phosphatidylserine to trigger the clotting system. Mutations in this gene are associated with Scott syndrome. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Mar 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200025 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200025">
		<rdfs:label rdf:datatype="&xsd;string">ASIC1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400376"/>
		<dto:entrez_xref>41</dto:entrez_xref>
		<dto:geneSymbol>ASIC1</dto:geneSymbol>
		<dto:geneSynonym>BNAC2</dto:geneSynonym>
		<dto:geneSynonym>ACCN2</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the acid-sensing ion channel (ASIC) family of proteins, which are part of the degenerin/epithelial sodium channel (DEG/ENaC) superfamily. Members of the ASIC family are sensitive to amiloride and function in neurotransmission. The encoded proteins function in learning, pain transduction, touch sensation, and development of memory and fear. Alternatively spliced transcript variants have been described. [provided by RefSeq, Feb 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200026 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200026">
		<rdfs:label rdf:datatype="&xsd;string">ASIC2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400377"/>
		<dto:entrez_xref>40</dto:entrez_xref>
		<dto:geneSymbol>ASIC2</dto:geneSymbol>
		<dto:geneSynonym>ACCN1</dto:geneSynonym>
		<dto:geneSynonym>BNAC1</dto:geneSynonym>
		<dto:geneSynonym>ACCN</dto:geneSynonym>
		<dto:geneSynonym>MDEG</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the degenerin/epithelial sodium channel (DEG/ENaC) superfamily. The members of this family are amiloride-sensitive sodium channels that contain intracellular N and C termini, 2 hydrophobic transmembrane regions, and a large extracellular loop, which has many cysteine residues with conserved spacing. The member encoded by this gene may play a role in neurotransmission. In addition, a heteromeric association between this member and acid-sensing (proton-gated) ion channel 3 has been observed to co-assemble into proton-gated channels sensitive to gadolinium. Alternative splicing has been observed at this locus and two variants, encoding distinct isoforms, have been identified. [provided by RefSeq, Feb 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200027 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200027">
		<rdfs:label rdf:datatype="&xsd;string">ASIC3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400378"/>
		<dto:entrez_xref>9311</dto:entrez_xref>
		<dto:geneSymbol>ASIC3</dto:geneSymbol>
		<dto:geneSynonym>SLNAC1</dto:geneSynonym>
		<dto:geneSynonym>TNAC1</dto:geneSynonym>
		<dto:geneSynonym>ACCN3</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the degenerin/epithelial sodium channel (DEG/ENaC) superfamily. The members of this family are amiloride-sensitive sodium channels that contain intracellular N and C termini, two hydrophobic transmembrane regions, and a large extracellular loop, which has many cysteine residues with conserved spacing. The member encoded by this gene is an acid sensor and may play an important role in the detection of lasting pH changes. In addition, a heteromeric association between this member and acid-sensing (proton-gated) ion channel 2 has been observed as proton-gated channels sensitive to gadolinium. Alternatively spliced transcript variants have been described. [provided by RefSeq, Feb 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200028 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200028">
		<rdfs:label rdf:datatype="&xsd;string">ASIC4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400379"/>
		<dto:entrez_xref>55515</dto:entrez_xref>
		<dto:geneSymbol>ASIC4</dto:geneSymbol>
		<dto:geneSynonym>ACCN4</dto:geneSynonym>
		<obo:IAO_0000115>This gene belongs to the superfamily of acid-sensing ion channels, which are proton-gated, amiloride-sensitive sodium channels. These channels have been implicated in synaptic transmission, pain perception as well as mechanoperception. This gene is predominantly expressed in the pituitary gland, and was considered a candidate for paroxysmal dystonic choreoathetosis (PDC), a movement disorder, however, no correlation was found between mutations in this gene and PDC. [provided by RefSeq, Feb 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200029 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200029">
		<rdfs:label rdf:datatype="&xsd;string">ASIC5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400380"/>
		<dto:entrez_xref>51802</dto:entrez_xref>
		<dto:geneSymbol>ASIC5</dto:geneSymbol>
		<dto:geneSynonym>HINAC</dto:geneSynonym>
		<dto:geneSynonym>ACCN5</dto:geneSynonym>
		<obo:IAO_0000115>This gene belongs to the amiloride-sensitive Na+ channel and degenerin (NaC/DEG) family, members of which have been identified in many animal species ranging from the nematode to human. The amiloride-sensitive Na(+) channel encoded by this gene is primarily expressed in the small intestine, however, its exact function is not known. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200030 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200030">
		<rdfs:label rdf:datatype="&xsd;string">BEST1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400331"/>
		<dto:entrez_xref>7439</dto:entrez_xref>
		<dto:geneSymbol>BEST1</dto:geneSymbol>
		<dto:geneSynonym>VMD2</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the bestrophin gene family. This small gene family is characterized by proteins with a highly conserved N-terminus with four to six transmembrane domains. Bestrophins may form chloride ion channels or may regulate voltage-gated L-type calcium-ion channels. Bestrophins are generally believed to form calcium-activated chloride-ion channels in epithelial cells but they have also been shown to be highly permeable to bicarbonate ion transport in retinal tissue. Mutations in this gene are responsible for juvenile-onset vitelliform macular dystrophy (VMD2), also known as Best macular dystrophy, in addition to adult-onset vitelliform macular dystrophy (AVMD) and other retinopathies. Alternative splicing results in multiple variants encoding distinct isoforms.[provided by RefSeq, Nov 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200031 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200031">
		<rdfs:label rdf:datatype="&xsd;string">BEST2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400331"/>
		<dto:entrez_xref>54831</dto:entrez_xref>
		<dto:geneSymbol>BEST2</dto:geneSymbol>
		<dto:geneSynonym>VMD2L1</dto:geneSynonym>
		<obo:IAO_0000115>This gene is a member of the bestrophin gene family of anion channels. Bestrophin genes share a similar gene structure with highly conserved exon-intron boundaries, but with distinct 3&apos; ends. Bestrophins are transmembrane proteins that contain a homologous region rich in aromatic residues, including an invariant arg-phe-pro motif. Mutation in one of the family members (bestrophin 1) is associated with vitelliform macular dystrophy. The bestrophin 2 gene is mainly expressed in the retinal pigment epithelium and colon. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200032 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200032">
		<rdfs:label rdf:datatype="&xsd;string">BEST3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400331"/>
		<dto:entrez_xref>144453</dto:entrez_xref>
		<dto:geneSymbol>BEST3</dto:geneSymbol>
		<dto:geneSynonym>VMD2L3</dto:geneSynonym>
		<obo:IAO_0000115>BEST3 belongs to the bestrophin family of anion channels, which includes BEST1 (MIM 607854), the gene mutant in vitelliform macular dystrophy (VMD; MIM 153700), and 2 other BEST1-like genes, BEST2 (MIM 607335) and BEST4 (MIM 607336). Bestrophins are transmembrane (TM) proteins that share a homology region containing a high content of aromatic residues, including an invariant arg-phe-pro (RFP) motif. The bestrophin genes share a conserved gene structure, with almost identical sizes of the 8 RFP-TM domain-encoding exons and highly conserved exon-intron boundaries. Each of the 4 bestrophin genes has a unique 3-prime end of variable length (Stohr et al., 2002 [PubMed 12032738]; Tsunenari et al., 2003 [PubMed 12907679]).[supplied by OMIM, Mar 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200033 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200033">
		<rdfs:label rdf:datatype="&xsd;string">BEST4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400331"/>
		<dto:entrez_xref>266675</dto:entrez_xref>
		<dto:geneSymbol>BEST4</dto:geneSymbol>
		<dto:geneSynonym>VMD2L2</dto:geneSynonym>
		<obo:IAO_0000115>This gene is a member of the bestrophin gene family of anion channels. Bestrophin genes share a similar gene structure with highly conserved exon-intron boundaries, but with distinct 3&apos; ends. Bestrophins are transmembrane proteins that contain a homologous region rich in aromatic residues, including an invariant arg-phe-pro motif. Mutation in one of the family members (bestrophin 1) is associated with vitelliform macular dystrophy. The bestrophin 4 gene is predominantly expressed in the colon. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200034 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200034">
		<rdfs:label rdf:datatype="&xsd;string">CACNA2D1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400332"/>
		<dto:entrez_xref>781</dto:entrez_xref>
		<dto:geneSymbol>CACNA2D1</dto:geneSymbol>
		<dto:geneSynonym>CCHL2A</dto:geneSynonym>
		<dto:geneSynonym>MHS3</dto:geneSynonym>
		<dto:geneSynonym>CACNL2A</dto:geneSynonym>
		<obo:IAO_0000115>The preproprotein encoded by this gene is cleaved into multiple chains that comprise the alpha-2 and delta subunits of the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization. Mutations in this gene can cause cardiac deficiencies, including Brugada syndrome and short QT syndrome. Alternate splicing results in multiple transcript variants, some of which may lack the delta subunit portion. [provided by RefSeq, Nov 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200035 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200035">
		<rdfs:label rdf:datatype="&xsd;string">CACNA2D2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400332"/>
		<dto:entrez_xref>9254</dto:entrez_xref>
		<dto:geneSymbol>CACNA2D2</dto:geneSymbol>
		<dto:geneSynonym>KIAA0558</dto:geneSynonym>
		<obo:IAO_0000115>Calcium channels mediate the entry of calcium ions into the cell upon membrane polarization. This gene encodes the alpha-2/delta subunit of the voltage-dependent calcium channel complex. The complex consists of the main channel-forming subunit alpha-1, and auxiliary subunits alpha-2/delta, beta, and gamma. The auxiliary subunits function in the assembly and membrane localization of the complex, and modulate calcium currents and channel activation/inactivation kinetics. The subunit encoded by this gene undergoes post-translational cleavage to yield the extracellular alpha2 peptide and a membrane-anchored delta polypeptide. This subunit is a receptor for the antiepileptic drug, gabapentin. Mutations in this gene are associated with early infantile epileptic encephalopathy. Single nucleotide polymorphisms in this gene are correlated with increased sensitivity to opioid drugs. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Mar 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200036 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200036">
		<rdfs:label rdf:datatype="&xsd;string">CACNA2D3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400332"/>
		<dto:entrez_xref>55799</dto:entrez_xref>
		<dto:geneSymbol>CACNA2D3</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the alpha-2/delta subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. Various versions of each of these subunits exist, either expressed from similar genes or the result of alternative splicing. Research on a highly similar protein in rabbit suggests the protein described in this record is cleaved into alpha-2 and delta subunits. Alternate transcriptional splice variants of this gene have been observed but have not been thoroughly characterized. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200037 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200037">
		<rdfs:label rdf:datatype="&xsd;string">CACNA2D4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400332"/>
		<dto:entrez_xref>93589</dto:entrez_xref>
		<dto:geneSymbol>CACNA2D4</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the alpha-2/delta subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. Various versions of each of these subunits exist, either expressed from similar genes or the result of alternative splicing. Research on a highly similar protein in rabbit suggests the protein described in this record is cleaved into alpha-2 and delta subunits. Alternate transcriptional splice variants of this gene have been observed but have not been thoroughly characterized. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200038 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200038">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400381"/>
		<dto:entrez_xref>773</dto:entrez_xref>
		<dto:geneSymbol>CACNA1A</dto:geneSymbol>
		<dto:geneSynonym>CACN3</dto:geneSynonym>
		<dto:geneSynonym>CACNL1A4</dto:geneSynonym>
		<dto:geneSynonym>CACH4</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-dependent calcium channels mediate the entry of calcium ions into excitable cells, and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, and gene expression. Calcium channels are multisubunit complexes composed of alpha-1, beta, alpha-2/delta, and gamma subunits. The channel activity is directed by the pore-forming alpha-1 subunit, whereas, the others act as auxiliary subunits regulating this activity. The distinctive properties of the calcium channel types are related primarily to the expression of a variety of alpha-1 isoforms, alpha-1A, B, C, D, E, and S. This gene encodes the alpha-1A subunit, which is predominantly expressed in neuronal tissue. Mutations in this gene are associated with 2 neurologic disorders, familial hemiplegic migraine and episodic ataxia 2. This gene also exhibits polymorphic variation due to (CAG)n-repeats. Multiple transcript variants encoding different isoforms have been found for this gene. In one set of transcript variants, the (CAG)n-repeats occur in the 3&apos; UTR, and are not associated with any disease. But in another set of variants, an insertion extends the coding region to include the (CAG)n-repeats which encode a polyglutamine tract. Expansion of the (CAG)n-repeats from the normal 4-16 to 21-28 in the coding region is associated with spinocerebellar ataxia 6. [provided by RefSeq, Mar 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200039 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200039">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1B gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400382"/>
		<dto:entrez_xref>774</dto:entrez_xref>
		<dto:geneSymbol>CACNA1B</dto:geneSymbol>
		<dto:geneSynonym>CACNL1A5</dto:geneSynonym>
		<dto:geneSynonym>CACH5</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene is the pore-forming subunit of an N-type voltage-dependent calcium channel, which controls neurotransmitter release from neurons. The encoded protein forms a complex with alpha-2, beta, and delta subunits to form the high-voltage activated channel. This channel is sensitive to omega-conotoxin-GVIA and omega-agatoxin-IIIA but insensitive to dihydropyridines. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200040 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200040">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1C gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400383"/>
		<dto:entrez_xref>775</dto:entrez_xref>
		<dto:geneSymbol>CACNA1C</dto:geneSymbol>
		<dto:geneSynonym>CACN2</dto:geneSynonym>
		<dto:geneSynonym>CACNL1A1</dto:geneSynonym>
		<dto:geneSynonym>CACH2</dto:geneSynonym>
		<dto:geneSynonym>CCHL1A1</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes an alpha-1 subunit of a voltage-dependent calcium channel. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization. The alpha-1 subunit consists of 24 transmembrane segments and forms the pore through which ions pass into the cell. The calcium channel consists of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. There are multiple isoforms of each of these proteins, either encoded by different genes or the result of alternative splicing of transcripts. The protein encoded by this gene binds to and is inhibited by dihydropyridine. Alternative splicing results in many transcript variants encoding different proteins. Some of the predicted proteins may not produce functional ion channel subunits. [provided by RefSeq, Oct 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200041 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200041">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1D gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400384"/>
		<dto:entrez_xref>776</dto:entrez_xref>
		<dto:geneSymbol>CACNA1D</dto:geneSymbol>
		<dto:geneSynonym>CACN4</dto:geneSynonym>
		<dto:geneSynonym>CACNL1A2</dto:geneSynonym>
		<dto:geneSynonym>CACH3</dto:geneSynonym>
		<dto:geneSynonym>CCHL1A2</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-dependent calcium channels mediate the entry of calcium ions into excitable cells, and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, and gene expression. Calcium channels are multisubunit complexes composed of alpha-1, beta, alpha-2/delta, and gamma subunits. The channel activity is directed by the pore-forming alpha-1 subunit, whereas the others act as auxiliary subunits regulating this activity. The distinctive properties of the calcium channel types are related primarily to the expression of a variety of alpha-1 isoforms, namely alpha-1A, B, C, D, E, and S. This gene encodes the alpha-1D subunit. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200042 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200042">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1E gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400385"/>
		<dto:entrez_xref>777</dto:entrez_xref>
		<dto:geneSymbol>CACNA1E</dto:geneSymbol>
		<dto:geneSynonym>CACNL1A6</dto:geneSynonym>
		<dto:geneSynonym>CACH6</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-dependent calcium channels are multisubunit complexes consisting of alpha-1, alpha-2, beta, and delta subunits in a 1:1:1:1 ratio. These channels mediate the entry of calcium ions into excitable cells, and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. This gene encodes the alpha-1E subunit of the R-type calcium channels, which belong to the &apos;high-voltage activated&apos; group that maybe involved in the modulation of firing patterns of neurons important for information processing. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Apr 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200043 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200043">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1F gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400386"/>
		<dto:entrez_xref>778</dto:entrez_xref>
		<dto:geneSymbol>CACNA1F</dto:geneSymbol>
		<dto:geneSynonym>CACNAF1</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a multipass transmembrane protein that functions as an alpha-1 subunit of the voltage-dependent calcium channel, which mediates the influx of calcium ions into the cell. The encoded protein forms a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. Mutations in this gene can cause X-linked eye disorders, including congenital stationary night blindness type 2A, cone-rod dystropy, and Aland Island eye disease. Alternatively spliced transcript variants encoding multiple isoforms have been observed. [provided by RefSeq, Aug 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200044 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200044">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1G gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400387"/>
		<dto:entrez_xref>8913</dto:entrez_xref>
		<dto:geneSymbol>CACNA1G</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-sensitive calcium channels mediate the entry of calcium ions into excitable cells, and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division, and cell death. This gene encodes a T-type, low-voltage activated calcium channel. The T-type channels generate currents that are both transient, owing to fast inactivation, and tiny, owing to small conductance. T-type channels are thought to be involved in pacemaker activity, low-threshold calcium spikes, neuronal oscillations and resonance, and rebound burst firing. Many alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Sep 2011]</obo:IAO_0000115>
		<dto:geneSynonym>KIAA1123</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200045 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200045">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1H gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400388"/>
		<dto:entrez_xref>8912</dto:entrez_xref>
		<dto:geneSymbol>CACNA1H</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a T-type member of the alpha-1 subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. The alpha-1 subunit has 24 transmembrane segments and forms the pore through which ions pass into the cell. There are multiple isoforms of each of the proteins in the complex, either encoded by different genes or the result of alternative splicing of transcripts. Alternate transcriptional splice variants, encoding different isoforms, have been characterized for the gene described here. Studies suggest certain mutations in this gene lead to childhood absence epilepsy (CAE). [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200046 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200046">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1I gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400389"/>
		<dto:entrez_xref>8911</dto:entrez_xref>
		<dto:geneSymbol>CACNA1I</dto:geneSymbol>
		<dto:geneSynonym>KIAA1120</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes the pore-forming alpha subunit of a voltage gated calcium channel. The encoded protein is a member of a subfamily of calcium channels referred to as is a low voltage-activated, T-type, calcium channel. The channel encoded by this protein is characterized by a slower activation and inactivation compared to other T-type calcium channels. This protein may be involved in calcium signaling in neurons. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Oct 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200047 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200047">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1S gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400390"/>
		<dto:entrez_xref>779</dto:entrez_xref>
		<dto:geneSymbol>CACNA1S</dto:geneSymbol>
		<dto:geneSynonym>CACN1</dto:geneSynonym>
		<dto:geneSynonym>CACNL1A3</dto:geneSynonym>
		<dto:geneSynonym>CACH1</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes one of the five subunits of the slowly inactivating L-type voltage-dependent calcium channel in skeletal muscle cells. Mutations in this gene have been associated with hypokalemic periodic paralysis, thyrotoxic periodic paralysis and malignant hyperthermia susceptibility. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200048 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200048">
		<rdfs:label rdf:datatype="&xsd;string">CACNB1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400334"/>
		<dto:entrez_xref>782</dto:entrez_xref>
		<dto:geneSymbol>CACNB1</dto:geneSymbol>
		<dto:geneSynonym>CACNLB1</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene belongs to the calcium channel beta subunit family. It plays an important role in the calcium channel by modulating G protein inhibition, increasing peak calcium current, controlling the alpha-1 subunit membrane targeting and shifting the voltage dependence of activation and inactivation. Alternative splicing occurs at this locus and three transcript variants encoding three distinct isoforms have been identified. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200049 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200049">
		<rdfs:label rdf:datatype="&xsd;string">CACNB2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400334"/>
		<dto:entrez_xref>783</dto:entrez_xref>
		<dto:geneSymbol>CACNB2</dto:geneSymbol>
		<dto:geneSynonym>MYSB</dto:geneSynonym>
		<dto:geneSynonym>CACNLB2</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a subunit of a voltage-dependent calcium channel protein that is a member of the voltage-gated calcium channel superfamily. The gene product was originally identified as an antigen target in Lambert-Eaton myasthenic syndrome, an autoimmune disorder. Mutations in this gene are associated with Brugada syndrome. Alternatively spliced variants encoding different isoforms have been described. [provided by RefSeq, Feb 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200050 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200050">
		<rdfs:label rdf:datatype="&xsd;string">CACNB3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400334"/>
		<dto:entrez_xref>784</dto:entrez_xref>
		<dto:geneSymbol>CACNB3</dto:geneSymbol>
		<dto:geneSynonym>CACNLB3</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a regulatory beta subunit of the voltage-dependent calcium channel. Beta subunits are composed of five domains, which contribute to the regulation of surface expression and gating of calcium channels and may also play a role in the regulation of transcription factors and calcium transport. [provided by RefSeq, Oct 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200051 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200051">
		<rdfs:label rdf:datatype="&xsd;string">CACNB4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400334"/>
		<dto:entrez_xref>785</dto:entrez_xref>
		<dto:geneSymbol>CACNB4</dto:geneSymbol>
		<dto:geneSynonym>CACNLB4</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the beta subunit family of voltage-dependent calcium channel complex proteins. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. Various versions of each of these subunits exist, either expressed from similar genes or the result of alternative splicing. The protein encoded by this locus plays an important role in calcium channel function by modulating G protein inhibition, increasing peak calcium current, controlling the alpha-1 subunit membrane targeting and shifting the voltage dependence of activation and inactivation. Certain mutations in this gene have been associated with idiopathic generalized epilepsy (IGE) and juvenile myoclonic epilepsy (JME). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200052 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200052">
		<rdfs:label rdf:datatype="&xsd;string">CALHM1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400335"/>
		<dto:entrez_xref>255022</dto:entrez_xref>
		<dto:geneSymbol>CALHM1</dto:geneSymbol>
		<dto:geneSynonym>FAM26C</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a calcium channel that plays a role in processing of amyloid-beta precursor protein. A polymorphism at this locus has been reported to be associated with susceptibility to late-onset Alzheimer&apos;s disease in some populations, but the pathogenicity of this polymorphism is unclear.[provided by RefSeq, Mar 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200053 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200053">
		<rdfs:label rdf:datatype="&xsd;string">CALHM2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400335"/>
		<dto:entrez_xref>51063</dto:entrez_xref>
		<dto:geneSymbol>CALHM2</dto:geneSymbol>
		<dto:geneSynonym>FAM26B</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200054 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200054">
		<rdfs:label rdf:datatype="&xsd;string">CALHM3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400335"/>
		<dto:entrez_xref>119395</dto:entrez_xref>
		<dto:geneSymbol>CALHM3</dto:geneSymbol>
		<dto:geneSynonym>FAM26A</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200055 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200055">
		<rdfs:label rdf:datatype="&xsd;string">CACNG1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400336"/>
		<dto:entrez_xref>786</dto:entrez_xref>
		<dto:geneSymbol>CACNG1</dto:geneSymbol>
		<dto:geneSynonym>CACNLG</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-dependent calcium channels are composed of five subunits. The protein encoded by this gene represents one of these subunits, gamma, and is one of two known gamma subunit proteins. This particular gamma subunit is part of skeletal muscle 1,4-dihydropyridine-sensitive calcium channels and is an integral membrane protein that plays a role in excitation-contraction coupling. This gene is part of a functionally diverse eight-member protein subfamily of the PMP-22/EMP/MP20 family and is located in a cluster with two family members that function as transmembrane AMPA receptor regulatory proteins (TARPs). [provided by RefSeq, Dec 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200056 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200056">
		<rdfs:label rdf:datatype="&xsd;string">CACNG2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400336"/>
		<dto:entrez_xref>10369</dto:entrez_xref>
		<dto:geneSymbol>CACNG2</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded by this gene is a type I transmembrane AMPA receptor regulatory protein (TARP). TARPs regulate both trafficking and channel gating of the AMPA receptors. This gene is part of a functionally diverse eight-member protein subfamily of the PMP-22/EMP/MP20 family. This gene is a susceptibility locus for schizophrenia. [provided by RefSeq, Dec 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200057 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200057">
		<rdfs:label rdf:datatype="&xsd;string">CACNG3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400336"/>
		<dto:entrez_xref>10368</dto:entrez_xref>
		<dto:geneSymbol>CACNG3</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded by this gene is a type I transmembrane AMPA receptor regulatory protein (TARP). TARPs regulate both trafficking and channel gating of the AMPA receptors. This gene is part of a functionally diverse eight-member protein subfamily of the PMP-22/EMP/MP20 family. This gene is a susceptibility locus for childhood absence epilepsy. [provided by RefSeq, Dec 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200058 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200058">
		<rdfs:label rdf:datatype="&xsd;string">CACNG4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400336"/>
		<dto:entrez_xref>27092</dto:entrez_xref>
		<dto:geneSymbol>CACNG4</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded by this gene is a type I transmembrane AMPA receptor regulatory protein (TARP). TARPs regulate both trafficking and channel gating of the AMPA receptors. This gene is part of a functionally diverse eight-member protein subfamily of the PMP-22/EMP/MP20 family and is located in a cluster with two family members, a type II TARP and a calcium channel gamma subunit. [provided by RefSeq, Dec 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200059 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200059">
		<rdfs:label rdf:datatype="&xsd;string">CACNG5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400336"/>
		<dto:entrez_xref>27091</dto:entrez_xref>
		<dto:geneSymbol>CACNG5</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded by this gene is a type II transmembrane AMPA receptor regulatory protein (TARP). TARPs regulate both trafficking and channel gating of the AMPA receptors. This gene is part of a functionally diverse eight-member protein subfamily of the PMP-22/EMP/MP20 family and is located in a cluster with two family members, a type I TARP and a calcium channel gamma subunit. This gene is a susceptibility locus for schizophrenia and bipolar disorder. [provided by RefSeq, Dec 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200060 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200060">
		<rdfs:label rdf:datatype="&xsd;string">CACNG6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400336"/>
		<dto:entrez_xref>59285</dto:entrez_xref>
		<dto:geneSymbol>CACNG6</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-dependent calcium channels are composed of five subunits. The protein encoded by this gene represents one of these subunits, gamma, and is one of two known gamma subunit proteins. This particular gamma subunit is an integral membrane protein that is thought to stabilize the calcium channel in an inactive (closed) state. This gene is part of a functionally diverse eight-member protein subfamily of the PMP-22/EMP/MP20 family and is located in a cluster with two family members that function as transmembrane AMPA receptor regulatory proteins (TARPs). Alternative splicing results in multiple transcript variants. Variants in this gene have been associated with aspirin-intolerant asthma. [provided by RefSeq, Dec 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200061 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200061">
		<rdfs:label rdf:datatype="&xsd;string">CACNG7 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400336"/>
		<dto:entrez_xref>59284</dto:entrez_xref>
		<dto:geneSymbol>CACNG7</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded by this gene is a type II transmembrane AMPA receptor regulatory protein (TARP). TARPs regulate both trafficking and channel gating of the AMPA receptors. This gene is part of a functionally diverse eight-member protein subfamily of the PMP-22/EMP/MP20 family and is located in a cluster with two family members, a type I TARP and a calcium channel gamma subunit. [provided by RefSeq, Dec 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200062 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200062">
		<rdfs:label rdf:datatype="&xsd;string">CACNG8 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400336"/>
		<dto:entrez_xref>59283</dto:entrez_xref>
		<dto:geneSymbol>CACNG8</dto:geneSymbol>
		<dto:geneSynonym>CACNG6</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene is a type I transmembrane AMPA receptor regulatory protein (TARP). TARPs regulate both trafficking and channel gating of the AMPA receptors. This gene is part of a functionally diverse eight-member protein subfamily of the PMP-22/EMP/MP20 family and is located in a cluster with two family members, a type II TARP and a calcium channel gamma subunit. The mRNA for this gene is believed to initiate translation from a non-AUG (CUG) start codon. [provided by RefSeq, Dec 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200063 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200063">
		<rdfs:label rdf:datatype="&xsd;string">TMEM37 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400391"/>
		<dto:entrez_xref>140738</dto:entrez_xref>
		<dto:geneSymbol>TMEM37</dto:geneSymbol>
		<dto:geneSynonym>PR</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200064 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200064">
		<rdfs:label rdf:datatype="&xsd;string">CFTR gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400392"/>
		<dto:entrez_xref>1080</dto:entrez_xref>
		<dto:geneSymbol>CFTR</dto:geneSymbol>
		<dto:geneSynonym>ABCC7</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MRP subfamily that is involved in multi-drug resistance. The encoded protein functions as a chloride channel and controls the regulation of other transport pathways. Mutations in this gene are associated with the autosomal recessive disorders cystic fibrosis and congenital bilateral aplasia of the vas deferens. Alternatively spliced transcript variants have been described, many of which result from mutations in this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200065 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200065">
		<rdfs:label rdf:datatype="&xsd;string">CLCA1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400339"/>
		<dto:entrez_xref>1179</dto:entrez_xref>
		<dto:geneSymbol>CLCA1</dto:geneSymbol>
		<dto:geneSynonym>CACC1</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the calcium sensitive chloride conductance protein family. To date, all members of this gene family map to the same region on chromosome 1p31-p22 and share a high degree of homology in size, sequence, and predicted structure, but differ significantly in their tissue distributions. The encoded protein is expressed as a precursor protein that is processed into two cell-surface-associated subunits, although the site at which the precursor is cleaved has not been precisely determined. The encoded protein may be involved in mediating calcium-activated chloride conductance in the intestine. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200066 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200066">
		<rdfs:label rdf:datatype="&xsd;string">CLCA2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400339"/>
		<dto:entrez_xref>9635</dto:entrez_xref>
		<dto:geneSymbol>CLCA2</dto:geneSymbol>
		<dto:geneSynonym>CACC3</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene belongs to the calcium sensitive chloride conductance protein family. To date, all members of this gene family map to the same site on chromosome 1p31-p22 and share high degrees of homology in size, sequence and predicted structure, but differ significantly in their tissue distributions. Since this protein is expressed predominantly in trachea and lung, it is suggested to play a role in the complex pathogenesis of cystic fibrosis. It may also serve as adhesion molecule for lung metastatic cancer cells, mediating vascular arrest and colonization, and furthermore, it has been implicated to act as a tumor suppressor gene for breast cancer. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200067 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200067">
		<rdfs:label rdf:datatype="&xsd;string">CLCA3P gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400339"/>
		<dto:entrez_xref>9629</dto:entrez_xref>
		<dto:geneSymbol>CLCA3P</dto:geneSymbol>
		<dto:geneSynonym>CLCA3</dto:geneSynonym>
		<obo:IAO_0000115>This gene is a transcribed pseudogene belonging to the calcium sensitive chloride conductance protein family. To date, all members of this gene family map to the same site on chromosome 1p31-p22 and share high degrees of homology in size, sequence and predicted structure, but differ significantly in their tissue distributions. This gene contains several nonsense codons compared to other family members that render the transcript a candidate for nonsense-mediated mRNA decay (NMD). Therefore, this gene is unlikely to be protein-coding. [provided by RefSeq, Jan 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200068 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200068">
		<rdfs:label rdf:datatype="&xsd;string">CLCA4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400339"/>
		<dto:entrez_xref>22802</dto:entrez_xref>
		<dto:geneSymbol>CLCA4</dto:geneSymbol>
		<dto:geneSynonym>CaCC2</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene belongs to the calcium sensitive chloride conductance protein family. To date, all members of this gene family map to the same site on chromosome 1p31-p22 and share high degrees of homology in size, sequence and predicted structure, but differ significantly in their tissue distributions. Alternative splicing results in multiple transcript variants, only one of which is thought to be protein coding. [provided by RefSeq, Dec 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200069 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200069">
		<rdfs:label rdf:datatype="&xsd;string">CLCC1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400340"/>
		<dto:entrez_xref>23155</dto:entrez_xref>
		<dto:geneSymbol>CLCC1</dto:geneSymbol>
		<dto:geneSynonym>MCLC</dto:geneSynonym>
		<dto:geneSynonym>KIAA0761</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200070 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200070">
		<rdfs:label rdf:datatype="&xsd;string">CLCNKA gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400393"/>
		<dto:entrez_xref>1187</dto:entrez_xref>
		<dto:geneSymbol>CLCNKA</dto:geneSymbol>
		<obo:IAO_0000115>This gene is a member of the CLC family of voltage-gated chloride channels. The encoded protein is predicted to have 12 transmembrane domains, and requires a beta subunit called barttin to form a functional channel. It is thought to function in salt reabsorption in the kidney and potassium recycling in the inner ear. The gene is highly similar to CLCNKB, which is located 10 kb downstream from this gene. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200071 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200071">
		<rdfs:label rdf:datatype="&xsd;string">CLCNKB gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400394"/>
		<dto:entrez_xref>1188</dto:entrez_xref>
		<dto:geneSymbol>CLCNKB</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded by this gene is a member of the family of voltage-gated chloride channels. Chloride channels have several functions, including the regulation of cell volume, membrane potential stabilization, signal transduction and transepithelial transport. This gene is expressed predominantly in the kidney and may be important for renal salt reabsorption. Mutations in this gene are associated with autosomal recessive Bartter syndrome type 3 (BS3). Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200072 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200072">
		<rdfs:label rdf:datatype="&xsd;string">CLCN1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400395"/>
		<dto:entrez_xref>1180</dto:entrez_xref>
		<dto:geneSymbol>CLCN1</dto:geneSymbol>
		<dto:geneSynonym>CLC1</dto:geneSynonym>
		<obo:IAO_0000115>The CLCN family of voltage-dependent chloride channel genes comprises nine members (CLCN1-7, Ka and Kb) which demonstrate quite diverse functional characteristics while sharing significant sequence homology. The protein encoded by this gene regulates the electric excitability of the skeletal muscle membrane. Mutations in this gene cause two forms of inherited human muscle disorders: recessive generalized myotonia congenita (Becker) and dominant myotonia (Thomsen). Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200073 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200073">
		<rdfs:label rdf:datatype="&xsd;string">CLCN2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400396"/>
		<dto:entrez_xref>1181</dto:entrez_xref>
		<dto:geneSymbol>CLCN2</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a voltage-gated chloride channel. The encoded protein is a transmembrane protein that maintains chloride ion homeostasis in various cells. Defects in this gene may be a cause of certain epilepsies. Four transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200074 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200074">
		<rdfs:label rdf:datatype="&xsd;string">CLCN3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400397"/>
		<dto:entrez_xref>1182</dto:entrez_xref>
		<dto:geneSymbol>CLCN3</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the voltage-gated chloride channel (ClC) family. The encoded protein is present in all cell types and localized in plasma membranes and in intracellular vesicles. It is a multi-pass membrane protein which contains a ClC domain and two additional C-terminal CBS (cystathionine beta-synthase) domains. The ClC domain catalyzes the selective flow of Cl- ions across cell membranes, and the CBS domain may have a regulatory function. This protein plays a role in both acidification and transmitter loading of GABAergic synaptic vesicles, and in smooth muscle cell activation and neointima formation. This protein is required for lysophosphatidic acid (LPA)-activated Cl- current activity and fibroblast-to-myofibroblast differentiation. The protein activity is regulated by Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) in glioma cells. Multiple alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Aug 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200075 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200075">
		<rdfs:label rdf:datatype="&xsd;string">CLCN4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400398"/>
		<dto:entrez_xref>1183</dto:entrez_xref>
		<dto:geneSymbol>CLCN4</dto:geneSymbol>
		<obo:IAO_0000115>The CLCN family of voltage-dependent chloride channel genes comprises nine members (CLCN1-7, Ka and Kb) which demonstrate quite diverse functional characteristics while sharing significant sequence homology. Chloride channel 4 has an evolutionary conserved CpG island and is conserved in both mouse and hamster. This gene is mapped in close proximity to APXL (Apical protein Xenopus laevis-like) and OA1 (Ocular albinism type I), which are both located on the human X chromosome at band p22.3. The physiological role of chloride channel 4 remains unknown but may contribute to the pathogenesis of neuronal disorders. Alternate splicing results in two transcript variants that encode different proteins. [provided by RefSeq, Mar 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200076 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200076">
		<rdfs:label rdf:datatype="&xsd;string">CLCN5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400399"/>
		<dto:entrez_xref>1184</dto:entrez_xref>
		<dto:geneSymbol>CLCN5</dto:geneSymbol>
		<dto:geneSynonym>CLCK2</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the ClC family of chloride ion channels and ion transporters. The encoded protein is primarily localized to endosomal membranes and may function to facilitate albumin uptake by the renal proximal tubule. Mutations in this gene have been found in Dent disease and renal tubular disorders complicated by nephrolithiasis. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jan 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200077 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200077">
		<rdfs:label rdf:datatype="&xsd;string">CLCN6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400400"/>
		<dto:entrez_xref>1185</dto:entrez_xref>
		<dto:geneSymbol>CLCN6</dto:geneSymbol>
		<dto:geneSynonym>KIAA0046</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the voltage-dependent chloride channel protein family. Members of this family can function as either chloride channels or antiporters. This protein is primarily localized to late endosomes and functions as a chloride/proton antiporter. Alternate splicing results in both coding and non-coding variants. Additional alternately spliced variants have been described but their full-length structure is unknown. [provided by RefSeq, Mar 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200078 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200078">
		<rdfs:label rdf:datatype="&xsd;string">CLCN7 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400401"/>
		<dto:entrez_xref>1186</dto:entrez_xref>
		<dto:geneSymbol>CLCN7</dto:geneSymbol>
		<obo:IAO_0000115>The product of this gene belongs to the CLC chloride channel family of proteins. Chloride channels play important roles in the plasma membrane and in intracellular organelles. This gene encodes chloride channel 7. Defects in this gene are the cause of osteopetrosis autosomal recessive type 4 (OPTB4), also called infantile malignant osteopetrosis type 2 as well as the cause of autosomal dominant osteopetrosis type 2 (OPTA2), also called autosomal dominant Albers-Schonberg disease or marble disease autosoml dominant. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. OPTA2 is the most common form of osteopetrosis, occurring in adolescence or adulthood. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200079 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200079">
		<rdfs:label rdf:datatype="&xsd;string">CLIC1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400342"/>
		<dto:entrez_xref>1192</dto:entrez_xref>
		<dto:geneSymbol>CLIC1</dto:geneSymbol>
		<dto:geneSynonym>NCC27</dto:geneSynonym>
		<dto:geneSynonym>G6</dto:geneSynonym>
		<obo:IAO_0000115>Chloride channels are a diverse group of proteins that regulate fundamental cellular processes including stabilization of cell membrane potential, transepithelial transport, maintenance of intracellular pH, and regulation of cell volume. Chloride intracellular channel 1  is a member of the p64 family; the protein localizes principally to the cell nucleus and exhibits both nuclear and plasma membrane chloride ion channel activity. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200080 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200080">
		<rdfs:label rdf:datatype="&xsd;string">CLIC2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400342"/>
		<dto:entrez_xref>1193</dto:entrez_xref>
		<dto:geneSymbol>CLIC2</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a chloride intracellular channel protein. Chloride channels are a diverse group of proteins that regulate fundamental cellular processes including stabilization of cell membrane potential, transepithelial transport, maintenance of intracellular pH, and regulation of cell volume. This protein may play a role in inhibiting the function of ryanodine receptor 2. A mutation in this gene is the cause of X-linked mental retardation-32. [provided by RefSeq, Aug 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200081 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200081">
		<rdfs:label rdf:datatype="&xsd;string">CLIC3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400342"/>
		<dto:entrez_xref>9022</dto:entrez_xref>
		<dto:geneSymbol>CLIC3</dto:geneSymbol>
		<obo:IAO_0000115>Chloride channels are a diverse group of proteins that regulate fundamental cellular processes including stabilization of cell membrane potential, transepithelial transport, maintenance of intracellular pH, and regulation of cell volume. Chloride intracellular channel 3 is a member of the p64 family and is predominantly localized in the nucleus and stimulates chloride ion channel activity. In addition, this protein may participate in cellular growth control, based on its association with ERK7, a member of the MAP kinase family. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200082 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200082">
		<rdfs:label rdf:datatype="&xsd;string">CLIC4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400342"/>
		<dto:entrez_xref>25932</dto:entrez_xref>
		<dto:geneSymbol>CLIC4</dto:geneSymbol>
		<obo:IAO_0000115>Chloride channels are a diverse group of proteins that regulate fundamental cellular processes including stabilization of cell membrane potential, transepithelial transport, maintenance of intracellular pH, and regulation of cell volume. Chloride intracellular channel 4 (CLIC4) protein, encoded by the CLIC4 gene, is a member of the p64 family; the gene is expressed in many tissues and exhibits a intracellular vesicular pattern in Panc-1 cells (pancreatic cancer cells). [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200083 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200083">
		<rdfs:label rdf:datatype="&xsd;string">CLIC5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400342"/>
		<dto:entrez_xref>53405</dto:entrez_xref>
		<dto:geneSymbol>CLIC5</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the chloride intracellular channel (CLIC) family of chloride ion channels. The encoded protein associates with actin-based cytoskeletal structures and may play a role in multiple processes including hair cell stereocilia formation, myoblast proliferation and glomerular podocyte and endothelial cell maintenance. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Dec 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200084 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200084">
		<rdfs:label rdf:datatype="&xsd;string">CLIC6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400342"/>
		<dto:entrez_xref>54102</dto:entrez_xref>
		<dto:geneSymbol>CLIC6</dto:geneSymbol>
		<dto:geneSynonym>CLIC1L</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the chloride intracellular channel family of proteins. The gene is part of a large triplicated region found on chromosomes 1, 6, and 21. An alternatively spliced transcript variant has been described, but its biological validity has not been determined. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200085 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200085">
		<rdfs:label rdf:datatype="&xsd;string">CNGA1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400402"/>
		<dto:entrez_xref>1259</dto:entrez_xref>
		<dto:geneSymbol>CNGA1</dto:geneSymbol>
		<dto:geneSynonym>CNCG1</dto:geneSynonym>
		<dto:geneSynonym>CNCG</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene is involved in phototransduction. Along with another protein, the encoded protein forms a cGMP-gated cation channel in the plasma membrane, allowing depolarization of rod photoreceptors. This represents the last step in the phototransduction pathway. Defects in this gene are a cause of retinitis pigmentosa autosomal recessive (ARRP) disease. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200086 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200086">
		<rdfs:label rdf:datatype="&xsd;string">CNGA2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400403"/>
		<dto:entrez_xref>1260</dto:entrez_xref>
		<dto:geneSymbol>CNGA2</dto:geneSymbol>
		<dto:geneSynonym>CNCA1</dto:geneSynonym>
		<dto:geneSynonym>CNCG2</dto:geneSynonym>
		<dto:geneSynonym>CNCA</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene represents the alpha subunit of a cyclic nucleotide-gated olfactory channel. The encoded protein contains a carboxy-terminal leucine zipper that mediates channel formation. [provided by RefSeq, Jan 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200087 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200087">
		<rdfs:label rdf:datatype="&xsd;string">CNGA3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400404"/>
		<dto:entrez_xref>1261</dto:entrez_xref>
		<dto:geneSymbol>CNGA3</dto:geneSymbol>
		<dto:geneSynonym>CNCG3</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the cyclic nucleotide-gated cation channel protein family which is required for normal vision and olfactory signal transduction. Mutations in this gene are associated with achromatopsia (rod monochromacy) and color blindness. Two alternatively spliced transcripts encoding different isoforms have been described. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200088 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200088">
		<rdfs:label rdf:datatype="&xsd;string">CNGA4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400405"/>
		<dto:entrez_xref>1262</dto:entrez_xref>
		<dto:geneSymbol>CNGA4</dto:geneSymbol>
		<obo:IAO_0000115>CNGA4 is a modulatory subunit of vertebrate cyclic nucleotide-gated membrane channels that transduce odorant signals (Munger et al., 2001 [PubMed 11739959]).[supplied by OMIM, Mar 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200089 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200089">
		<rdfs:label rdf:datatype="&xsd;string">CNGB1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400406"/>
		<dto:entrez_xref>1258</dto:entrez_xref>
		<dto:geneSymbol>CNGB1</dto:geneSymbol>
		<dto:geneSynonym>CNCG3L</dto:geneSynonym>
		<dto:geneSynonym>CNCG4</dto:geneSynonym>
		<dto:geneSynonym>CNCG2</dto:geneSynonym>
		<dto:geneSynonym>RCNC2</dto:geneSynonym>
		<obo:IAO_0000115>In humans, the rod photoreceptor cGMP-gated cation channel helps regulate ion flow into the rod photoreceptor outer segment in response to light-induced alteration of the levels of intracellular cGMP. This channel consists of two subunits, alpha and beta, with the protein encoded by this gene representing the beta subunit. Defects in this gene are a cause of cause of retinitis pigmentosa type 45. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200090 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200090">
		<rdfs:label rdf:datatype="&xsd;string">CNGB3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400407"/>
		<dto:entrez_xref>54714</dto:entrez_xref>
		<dto:geneSymbol>CNGB3</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes the beta subunit of a cyclic nucleotide-gated ion channel. The encoded beta subunit appears to play a role in modulation of channel function in cone photoreceptors. This heterotetrameric channel is necessary for sensory transduction, and mutations in this gene have been associated with achromatopsia 3, progressive cone dystrophy, and juvenile macular degeneration, also known as Stargardt Disease. [provided by RefSeq, Feb 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200091 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200091">
		<rdfs:label rdf:datatype="&xsd;string">ORAI1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400344"/>
		<dto:entrez_xref>84876</dto:entrez_xref>
		<dto:geneSymbol>ORAI1</dto:geneSymbol>
		<dto:geneSynonym>TMEM142A</dto:geneSynonym>
		<dto:geneSynonym>CRACM1</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene is a membrane calcium channel subunit that is activated by the calcium sensor STIM1 when calcium stores are depleted. This type of channel is the primary way for calcium influx into T-cells. Defects in this gene are a cause of immune dysfunction with T-cell inactivation due to calcium entry defect type 1 (IDTICED1). [provided by RefSeq, Sep 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200092 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200092">
		<rdfs:label rdf:datatype="&xsd;string">KCNIP3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
		<dto:geneSymbol>KCNIP3</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200093 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200093">
		<rdfs:label rdf:datatype="&xsd;string">CATSPER1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400345"/>
		<dto:entrez_xref>117144</dto:entrez_xref>
		<dto:geneSymbol>CATSPER1</dto:geneSymbol>
		<obo:IAO_0000115>Calcium ions play a primary role in the regulation of sperm motility. This gene belongs to a family of putative cation channels that are specific to spermatozoa and localize to the flagellum. The protein family features a single repeat with six membrane-spanning segments and a predicted calcium-selective pore region. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200094 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200094">
		<rdfs:label rdf:datatype="&xsd;string">CATSPER2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400345"/>
		<dto:entrez_xref>117155</dto:entrez_xref>
		<dto:geneSymbol>CATSPER2</dto:geneSymbol>
		<obo:IAO_0000115>Calcium ions play a primary role in the regulation of sperm motility. This gene belongs to a family of putative cation channels that are specific to spermatozoa and localize to the flagellum. The protein family features a single repeat with six membrane-spanning segments and a predicted calcium-selective pore region. This gene is part of a tandem repeat on chromosome 15q15; the second copy of this gene is thought to be a pseudogene. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jan 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200095 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200095">
		<rdfs:label rdf:datatype="&xsd;string">CATSPER3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400345"/>
		<dto:entrez_xref>347732</dto:entrez_xref>
		<dto:geneSymbol>CATSPER3</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200096 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200096">
		<rdfs:label rdf:datatype="&xsd;string">CATSPER4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400345"/>
		<dto:entrez_xref>378807</dto:entrez_xref>
		<dto:geneSymbol>CATSPER4</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200097 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200097">
		<rdfs:label rdf:datatype="&xsd;string">CYBB gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400346"/>
		<dto:entrez_xref>1536</dto:entrez_xref>
		<dto:geneSymbol>CYBB</dto:geneSymbol>
		<dto:geneSynonym>NOX2</dto:geneSynonym>
		<obo:IAO_0000115>Cytochrome b (-245) is composed of cytochrome b alpha (CYBA) and beta (CYBB) chain. It has been proposed as a primary component of the microbicidal oxidase system of phagocytes. CYBB deficiency is one of five described biochemical defects associated with chronic granulomatous disease (CGD). In this disorder, there is decreased activity of phagocyte NADPH oxidase; neutrophils are able to phagocytize bacteria but cannot kill them in the phagocytic vacuoles. The cause of the killing defect is an inability to increase the cell&apos;s respiration and consequent failure to deliver activated oxygen into the phagocytic vacuole. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200098 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200098">
		<rdfs:label rdf:datatype="&xsd;string">FAM26D gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400335"/>
		<dto:entrez_xref>221301</dto:entrez_xref>
		<dto:geneSymbol>FAM26D</dto:geneSymbol>
		<dto:geneSynonym>C6orf78</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200099 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200099">
		<rdfs:label rdf:datatype="&xsd;string">FAM26E gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400347"/>
		<dto:entrez_xref>254228</dto:entrez_xref>
		<dto:geneSymbol>FAM26E</dto:geneSymbol>
		<dto:geneSynonym>C6orf188</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200100 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200100">
		<rdfs:label rdf:datatype="&xsd;string">FAM26F gene</rdfs:label>
		<dto:geneSymbol>Protein FAM26F</dto:geneSymbol>
		<obo:IAO_0000115>A protein FAM26F that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q5R3K3] </obo:IAO_0000115>
		<dto:entrez_xref>441168</dto:entrez_xref>
		<dto:geneSynonym>C6orf187</dto:geneSynonym>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400347"/>
		<dto:geneSymbol>FAM26F</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200101 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200101">
		<rdfs:label rdf:datatype="&xsd;string">FXYD3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400348"/>
		<dto:entrez_xref>5349</dto:entrez_xref>
		<dto:geneSymbol>FXYD3</dto:geneSymbol>
		<dto:geneSynonym>PLML</dto:geneSynonym>
		<dto:geneSynonym>MAT8</dto:geneSynonym>
		<obo:IAO_0000115>This gene belongs to a small family of FXYD-domain containing regulators of Na+/K+ ATPases which share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD, and containing 7 invariant and 6 highly conserved amino acids. This gene encodes a cell membrane protein that may regulate the function of ion-pumps and ion-channels. This gene may also play a role in tumor progression. Alternative splicing results in multiple transcript variants encoding distinct isoforms.[provided by RefSeq, Oct 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200102 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200102">
		<rdfs:label rdf:datatype="&xsd;string">FXYD4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400348"/>
		<dto:entrez_xref>53828</dto:entrez_xref>
		<dto:geneSymbol>FXYD4</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. FXYD4, originally named CHIF for channel-inducing factor, has been shown to modulate the properties of the Na,K-ATPase, as has FXYD2, also known as the gamma subunit of the Na,K-ATPase, and FXYD7. Transmembrane topology has been established for FXYD4 and two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. Alternatively spliced transcript variants encoding the same protein have been found.[provided by RefSeq, May 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200103 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200103">
		<rdfs:label rdf:datatype="&xsd;string">FXYD5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400349"/>
		<dto:entrez_xref>53827</dto:entrez_xref>
		<dto:geneSymbol>FXYD5</dto:geneSymbol>
		<dto:geneSynonym>IWU1</dto:geneSynonym>
		<dto:geneSynonym>DYSAD</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Mouse FXYD5 has been termed RIC (Related to Ion Channel). FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. This gene product, FXYD5, is a glycoprotein that functions in the up-regulation of chemokine production, and it is involved in the reduction of cell adhesion via its ability to down-regulate E-cadherin. It also promotes metastasis, and has been linked to a variety of cancers. Alternative splicing results in multiple transcript variants. [RefSeq curation by Kathleen J. Sweadner, Ph.D., sweadner@helix.mgh.harvard.edu., Sep 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200104 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200104">
		<rdfs:label rdf:datatype="&xsd;string">FXYD6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400349"/>
		<dto:entrez_xref>100533181</dto:entrez_xref>
		<dto:entrez_xref>53826</dto:entrez_xref>
		<dto:geneSymbol>FXYD6</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the FXYD family of transmembrane proteins. This particular protein encodes phosphohippolin, which likely affects the activity of Na,K-ATPase. Multiple alternatively spliced transcript variants encoding the same protein have been described. Related pseudogenes have been identified on chromosomes 10 and X. Read-through transcripts have been observed between this locus and the downstream sodium/potassium-transporting ATPase subunit gamma (FXYD2, GeneID 486) locus.[provided by RefSeq, Feb 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200105 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200105">
		<rdfs:label rdf:datatype="&xsd;string">FXYD7 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400348"/>
		<dto:entrez_xref>53822</dto:entrez_xref>
		<dto:geneSymbol>FXYD7</dto:geneSymbol>
		<obo:IAO_0000115>This reference sequence was derived from multiple replicate ESTs and validated by similar human genomic sequence. This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. This gene product, FXYD7, is novel and has not been characterized as a protein. [RefSeq curation by Kathleen J. Sweadner, Ph.D., sweadner@helix.mgh.harvard.edu., Dec 2000]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200106 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200106">
		<rdfs:label rdf:datatype="&xsd;string">FXYD6P3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400348"/>
		<dto:entrez_xref>406875</dto:entrez_xref>
		<dto:geneSymbol>FXYD6P3</dto:geneSymbol>
		<dto:geneSynonym>FXYD8</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200107 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200107">
		<rdfs:label rdf:datatype="&xsd;string">GABRA1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400506"/>
		<dto:entrez_xref>2554</dto:entrez_xref>
		<dto:geneSymbol>GABRA1</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. Mutations in this gene cause juvenile myoclonic epilepsy and childhood absence epilepsy type 4. Multiple transcript variants encoding the same protein have been identified for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200108 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200108">
		<rdfs:label rdf:datatype="&xsd;string">GABRA2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400507"/>
		<dto:entrez_xref>2555</dto:entrez_xref>
		<dto:geneSymbol>GABRA2</dto:geneSymbol>
		<obo:IAO_0000115>GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200109 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200109">
		<rdfs:label rdf:datatype="&xsd;string">GABRA3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400508"/>
		<dto:entrez_xref>2556</dto:entrez_xref>
		<dto:geneSymbol>GABRA3</dto:geneSymbol>
		<obo:IAO_0000115>GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200110 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200110">
		<rdfs:label rdf:datatype="&xsd;string">GABRA4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400509"/>
		<dto:entrez_xref>2557</dto:entrez_xref>
		<dto:geneSymbol>GABRA4</dto:geneSymbol>
		<obo:IAO_0000115>Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. This gene encodes subunit alpha-4, which is involved in the etiology of autism and eventually increases autism risk through interaction with another subunit, gamma-aminobutyric acid receptor beta-1 (GABRB1). Alternatively spliced transcript variants encoding different isoforms have been found in this gene.[provided by RefSeq, Feb 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200111 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200111">
		<rdfs:label rdf:datatype="&xsd;string">GABRA5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400510"/>
		<dto:entrez_xref>2558</dto:entrez_xref>
		<dto:geneSymbol>GABRA5</dto:geneSymbol>
		<obo:IAO_0000115>GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Transcript variants utilizing three different alternative non-coding first exons have been described. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200112 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200112">
		<rdfs:label rdf:datatype="&xsd;string">GABRA6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400511"/>
		<dto:entrez_xref>2559</dto:entrez_xref>
		<dto:geneSymbol>GABRA6</dto:geneSymbol>
		<obo:IAO_0000115>GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200113 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200113">
		<rdfs:label rdf:datatype="&xsd;string">GABRB1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400512"/>
		<dto:entrez_xref>2560</dto:entrez_xref>
		<dto:geneSymbol>GABRB1</dto:geneSymbol>
		<obo:IAO_0000115>The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes GABA A receptor, beta 1 subunit. It is mapped to chromosome 4p12 in a cluster comprised of genes encoding alpha 4, alpha 2 and gamma 1 subunits of the GABA A receptor. Alteration of this gene is implicated in the pathogenetics of schizophrenia. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200114 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200114">
		<rdfs:label rdf:datatype="&xsd;string">GABRB2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400513"/>
		<dto:entrez_xref>2561</dto:entrez_xref>
		<dto:geneSymbol>GABRB2</dto:geneSymbol>
		<obo:IAO_0000115>The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes GABA A receptor, beta 2 subunit. It is mapped to chromosome 5q34 in a cluster comprised of genes encoding alpha 1 and gamma 2 subunits of the GABA A receptor. Alternative splicing of this gene generates 2 transcript variants, differing by a 114 bp insertion. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200115 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200115">
		<rdfs:label rdf:datatype="&xsd;string">GABRB3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400514"/>
		<dto:entrez_xref>2562</dto:entrez_xref>
		<dto:geneSymbol>GABRB3</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the ligand-gated ionic channel family. The encoded protein is one the subunits of a multi-subunit chloride channel that serves as the receptor for gamma-aminobutyric acid, a major inhibitory neurotransmitter of the mammalian nervous system. This gene is located on the long arm of chromosome 15 in a cluster with two other genes encoding related subunits of the family. This gene may be associated with the pathogenesis of several disorders including Angelman syndrome, Prader-Willi syndrome, nonsyndromic orofacial clefts, epilepsy and autism. Alternatively spliced transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Jul 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200116 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200116">
		<rdfs:label rdf:datatype="&xsd;string">GABRD gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400515"/>
		<dto:entrez_xref>2563</dto:entrez_xref>
		<dto:geneSymbol>GABRD</dto:geneSymbol>
		<obo:IAO_0000115>Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. The GABA-A receptor is generally pentameric and there are five types of subunits: alpha, beta, gamma, delta, and rho. This gene encodes the delta subunit. Mutations in this gene have been associated with susceptibility to generalized epilepsy with febrile seizures, type 5. Alternatively spliced transcript variants have been described for this gene, but their biological validity has not been determined. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200117 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200117">
		<rdfs:label rdf:datatype="&xsd;string">GABRE gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400516"/>
		<dto:entrez_xref>2564</dto:entrez_xref>
		<dto:geneSymbol>GABRE</dto:geneSymbol>
		<obo:IAO_0000115>The product of this gene belongs to the ligand-gated ionic channel (TC 1.A.9) family. It encodes the gamma-aminobutyric acid (GABA) A receptor which is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes an epsilon subunit. It is mapped to chromosome Xq28 in a cluster comprised of genes encoding alpha 3, beta 4 and theta subunits of the same receptor. Alternatively spliced transcript variants have been identified, but only one is thought to encode a protein. [provided by RefSeq, Oct 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200118 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200118">
		<rdfs:label rdf:datatype="&xsd;string">GABRG1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400517"/>
		<dto:entrez_xref>2565</dto:entrez_xref>
		<dto:geneSymbol>GABRG1</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded by this gene belongs to the ligand-gated ionic channel family. It is an integral membrane protein and plays an important role in inhibiting neurotransmission by binding to the benzodiazepine receptor and opening an integral chloride channel. This gene is clustered with three other family members on chromosome 4. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200119 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200119">
		<rdfs:label rdf:datatype="&xsd;string">GABRG2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400518"/>
		<dto:entrez_xref>2566</dto:entrez_xref>
		<dto:geneSymbol>GABRG2</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammlian brain, where it acts at GABA-A receptors, which are ligand-gated chloride channels. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. Mutations in this gene have been associated with epilepsy and febrile seizures. Multiple transcript variants encoding different isoforms have been identified for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200120 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200120">
		<rdfs:label rdf:datatype="&xsd;string">GABRG3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400519"/>
		<dto:entrez_xref>2567</dto:entrez_xref>
		<dto:geneSymbol>GABRG3</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. The protein encoded by this gene is a gamma subunit, which contains the benzodiazepine binding site. Two transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Aug 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200121 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200121">
		<rdfs:label rdf:datatype="&xsd;string">GABRP gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400520"/>
		<dto:entrez_xref>2568</dto:entrez_xref>
		<dto:geneSymbol>GABRP</dto:geneSymbol>
		<obo:IAO_0000115>The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. The subunit encoded by this gene is expressed in several non-neuronal tissues including the uterus and ovaries. This subunit can assemble with known GABA A receptor subunits, and the presence of this subunit alters the sensitivity of recombinant receptors to modulatory agents such as pregnanolone. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200122 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200122">
		<rdfs:label rdf:datatype="&xsd;string">GABRR1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400521"/>
		<dto:entrez_xref>2569</dto:entrez_xref>
		<dto:geneSymbol>GABRR1</dto:geneSymbol>
		<obo:IAO_0000115>GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA receptors, which are ligand-gated chloride channels. GABRR1 is a member of the rho subunit family. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200123 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200123">
		<rdfs:label rdf:datatype="&xsd;string">GABRR2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400522"/>
		<dto:entrez_xref>2570</dto:entrez_xref>
		<dto:geneSymbol>GABRR2</dto:geneSymbol>
		<obo:IAO_0000115>GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA receptors, which are ligand-gated chloride channels. The protein encoded by this gene is a member of the rho subunit family and is a component of the GABA receptor complex. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200124 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200124">
		<rdfs:label rdf:datatype="&xsd;string">GABRR3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400523"/>
		<dto:entrez_xref>200959</dto:entrez_xref>
		<dto:geneSymbol>GABRR3</dto:geneSymbol>
		<obo:IAO_0000115>The neurotransmitter gamma-aminobutyric acid (GABA) functions in the central nervous system to regulate synaptic transmission of neurons. This gene encodes one of three related subunits, which combine as homo- or hetero-pentamers to form GABA(C) receptors. In humans, some individuals contain a single-base polymorphism (dbSNP rs832032) that is predicted to inactivate the gene product. [provided by RefSeq, Jan 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200125 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200125">
		<rdfs:label rdf:datatype="&xsd;string">GABRQ gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400524"/>
		<dto:entrez_xref>55879</dto:entrez_xref>
		<dto:geneSymbol>GABRQ</dto:geneSymbol>
		<obo:IAO_0000115>The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes the theta subunit of the GABA A receptor. The gene is mapped to chromosome Xq28 in a cluster of genes including those that encode the alpha 3 and epsilon subunits of the GABA A receptor. This gene location is also the candidate region of two different neurologic diseases: early-onset parkinsonism (Waisman syndrome) and X-linked mental retardation (MRX3). [provided by RefSeq, Nov 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200126 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200126">
		<rdfs:label rdf:datatype="&xsd;string">GLRA1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400525"/>
		<dto:entrez_xref>2741</dto:entrez_xref>
		<dto:geneSymbol>GLRA1</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded by this gene is a subunit of a pentameric inhibitory glycine receptor. The receptor mediates postsynaptic inhibition in the central nervous system. Defects in this gene are a cause of startle disease (STHE), also known as hereditary hyperekplexia or congenital stiff-person syndrome. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200127 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200127">
		<rdfs:label rdf:datatype="&xsd;string">GLRA2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400526"/>
		<dto:entrez_xref>2742</dto:entrez_xref>
		<dto:geneSymbol>GLRA2</dto:geneSymbol>
		<obo:IAO_0000115>The glycine receptor consists of two subunits, alpha and beta, and acts as a pentamer. The protein encoded by this gene is an alpha subunit and can bind strychnine. Several transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200128 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200128">
		<rdfs:label rdf:datatype="&xsd;string">GLRA3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400527"/>
		<dto:entrez_xref>8001</dto:entrez_xref>
		<dto:geneSymbol>GLRA3</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the ligand-gated ion channel protein family. The encoded protein is a member of the glycine receptor subfamily. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200129 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200129">
		<rdfs:label rdf:datatype="&xsd;string">GLRA4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400528"/>
		<dto:entrez_xref>441509</dto:entrez_xref>
		<dto:geneSymbol>GLRA4</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a protein which has a neurotransmitter-gated ion-channel ligand binding domain. The encoded protein is very similar to a mouse protein which is a subunit of the retinal glycine receptor. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200130 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200130">
		<rdfs:label rdf:datatype="&xsd;string">GLRB gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400529"/>
		<dto:entrez_xref>2743</dto:entrez_xref>
		<dto:geneSymbol>GLRB</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes the beta subunit of the glycine receptor, which is a pentamer composed of alpha and beta subunits. The receptor functions as a neurotransmitter-gated ion channel, which produces hyperpolarization via increased chloride conductance due to the binding of glycine to the receptor. Mutations in this gene cause startle disease, also known as hereditary hyperekplexia or congenital stiff-person syndrome, a disease characterized by muscular rigidity. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200131 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200131">
		<rdfs:label rdf:datatype="&xsd;string">GPR89A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400350"/>
		<dto:entrez_xref>51463</dto:entrez_xref>
		<dto:entrez_xref>653519</dto:entrez_xref>
		<dto:geneSymbol>GPR89A</dto:geneSymbol>
		<dto:geneSynonym>GPR89</dto:geneSynonym>
		<dto:geneSynonym>SH120</dto:geneSynonym>
		<dto:geneSynonym>GPHRA</dto:geneSynonym>
		<obo:IAO_0000115>GPR89A is a nearly identical copy of the GPR89B gene (MIM 612806).[supplied by OMIM, Jun 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200132 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200132">
		<rdfs:label rdf:datatype="&xsd;string">GPR89B gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400350"/>
		<dto:entrez_xref>51463</dto:entrez_xref>
		<dto:entrez_xref>653519</dto:entrez_xref>
		<dto:geneSymbol>GPR89B</dto:geneSymbol>
		<dto:geneSynonym>GPHRB</dto:geneSynonym>
		<obo:IAO_0000115>GPR89A is a nearly identical copy of the GPR89B gene (MIM 612806).[supplied by OMIM, Jun 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200133 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200133">
		<rdfs:label rdf:datatype="&xsd;string">GRIA1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400410"/>
		<dto:entrez_xref>2890</dto:entrez_xref>
		<dto:geneSymbol>GRIA1</dto:geneSymbol>
		<dto:geneSynonym>GLUR1</dto:geneSynonym>
		<dto:geneSynonym>GLUH1</dto:geneSynonym>
		<obo:IAO_0000115>Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes with multiple subunits, each possessing transmembrane regions, and all arranged to form a ligand-gated ion channel. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. This gene belongs to a family of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200134 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200134">
		<rdfs:label rdf:datatype="&xsd;string">GRIA2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400411"/>
		<dto:entrez_xref>2891</dto:entrez_xref>
		<dto:geneSymbol>GRIA2</dto:geneSymbol>
		<dto:geneSynonym>GLUR2</dto:geneSynonym>
		<obo:IAO_0000115>Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. This gene product belongs to a family of glutamate receptors that are sensitive to alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), and function as ligand-activated cation channels. These channels are assembled from 4 related subunits, GRIA1-4. The subunit encoded by this gene (GRIA2) is subject to RNA editing (CAG-&amp;gt;CGG; Q-&amp;gt;R) within the second transmembrane domain, which is thought to render the channel impermeable to Ca(2+). Human and animal studies suggest that pre-mRNA editing is essential for brain function, and defective GRIA2 RNA editing at the Q/R site may be relevant to amyotrophic lateral sclerosis (ALS) etiology. Alternative splicing, resulting in transcript variants encoding different isoforms, (including the flip and flop isoforms that vary in their signal transduction properties), has been noted for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200135 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200135">
		<rdfs:label rdf:datatype="&xsd;string">GRIA3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400412"/>
		<dto:entrez_xref>2892</dto:entrez_xref>
		<dto:geneSymbol>GRIA3</dto:geneSymbol>
		<dto:geneSynonym>GLURC</dto:geneSynonym>
		<dto:geneSynonym>GLUR3</dto:geneSynonym>
		<obo:IAO_0000115>Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes composed of multiple subunits, arranged to form ligand-gated ion channels. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. The subunit encoded by this gene belongs to a family of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate)-sensitive glutamate receptors, and is subject to RNA editing (AGA-&amp;gt;GGA; R-&amp;gt;G). Alternative splicing at this locus results in different isoforms, which may vary in their signal transduction properties. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200136 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200136">
		<rdfs:label rdf:datatype="&xsd;string">GRIA4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400413"/>
		<dto:entrez_xref>2893</dto:entrez_xref>
		<dto:geneSymbol>GRIA4</dto:geneSymbol>
		<dto:geneSynonym>GLUR4</dto:geneSynonym>
		<obo:IAO_0000115>Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes composed of multiple subunits, arranged to form ligand-gated ion channels. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. The subunit encoded by this gene belongs to a family of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate)-sensitive glutamate receptors, and is subject to RNA editing (AGA-&amp;gt;GGA; R-&amp;gt;G). Alternative splicing of this gene results in transcript variants encoding different isoforms, which may vary in their signal transduction properties. Some haplotypes of this gene show a positive association with schizophrenia. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200137 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200137">
		<rdfs:label rdf:datatype="&xsd;string">GRID1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400414"/>
		<dto:entrez_xref>2894</dto:entrez_xref>
		<dto:geneSymbol>GRID1</dto:geneSymbol>
		<dto:geneSynonym>KIAA1220</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a subunit of glutamate receptor channels. These channels mediate most of the fast excitatory synaptic transmission in the central nervous system and play key roles in synaptic plasticity.[provided by RefSeq, Jan 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200138 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200138">
		<rdfs:label rdf:datatype="&xsd;string">GRID2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400415"/>
		<dto:entrez_xref>2895</dto:entrez_xref>
		<dto:geneSymbol>GRID2</dto:geneSymbol>
		<dto:geneSynonym>GLURD2</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene is a member of the family of ionotropic glutamate receptors which are the predominant excitatory neurotransmitter receptors in the mammalian brain. The encoded protein is a multi-pass membrane protein that is expressed selectively in cerebellar Purkinje cells. A point mutation in the mouse ortholog, associated with the phenotype named &apos;lurcher&apos;, in the heterozygous state leads to ataxia resulting from selective, cell-autonomous apoptosis of cerebellar Purkinje cells during postnatal development. Mice homozygous for this mutation die shortly after birth from massive loss of mid- and hindbrain neurons during late embryogenesis. This protein also plays a role in synapse organization between parallel fibers and Purkinje cells. Alternate splicing results in multiple transcript variants encoding distinct isoforms. Mutations in this gene cause cerebellar ataxia in humans. [provided by RefSeq, Apr 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200139 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200139">
		<rdfs:label rdf:datatype="&xsd;string">GRIK1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400416"/>
		<dto:entrez_xref>2897</dto:entrez_xref>
		<dto:geneSymbol>GRIK1</dto:geneSymbol>
		<dto:geneSynonym>GLUR5</dto:geneSynonym>
		<obo:IAO_0000115>Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. This gene product belongs to the kainate family of glutamate receptors, which are composed of four subunits and function as ligand-activated ion channels. The subunit encoded by this gene is subject to RNA editing (CAG-&amp;gt;CGG; Q-&amp;gt;R) within the second transmembrane domain, which is thought to alter the properties of ion flow. Alternative splicing, resulting in transcript variants encoding different isoforms, has been noted for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200140 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200140">
		<rdfs:label rdf:datatype="&xsd;string">GRIK2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400417"/>
		<dto:entrez_xref>2898</dto:entrez_xref>
		<dto:geneSymbol>GRIK2</dto:geneSymbol>
		<dto:geneSynonym>GLUR6</dto:geneSynonym>
		<obo:IAO_0000115>Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. This gene product belongs to the kainate family of glutamate receptors, which are composed of four subunits and function as ligand-activated ion channels. The subunit encoded by this gene is subject to RNA editing at multiple sites within the first and second transmembrane domains, which is thought to alter the structure and function of the receptor complex. Alternatively spliced transcript variants encoding different isoforms have also been described for this gene. Mutations in this gene have been associated with autosomal recessive mental retardation. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200141 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200141">
		<rdfs:label rdf:datatype="&xsd;string">GRIK3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400418"/>
		<dto:entrez_xref>2899</dto:entrez_xref>
		<dto:geneSymbol>GRIK3</dto:geneSymbol>
		<dto:geneSynonym>GLUR7</dto:geneSynonym>
		<obo:IAO_0000115>Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. This gene product belongs to the kainate family of glutamate receptors, which are composed of four subunits and function as ligand-activated ion channels. It is not certain if the subunit encoded by this gene is subject to RNA editing as the other 2 family members (GRIK1 and GRIK2). A Ser310Ala polymorphism has been associated with schizophrenia, and there are conflicting reports of its association with the pathogenesis of delirium tremens in alcoholics. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200142 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200142">
		<rdfs:label rdf:datatype="&xsd;string">GRIK4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400419"/>
		<dto:entrez_xref>2900</dto:entrez_xref>
		<dto:geneSymbol>GRIK4</dto:geneSymbol>
		<dto:geneSynonym>GRIK</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a protein that belongs to the glutamate-gated ionic channel family. Glutamate functions as the major excitatory neurotransmitter in the central nervous system through activation of ligand-gated ion channels and G protein-coupled membrane receptors. The protein encoded by this gene forms functional heteromeric kainate-preferring ionic channels with the subunits encoded by related gene family members. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200143 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200143">
		<rdfs:label rdf:datatype="&xsd;string">GRIK5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400420"/>
		<dto:entrez_xref>2901</dto:entrez_xref>
		<dto:geneSymbol>GRIK5</dto:geneSymbol>
		<dto:geneSynonym>GRIK2</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a protein that belongs to the glutamate-gated ionic channel family. Glutamate functions as the major excitatory neurotransmitter in the central nervous system through activation of ligand-gated ion channels and G protein-coupled membrane receptors. The protein encoded by this gene forms functional heteromeric kainate-preferring ionic channels with the subunits encoded by related gene family members. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200144 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200144">
		<rdfs:label rdf:datatype="&xsd;string">HCN1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400343"/>
		<dto:entrez_xref>348980</dto:entrez_xref>
		<dto:geneSymbol>HCN1</dto:geneSymbol>
		<dto:geneSynonym>BCNG1</dto:geneSynonym>
		<obo:IAO_0000115>The membrane protein encoded by this gene is a hyperpolarization-activated cation channel that contributes to the native pacemaker currents in heart and neurons. The encoded protein can homodimerize or heterodimerize with other pore-forming subunits to form a potassium channel. This channel may act as a receptor for sour tastes. [provided by RefSeq, Oct 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200145 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200145">
		<rdfs:label rdf:datatype="&xsd;string">HCN2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400343"/>
		<dto:entrez_xref>610</dto:entrez_xref>
		<dto:geneSymbol>HCN2</dto:geneSymbol>
		<dto:geneSynonym>BCNG2</dto:geneSynonym>
		<obo:IAO_0000115>Hyperpolarization-activated cation channels of the HCN gene family, such as HCN2, contribute to spontaneous rhythmic activity in both heart and brain.[supplied by OMIM, Jul 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200146 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200146">
		<rdfs:label rdf:datatype="&xsd;string">HCN3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400343"/>
		<dto:entrez_xref>57657</dto:entrez_xref>
		<dto:geneSymbol>HCN3</dto:geneSymbol>
		<dto:geneSynonym>KIAA1535</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a multi-pass membrane protein that functions as a voltage gated cation channel. The encoded protein is a member of a family of closely related cyclic adenosine monophosphate-binding channel proteins. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200147 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200147">
		<rdfs:label rdf:datatype="&xsd;string">HCN4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400343"/>
		<dto:entrez_xref>10021</dto:entrez_xref>
		<dto:geneSymbol>HCN4</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the hyperpolarization-activated cyclic nucleotide-gated potassium channels. The encoded protein shows slow kinetics of activation and inactivation, and is necessary for the cardiac pacemaking process. This channel may also mediate responses to sour stimuli. Mutations in this gene have been linked to sick sinus syndrome 2, also known as atrial fibrillation with bradyarrhythmia or familial sinus bradycardia. Two pseudogenes have been identified on chromosome 15. [provided by RefSeq, Oct 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200148 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200148">
		<rdfs:label rdf:datatype="&xsd;string">HVCN1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400352"/>
		<dto:entrez_xref>84329</dto:entrez_xref>
		<dto:geneSymbol>HVCN1</dto:geneSymbol>
		<dto:geneSynonym>VSOP</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a voltage-gated protein channel protein expressed more highly in certain cells of the immune system. Phagocytic cells produce superoxide anions which require this channel protein, and in B cells this same process facilitates antibody production. This same channel protein, however, can also regulate functions in other cells including spermatozoa. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200149 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200149">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ10 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400421"/>
		<dto:entrez_xref>3766</dto:entrez_xref>
		<dto:geneSymbol>KCNJ10</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the inward rectifier-type potassium channel family, characterized by having a greater tendency to allow potassium to flow into, rather than out of, a cell. The encoded protein may form a heterodimer with another potassium channel protein and may be responsible for the potassium buffering action of glial cells in the brain. Mutations in this gene have been associated with seizure susceptibility of common idiopathic generalized epilepsy syndromes. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200150 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200150">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ11 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400422"/>
		<dto:entrez_xref>3767</dto:entrez_xref>
		<dto:geneSymbol>KCNJ11</dto:geneSymbol>
		<obo:IAO_0000115>Potassium channels are present in most mammalian cells, where they participate in a wide range of physiologic responses. The protein encoded by this gene is an integral membrane protein and inward-rectifier type potassium channel. The encoded protein, which has a greater tendency to allow potassium to flow into a cell rather than out of a cell, is controlled by G-proteins and is found associated with the sulfonylurea receptor SUR. Mutations in this gene are a cause of familial persistent hyperinsulinemic hypoglycemia of infancy (PHHI), an autosomal recessive disorder characterized by unregulated insulin secretion. Defects in this gene may also contribute to autosomal dominant non-insulin-dependent diabetes mellitus type II (NIDDM), transient neonatal diabetes mellitus type 3 (TNDM3), and permanent neonatal diabetes mellitus (PNDM). Multiple alternatively spliced transcript variants that encode different protein isoforms have been described for this gene. [provided by RefSeq, Oct 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200151 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200151">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ12 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400423"/>
		<dto:entrez_xref>3768</dto:entrez_xref>
		<dto:geneSymbol>KCNJ12</dto:geneSymbol>
		<dto:geneSynonym>KCNJN1</dto:geneSynonym>
		<dto:geneSynonym>IRK2</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes an inwardly rectifying K+ channel which may be blocked by divalent cations. This protein is thought to be one of multiple inwardly rectifying channels which contribute to the cardiac inward rectifier current (IK1). The gene is located within the Smith-Magenis syndrome region on chromosome 17. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200152 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200152">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ13 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400424"/>
		<dto:entrez_xref>3769</dto:entrez_xref>
		<dto:geneSymbol>KCNJ13</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the inwardly rectifying potassium channel family of proteins. Members of this family form ion channel pores that allow potassium ions to pass into a cell. The encoded protein belongs to a subfamily of low signal channel conductance proteins that have a low dependence on potassium concentration. Mutations in this gene are associated with snowflake vitreoretinal degeneration. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Feb 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200153 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200153">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ14 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400425"/>
		<dto:entrez_xref>3770</dto:entrez_xref>
		<dto:geneSymbol>KCNJ14</dto:geneSymbol>
		<dto:geneSynonym>IRK4</dto:geneSynonym>
		<obo:IAO_0000115>Potassium channels are present in most mammalian cells, where they participate in a wide range of physiologic responses. The protein encoded by this gene is an integral membrane protein and inward-rectifier type potassium channel, and probably has a role in controlling the excitability of motor neurons. [provided by RefSeq, Feb 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200154 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200154">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ15 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400426"/>
		<dto:entrez_xref>3772</dto:entrez_xref>
		<dto:geneSymbol>KCNJ15</dto:geneSymbol>
		<dto:geneSynonym>KCNJ14</dto:geneSynonym>
		<obo:IAO_0000115>Potassium channels are present in most mammalian cells, where they participate in a wide range of physiologic responses. The protein encoded by this gene is an integral membrane protein and inward-rectifier type potassium channel. The encoded protein has a greater tendency to allow potassium to flow into a cell rather than out of a cell. Eight transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Feb 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200155 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200155">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ16 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400427"/>
		<dto:entrez_xref>3773</dto:entrez_xref>
		<dto:geneSymbol>KCNJ16</dto:geneSymbol>
		<obo:IAO_0000115>Potassium channels are present in most mammalian cells, where they participate in a wide range of physiologic responses. The protein encoded by this gene is an integral membrane protein and inward-rectifier type potassium channel. The encoded protein, which tends to allow potassium to flow into rather than out of a cell, can form heterodimers with two other inward-rectifier type potassium channels. It may function in fluid and pH balance regulation. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Apr 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200156 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200156">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ18 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400423"/>
		<dto:entrez_xref>100134444</dto:entrez_xref>
		<dto:geneSymbol>KCNJ18</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the inwardly rectifying potassium channel family. Transcription of this locus is regulated by thyroid hormone, and the encoded protein plays a role in resting membrane potential maintenance. Mutations in this locus have been associated with thyrotoxic hypokalemic periodic paralysis. [provided by RefSeq, Jan 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200157 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200157">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400428"/>
		<dto:entrez_xref>3758</dto:entrez_xref>
		<dto:geneSymbol>KCNJ1</dto:geneSymbol>
		<dto:geneSynonym>ROMK1</dto:geneSynonym>
		<obo:IAO_0000115>Potassium channels are present in most mammalian cells, where they participate in a wide range of physiologic responses. The protein encoded by this gene is an integral membrane protein and inward-rectifier type potassium channel. It is activated by internal ATP and probably plays an important role in potassium homeostasis. The encoded protein has a greater tendency to allow potassium to flow into a cell rather than out of a cell. Mutations in this gene have been associated with antenatal Bartter syndrome, which is characterized by salt wasting, hypokalemic alkalosis, hypercalciuria, and low blood pressure. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200158 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200158">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400429"/>
		<dto:entrez_xref>3759</dto:entrez_xref>
		<dto:geneSymbol>KCNJ2</dto:geneSymbol>
		<dto:geneSynonym>IRK1</dto:geneSynonym>
		<obo:IAO_0000115>Potassium channels are present in most mammalian cells, where they participate in a wide range of physiologic responses. The protein encoded by this gene is an integral membrane protein and inward-rectifier type potassium channel. The encoded protein, which has a greater tendency to allow potassium to flow into a cell rather than out of a cell, probably participates in establishing action potential waveform and excitability of neuronal and muscle tissues. Mutations in this gene have been associated with Andersen syndrome, which is characterized by periodic paralysis, cardiac arrhythmias, and dysmorphic features. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200159 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200159">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400430"/>
		<dto:entrez_xref>3760</dto:entrez_xref>
		<dto:geneSymbol>KCNJ3</dto:geneSymbol>
		<dto:geneSynonym>GIRK1</dto:geneSynonym>
		<obo:IAO_0000115>Potassium channels are present in most mammalian cells, where they participate in a wide range of physiologic responses. The protein encoded by this gene is an integral membrane protein and inward-rectifier type potassium channel. The encoded protein, which has a greater tendency to allow potassium to flow into a cell rather than out of a cell, is controlled by G-proteins and plays an important role in regulating heartbeat. It associates with three other G-protein-activated potassium channels to form a heteromultimeric pore-forming complex that also couples to neurotransmitter receptors in the brain and whereby channel activation can inhibit action potential firing by hyperpolarizing the plasma membrane. These multimeric G-protein-gated inwardly-rectifying potassium (GIRK) channels may play a role in the pathophysiology of epilepsy, addiction, Down&apos;s syndrome, ataxia, and Parkinson&apos;s disease. Alternative splicing results in multiple transcript variants encoding distinct proteins. [provided by RefSeq, May 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200160 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200160">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400431"/>
		<dto:entrez_xref>3761</dto:entrez_xref>
		<dto:geneSymbol>KCNJ4</dto:geneSymbol>
		<dto:geneSynonym>IRK3</dto:geneSynonym>
		<obo:IAO_0000115>Several different potassium channels are known to be involved with electrical signaling in the nervous system. One class is activated by depolarization whereas a second class is not. The latter are referred to as inwardly rectifying K+ channels, and they have a greater tendency to allow potassium to flow into the cell rather than out of it. This asymmetry in potassium ion conductance plays a key role in the excitability of muscle cells and neurons. The protein encoded by this gene is an integral membrane protein and member of the inward rectifier potassium channel family. The encoded protein has a small unitary conductance compared to other members of this protein family. Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200161 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200161">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400432"/>
		<dto:entrez_xref>3762</dto:entrez_xref>
		<dto:geneSymbol>KCNJ5</dto:geneSymbol>
		<dto:geneSynonym>GIRK4</dto:geneSynonym>
		<obo:IAO_0000115>Potassium channels are present in most mammalian cells, where they participate in a wide range of physiologic responses. The protein encoded by this gene is an integral membrane protein and inward-rectifier type potassium channel. The encoded protein, which has a greater tendency to allow potassium to flow into a cell rather than out of a cell, is controlled by G-proteins. It may associate with two other G-protein-activated potassium channels to form a heteromultimeric pore-forming complex. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200162 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200162">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400433"/>
		<dto:entrez_xref>3763</dto:entrez_xref>
		<dto:geneSymbol>KCNJ6</dto:geneSymbol>
		<obo:IAO_0000115>Potassium channels are present in most mammalian cells, where they participate in a wide range of physiologic responses. The protein encoded by this gene is an integral membrane protein and inward-rectifier type potassium channel. The encoded protein, which has a greater tendency to allow potassium to flow into a cell rather than out of a cell, is controlled by G-proteins and may be involved in the regulation of insulin secretion by glucose. It associates with two other G-protein-activated potassium channels to form a heteromultimeric pore-forming complex. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
		<dto:geneSynonym>GIRK2</dto:geneSynonym>
		<dto:geneSynonym>KATP2</dto:geneSynonym>
		<dto:geneSynonym>KCNJ7</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200163 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200163">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ8 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400434"/>
		<dto:entrez_xref>3764</dto:entrez_xref>
		<dto:geneSymbol>KCNJ8</dto:geneSymbol>
		<obo:IAO_0000115>Potassium channels are present in most mammalian cells, where they participate in a wide range of physiologic responses. The protein encoded by this gene is an integral membrane protein and inward-rectifier type potassium channel. The encoded protein, which has a greater tendency to allow potassium to flow into a cell rather than out of a cell, is controlled by G-proteins. Defects in this gene may be a cause of J-wave syndromes and sudden infant death syndrome (SIDS). [provided by RefSeq, May 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200164 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200164">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ9 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400435"/>
		<dto:entrez_xref>3765</dto:entrez_xref>
		<dto:geneSymbol>KCNJ9</dto:geneSymbol>
		<dto:geneSynonym>GIRK3</dto:geneSynonym>
		<obo:IAO_0000115>Potassium channels are present in most mammalian cells, where they participate in a wide range of physiologic responses. The protein encoded by this gene is an integral membrane protein and inward-rectifier type potassium channel. The encoded protein, which has a greater tendency to allow potassium to flow into a cell rather than out of a cell, is controlled by G-proteins. It associates with another G-protein-activated potassium channel to form a heteromultimeric pore-forming complex. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200165 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200165">
		<rdfs:label rdf:datatype="&xsd;string">ITPR1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400354"/>
		<dto:entrez_xref>3708</dto:entrez_xref>
		<dto:geneSymbol>ITPR1</dto:geneSymbol>
		<dto:geneSynonym>INSP3R1</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes an intracellular receptor for inositol 1,4,5-trisphosphate. Upon stimulation by inositol 1,4,5-trisphosphate, this receptor mediates calcium release from the endoplasmic reticulum. Mutations in this gene cause spinocerebellar ataxia type 15, a disease associated with an heterogeneous group of cerebellar disorders. Multiple transcript variants have been identified for this gene. [provided by RefSeq, Nov 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200166 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200166">
		<rdfs:label rdf:datatype="&xsd;string">ITPR2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400354"/>
		<dto:entrez_xref>3709</dto:entrez_xref>
		<dto:geneSymbol>ITPR2</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200167 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200167">
		<rdfs:label rdf:datatype="&xsd;string">ITPR3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400354"/>
		<dto:entrez_xref>3710</dto:entrez_xref>
		<dto:geneSymbol>ITPR3</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a receptor for inositol 1,4,5-trisphosphate, a second messenger that mediates the release of intracellular calcium. The receptor contains a calcium channel at the C-terminus and the ligand-binding site at the N-terminus. Knockout studies in mice suggest that type 2 and type 3 inositol 1,4,5-trisphosphate receptors play a key role in exocrine secretion underlying energy metabolism and growth. [provided by RefSeq, Aug 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200168 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200168">
		<rdfs:label rdf:datatype="&xsd;string">KCNA10 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400530"/>
		<dto:entrez_xref>3744</dto:entrez_xref>
		<dto:geneSymbol>KCNA10</dto:geneSymbol>
		<obo:IAO_0000115>Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. This member contains six membrane-spanning domains with a shaker-type repeat in the fourth segment. It is specifically regulated by cGMP and postulated to mediate the effects of substances that increase intracellular cGMP. This gene is intronless, and the gene is clustered with genes KCNA2 and KCNA3 on chromosome 1. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200169 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200169">
		<rdfs:label rdf:datatype="&xsd;string">KCNAB1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400356"/>
		<dto:entrez_xref>7881</dto:entrez_xref>
		<dto:geneSymbol>KCNAB1</dto:geneSymbol>
		<dto:geneSynonym>KCNA1B</dto:geneSynonym>
		<obo:IAO_0000115>Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. This member includes three distinct isoforms which are encoded by three alternatively spliced transcript variants of this gene. These three isoforms are beta subunits, which form heteromultimeric complex with alpha subunits and modulate the activity of the pore-forming alpha subunits. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200170 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200170">
		<rdfs:label rdf:datatype="&xsd;string">KCNAB2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400356"/>
		<dto:entrez_xref>8514</dto:entrez_xref>
		<dto:geneSymbol>KCNAB2</dto:geneSymbol>
		<dto:geneSynonym>KCNK2</dto:geneSynonym>
		<dto:geneSynonym>KCNA2B</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. This member is one of the beta subunits, which are auxiliary proteins associating with functional Kv-alpha subunits. This member alters functional properties of the KCNA4 gene product. Alternative splicing of this gene results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Dec 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200171 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200171">
		<rdfs:label rdf:datatype="&xsd;string">KCNAB3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400356"/>
		<dto:entrez_xref>9196</dto:entrez_xref>
		<dto:geneSymbol>KCNAB3</dto:geneSymbol>
		<dto:geneSynonym>KCNA3B</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. The encoded protein is one of the beta subunits, which are auxiliary proteins associating with functional Kv-alpha subunits. The encoded protein forms a heterodimer with the potassium voltage-gated channel, shaker-related subfamily, member 5 gene product and regulates the activity of the alpha subunit. [provided by RefSeq, May 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200172 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200172">
		<rdfs:label rdf:datatype="&xsd;string">KCNIP1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
		<dto:geneSymbol>KCNIP1</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200173 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200173">
		<rdfs:label rdf:datatype="&xsd;string">KCNIP2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
		<dto:geneSymbol>KCNIP2</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200174 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200174">
		<rdfs:label rdf:datatype="&xsd;string">KCNIP4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400357"/>
		<dto:entrez_xref>80333</dto:entrez_xref>
		<dto:geneSymbol>KCNIP4</dto:geneSymbol>
		<dto:geneSynonym>KCHIP4</dto:geneSynonym>
		<dto:geneSynonym>CALP</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the family of voltage-gated potassium (Kv) channel-interacting proteins (KCNIPs), which belong to the recoverin branch of the EF-hand superfamily. Members of the KCNIP family are small calcium binding proteins. They all have EF-hand-like domains, and differ from each other in the N-terminus. They are integral subunit components of native Kv4 channel complexes. They may regulate A-type currents, and hence neuronal excitability, in response to changes in intracellular calcium. This protein member also interacts with presenilin. Multiple alternatively spliced transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200175 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200175">
		<rdfs:label rdf:datatype="&xsd;string">KCNMA1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400531"/>
		<dto:entrez_xref>3778</dto:entrez_xref>
		<dto:geneSymbol>KCNMA1</dto:geneSymbol>
		<dto:geneSynonym>SLO</dto:geneSynonym>
		<dto:geneSynonym>KCNMA</dto:geneSynonym>
		<obo:IAO_0000115>MaxiK channels are large conductance, voltage and calcium-sensitive potassium channels which are fundamental to the control of smooth muscle tone and neuronal excitability. MaxiK channels can be formed by 2 subunits: the pore-forming alpha subunit, which is the product of this gene, and the modulatory beta subunit. Intracellular calcium regulates the physical association between the alpha and beta subunits. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200176 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200176">
		<rdfs:label rdf:datatype="&xsd;string">KCNMB1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400438"/>
		<dto:entrez_xref>3779</dto:entrez_xref>
		<dto:geneSymbol>KCNMB1</dto:geneSymbol>
		<obo:IAO_0000115>MaxiK channels are large conductance, voltage and calcium-sensitive potassium channels which are fundamental to the control of smooth muscle tone and neuronal excitability. MaxiK channels can be formed by 2 subunits: the pore-forming alpha subunit and the product of this gene, the modulatory beta subunit. Intracellular calcium regulates the physical association between the alpha and beta subunits. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200177 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200177">
		<rdfs:label rdf:datatype="&xsd;string">KCNMB2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400439"/>
		<dto:entrez_xref>10242</dto:entrez_xref>
		<dto:geneSymbol>KCNMB2</dto:geneSymbol>
		<obo:IAO_0000115>MaxiK channels are large conductance, voltage and calcium-sensitive potassium channels which are fundamental to the control of smooth muscle tone and neuronal excitability. MaxiK channels can be formed by 2 subunits: the pore-forming alpha subunit and the modulatory beta subunit. The protein encoded by this gene is an auxiliary beta subunit which decreases the activation time of MaxiK alpha subunit currents. Alternative splicing results in multiple transcript variants of this gene. Additional variants are discussed in the literature, but their full length nature has not been described. [provided by RefSeq, Jul 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200178 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200178">
		<rdfs:label rdf:datatype="&xsd;string">KCNMB3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400440"/>
		<dto:entrez_xref>27094</dto:entrez_xref>
		<dto:geneSymbol>KCNMB3</dto:geneSymbol>
		<dto:geneSynonym>KCNMBL</dto:geneSynonym>
		<dto:geneSynonym>KCNMB2</dto:geneSynonym>
		<obo:IAO_0000115>MaxiK channels are large conductance, voltage and calcium-sensitive potassium channels which are fundamental to the control of smooth muscle tone and neuronal excitability. MaxiK channels can be formed by 2 subunits: the pore-forming alpha subunit and the modulatory beta subunit. The protein encoded by this gene is an auxiliary beta subunit which may partially inactivate or slightly decrease the activation time of MaxiK alpha subunit currents. Alternative splicing results in multiple transcript variants. A related pseudogene has been identified on chromosome 22. [provided by RefSeq, Jul 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200179 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200179">
		<rdfs:label rdf:datatype="&xsd;string">KCNMB4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400441"/>
		<dto:entrez_xref>27345</dto:entrez_xref>
		<dto:geneSymbol>KCNMB4</dto:geneSymbol>
		<obo:IAO_0000115>MaxiK channels are large conductance, voltage and calcium-sensitive potassium channels which are fundamental to the control of smooth muscle tone and neuronal excitability. MaxiK channels can be formed by 2 subunits: the pore-forming alpha subunit and the modulatory beta subunit. The protein encoded by this gene is an auxiliary beta subunit which slows activation kinetics, leads to steeper calcium sensitivity, and shifts the voltage range of current activation to more negative potentials than does the beta 1 subunit. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200180 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200180">
		<rdfs:label rdf:datatype="&xsd;string">KCNA1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400532"/>
		<dto:entrez_xref>3736</dto:entrez_xref>
		<dto:geneSymbol>KCNA1</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a voltage-gated delayed potassium channel that is phylogenetically related to the Drosophila Shaker channel. The encoded protein has six putative transmembrane segments (S1-S6), and the loop between S5 and S6 forms the pore and contains the conserved selectivity filter motif (GYGD). The functional channel is a homotetramer. The N-terminus of the channel is associated with beta subunits that can modify the inactivation properties of the channel as well as affect expression levels. The C-terminus of the channel is complexed to a PDZ domain protein that is responsible for channel targeting. Mutations in this gene have been associated with myokymia with periodic ataxia (AEMK). [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200181 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200181">
		<rdfs:label rdf:datatype="&xsd;string">KCNA2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400533"/>
		<dto:entrez_xref>3737</dto:entrez_xref>
		<dto:geneSymbol>KCNA2</dto:geneSymbol>
		<obo:IAO_0000115>Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. This member contains six membrane-spanning domains with a shaker-type repeat in the fourth segment. It belongs to the delayed rectifier class, members of which allow nerve cells to efficiently repolarize following an action potential. The coding region of this gene is intronless, and the gene is clustered with genes KCNA3 and KCNA10 on chromosome 1. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200182 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200182">
		<rdfs:label rdf:datatype="&xsd;string">KCNA3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400534"/>
		<dto:entrez_xref>3738</dto:entrez_xref>
		<dto:geneSymbol>KCNA3</dto:geneSymbol>
		<dto:geneSynonym>HGK5</dto:geneSynonym>
		<obo:IAO_0000115>Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. This member contains six membrane-spanning domains with a shaker-type repeat in the fourth segment. It belongs to the delayed rectifier class, members of which allow nerve cells to efficiently repolarize following an action potential. It plays an essential role in T-cell proliferation and activation. This gene appears to be intronless and it is clustered together with KCNA2 and KCNA10 genes on chromosome 1. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200183 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200183">
		<rdfs:label rdf:datatype="&xsd;string">KCNA4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400535"/>
		<dto:entrez_xref>3739</dto:entrez_xref>
		<dto:geneSymbol>KCNA4</dto:geneSymbol>
		<dto:geneSynonym>KCNA4L</dto:geneSynonym>
		<obo:IAO_0000115>Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. This member contains six membrane-spanning domains with a shaker-type repeat in the fourth segment. It belongs to the A-type potassium current class, the members of which may be important in the regulation of the fast repolarizing phase of action potentials in heart and thus may influence the duration of cardiac action potential.[provided by RefSeq, Mar 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200184 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200184">
		<rdfs:label rdf:datatype="&xsd;string">KCNA5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400536"/>
		<dto:entrez_xref>3741</dto:entrez_xref>
		<dto:geneSymbol>KCNA5</dto:geneSymbol>
		<obo:IAO_0000115>Potassium channels represent the most complex class of voltage-gated ino channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. This member contains six membrane-spanning domains with a shaker-type repeat in the fourth segment. It belongs to the delayed rectifier class, the function of which could restore the resting membrane potential of beta cells after depolarization and thereby contribute to the regulation of insulin secretion. This gene is intronless, and the gene is clustered with genes KCNA1 and KCNA6 on chromosome 12. Defects in this gene are a cause of familial atrial fibrillation type 7 (ATFB7). [provided by RefSeq, May 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200185 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200185">
		<rdfs:label rdf:datatype="&xsd;string">KCNA6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400537"/>
		<dto:entrez_xref>3742</dto:entrez_xref>
		<dto:geneSymbol>KCNA6</dto:geneSymbol>
		<obo:IAO_0000115>Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. This member contains six membrane-spanning domains with a shaker-type repeat in the fourth segment. It belongs to the delayed rectifier class. The coding region of this gene is intronless, and the gene is clustered with genes KCNA1 and KCNA5 on chromosome 12. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200186 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200186">
		<rdfs:label rdf:datatype="&xsd;string">KCNA7 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400538"/>
		<dto:entrez_xref>3743</dto:entrez_xref>
		<dto:geneSymbol>KCNA7</dto:geneSymbol>
		<obo:IAO_0000115>Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. This member contains six membrane-spanning domains with a shaker-type repeat in the fourth segment. The gene is expressed preferentially in skeletal muscle, heart and kidney. It is a candidate gene for inherited cardiac disorders. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200187 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200187">
		<rdfs:label rdf:datatype="&xsd;string">KCNB1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400539"/>
		<dto:entrez_xref>3745</dto:entrez_xref>
		<dto:geneSymbol>KCNB1</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shab-related subfamily. This member is a delayed rectifier potassium channel and its activity is modulated by some other family members. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200188 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200188">
		<rdfs:label rdf:datatype="&xsd;string">KCNB2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400540"/>
		<dto:entrez_xref>9312</dto:entrez_xref>
		<dto:geneSymbol>KCNB2</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shab-related subfamily. This member is a delayed rectifier potassium channel. The gene is expressed in gastrointestinal smooth muscle cells. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200189 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200189">
		<rdfs:label rdf:datatype="&xsd;string">KCNC1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400541"/>
		<dto:entrez_xref>3746</dto:entrez_xref>
		<dto:geneSymbol>KCNC1</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200190 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200190">
		<rdfs:label rdf:datatype="&xsd;string">KCNC2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400542"/>
		<dto:entrez_xref>3747</dto:entrez_xref>
		<dto:geneSymbol>KCNC2</dto:geneSymbol>
		<obo:IAO_0000115>The Shaker gene family of Drosophila encodes components of voltage-gated potassium channels and is comprised of four subfamilies. Based on sequence similarity, this gene is similar to one of these subfamilies, namely the Shaw subfamily. The protein encoded by this gene belongs to the delayed rectifier class of channel proteins and is an integral membrane protein that mediates the voltage-dependent potassium ion permeability of excitable membranes. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200191 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200191">
		<rdfs:label rdf:datatype="&xsd;string">KCNC3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400543"/>
		<dto:entrez_xref>3748</dto:entrez_xref>
		<dto:geneSymbol>KCNC3</dto:geneSymbol>
		<obo:IAO_0000115>The Shaker gene family of Drosophila encodes components of voltage-gated potassium channels and is comprised of four subfamilies. Based on sequence similarity, this gene is similar to one of these subfamilies, namely the Shaw subfamily. The protein encoded by this gene belongs to the delayed rectifier class of channel proteins and is an integral membrane protein that mediates the voltage-dependent potassium ion permeability of excitable membranes. Alternate splicing results in several transcript variants. [provided by RefSeq, Mar 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200192 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200192">
		<rdfs:label rdf:datatype="&xsd;string">KCNC4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400544"/>
		<dto:entrez_xref>3749</dto:entrez_xref>
		<dto:geneSymbol>KCNC4</dto:geneSymbol>
		<obo:IAO_0000115>The Shaker gene family of Drosophila encodes components of voltage-gated potassium channels and is comprised of four subfamilies. Based on sequence similarity, this gene is similar to the Shaw subfamily. The protein encoded by this gene belongs to the delayed rectifier class of channel proteins and is an integral membrane protein that mediates the voltage-dependent potassium ion permeability of excitable membranes. It generates atypical voltage-dependent transient current that may be important for neuronal excitability. Multiple transcript variants have been found for this gene. [provided by RefSeq, Jul 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200193 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200193">
		<rdfs:label rdf:datatype="&xsd;string">KCND1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400545"/>
		<dto:entrez_xref>3750</dto:entrez_xref>
		<dto:geneSymbol>KCND1</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a multipass membrane protein that comprises the pore subunit of the voltage-gated A-type potassium channel, which functions in the repolarization of membrane action potentials. Activity of voltage-gated potassium channels is important in a number of physiological processes, among them the regulation of neurotransmitter release, heart rate, insulin secretion, and smooth muscle contraction. [provided by RefSeq, Aug 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200194 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200194">
		<rdfs:label rdf:datatype="&xsd;string">KCND2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400546"/>
		<dto:entrez_xref>3751</dto:entrez_xref>
		<dto:geneSymbol>KCND2</dto:geneSymbol>
		<dto:geneSynonym>KIAA1044</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shal-related subfamily, members of which form voltage-activated A-type potassium ion channels and are prominent in the repolarization phase of the action potential. This member mediates a rapidly inactivating, A-type outward potassium current which is not under the control of the N terminus as it is in Shaker channels. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200195 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200195">
		<rdfs:label rdf:datatype="&xsd;string">KCND3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400547"/>
		<dto:entrez_xref>3752</dto:entrez_xref>
		<dto:geneSymbol>KCND3</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shal-related subfamily, members of which form voltage-activated A-type potassium ion channels and are prominent in the repolarization phase of the action potential. This member includes two isoforms with different sizes, which are encoded by alternatively spliced transcript variants of this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200196 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200196">
		<rdfs:label rdf:datatype="&xsd;string">KCNE1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400445"/>
		<dto:entrez_xref>3753</dto:entrez_xref>
		<dto:geneSymbol>KCNE1</dto:geneSymbol>
		<obo:IAO_0000115>The product of this gene belongs to the potassium channel KCNE family. Potassium ion channels are essential to many cellular functions and show a high degree of diversity, varying in their electrophysiologic and pharmacologic properties. This gene encodes a transmembrane protein known to associate with the product of the KVLQT1 gene to form the delayed rectifier potassium channel. Mutation in this gene are associated with both Jervell and Lange-Nielsen and Romano-Ward forms of long-QT syndrome. Alternatively spliced transcript variants encoding the same protein have been identified. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200197 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200197">
		<rdfs:label rdf:datatype="&xsd;string">KCNE2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400445"/>
		<dto:entrez_xref>9992</dto:entrez_xref>
		<dto:geneSymbol>KCNE2</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium channel, voltage-gated, isk-related subfamily. This member is a small integral membrane subunit that assembles with the KCNH2 gene product, a pore-forming protein, to alter its function. This gene is expressed in heart and muscle and the gene mutations are associated with cardiac arrhythmia. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200198 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200198">
		<rdfs:label rdf:datatype="&xsd;string">KCNE3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400445"/>
		<dto:entrez_xref>10008</dto:entrez_xref>
		<dto:geneSymbol>KCNE3</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium channel, voltage-gated, isk-related subfamily. This member is a type I membrane protein, and a beta subunit that assembles with a potassium channel alpha-subunit to modulate the gating kinetics and enhance stability of the multimeric complex. This gene is prominently expressed in the kidney. A missense mutation in this gene is associated with hypokalemic periodic paralysis. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200199 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200199">
		<rdfs:label rdf:datatype="&xsd;string">KCNE4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400445"/>
		<dto:entrez_xref>23704</dto:entrez_xref>
		<dto:geneSymbol>KCNE4</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium channel, voltage-gated, isk-related subfamily. This member is a type I membrane protein, and a beta subunit that assembles with a potassium channel alpha-subunit to modulate the gating kinetics and enhance stability of the multimeric complex. This gene is prominently expressed in the embryo and in adult uterus. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200200 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200200">
		<rdfs:label rdf:datatype="&xsd;string">KCNF1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400548"/>
		<dto:entrez_xref>3754</dto:entrez_xref>
		<dto:geneSymbol>KCNF1</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium channel, voltage-gated, subfamily F. This gene is intronless and expressed in all tissues tested, including the heart, skeletal muscle, brain, kidney, and pancreas. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200201 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200201">
		<rdfs:label rdf:datatype="&xsd;string">KCNG1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400549"/>
		<dto:entrez_xref>3755</dto:entrez_xref>
		<dto:geneSymbol>KCNG1</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium channel, voltage-gated, subfamily G. This gene is abundantly expressed in skeletal muscle. Multiple alternatively spliced transcript variants have been found in normal and cancerous tissues. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200202 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200202">
		<rdfs:label rdf:datatype="&xsd;string">KCNG2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400550"/>
		<dto:entrez_xref>26251</dto:entrez_xref>
		<dto:geneSymbol>KCNG2</dto:geneSymbol>
		<dto:geneSynonym>KCNF2</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium channel, voltage-gated, subfamily G. This member is a gamma subunit of the voltage-gated potassium channel. The delayed-rectifier type channels containing this subunit may contribute to cardiac action potential repolarization. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200203 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200203">
		<rdfs:label rdf:datatype="&xsd;string">KCNG3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400551"/>
		<dto:entrez_xref>170850</dto:entrez_xref>
		<dto:geneSymbol>KCNG3</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium channel, voltage-gated, subfamily G. This member is a gamma subunit functioning as a modulatory molecule. Alternative splicing results in two transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200204 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200204">
		<rdfs:label rdf:datatype="&xsd;string">KCNG4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400552"/>
		<dto:entrez_xref>93107</dto:entrez_xref>
		<dto:geneSymbol>KCNG4</dto:geneSymbol>
		<dto:geneSynonym>KCNG3</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium channel, voltage-gated, subfamily G. This member functions as a modulatory subunit. The gene has strong expression in brain. Multiple alternatively spliced variants have been found in normal and cancerous tissues. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200205 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200205">
		<rdfs:label rdf:datatype="&xsd;string">KCNH1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400553"/>
		<dto:entrez_xref>3756</dto:entrez_xref>
		<dto:geneSymbol>KCNH1</dto:geneSymbol>
		<dto:geneSynonym>EAG1</dto:geneSynonym>
		<dto:geneSynonym>EAG</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium channel, voltage-gated, subfamily H. This member is a pore-forming (alpha) subunit of a voltage-gated non-inactivating delayed rectifier potassium channel. It is activated at the onset of myoblast differentiation. The gene is highly expressed in brain and in myoblasts. Overexpression of the gene may confer a growth advantage to cancer cells and favor tumor cell proliferation. Alternative splicing of this gene results in two transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200206 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200206">
		<rdfs:label rdf:datatype="&xsd;string">KCNH2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400554"/>
		<dto:entrez_xref>3757</dto:entrez_xref>
		<dto:geneSymbol>KCNH2</dto:geneSymbol>
		<dto:geneSynonym>ERG1</dto:geneSynonym>
		<dto:geneSynonym>HERG</dto:geneSynonym>
		<dto:geneSynonym>ERG</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a voltage-activated potassium channel belonging to the eag family. It shares sequence similarity with the Drosophila ether-a-go-go (eag) gene. Mutations in this gene can cause long QT syndrome type 2 (LQT2). Transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200207 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200207">
		<rdfs:label rdf:datatype="&xsd;string">KCNH3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400555"/>
		<dto:entrez_xref>23416</dto:entrez_xref>
		<dto:geneSymbol>KCNH3</dto:geneSymbol>
		<dto:geneSynonym>KIAA1282</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200208 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200208">
		<rdfs:label rdf:datatype="&xsd;string">KCNH4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400556"/>
		<dto:entrez_xref>23415</dto:entrez_xref>
		<dto:geneSymbol>KCNH4</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium channel, voltage-gated, subfamily H. This member is a pore-forming (alpha) subunit. The gene is brain-specific, and located in the neocortex and the striatum. It may be involved in cellular excitability of restricted neurons in the central nervous system. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200209 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200209">
		<rdfs:label rdf:datatype="&xsd;string">KCNH5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400557"/>
		<dto:entrez_xref>27133</dto:entrez_xref>
		<dto:geneSymbol>KCNH5</dto:geneSymbol>
		<dto:geneSynonym>EAG2</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of voltage-gated potassium channels. Members of this family have diverse functions, including regulating neurotransmitter and hormone release, cardiac function, and cell volume. This protein is an outward-rectifying, noninactivating channel. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200210 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200210">
		<rdfs:label rdf:datatype="&xsd;string">KCNH6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400558"/>
		<dto:entrez_xref>81033</dto:entrez_xref>
		<dto:geneSymbol>KCNH6</dto:geneSymbol>
		<dto:geneSynonym>ERG2</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium channel, voltage-gated, subfamily H. This member is a pore-forming (alpha) subunit. Alternative splicing results in multiple transcript variants that encode different isoforms. [provided by RefSeq, Jul 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200211 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200211">
		<rdfs:label rdf:datatype="&xsd;string">KCNH7 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400559"/>
		<dto:entrez_xref>90134</dto:entrez_xref>
		<dto:geneSymbol>KCNH7</dto:geneSymbol>
		<dto:geneSynonym>ERG3</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium channel, voltage-gated, subfamily H. This member is a pore-forming (alpha) subunit. There are at least two alternatively spliced transcript variants derived from this gene and encoding distinct isoforms. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200212 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200212">
		<rdfs:label rdf:datatype="&xsd;string">KCNH8 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400560"/>
		<dto:entrez_xref>131096</dto:entrez_xref>
		<dto:geneSymbol>KCNH8</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium channel, voltage-gated, subfamily H. This member is a pore-forming (alpha) subunit. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200213 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200213">
		<rdfs:label rdf:datatype="&xsd;string">KCNK1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>3775</dto:entrez_xref>
		<dto:geneSymbol>KCNK1</dto:geneSymbol>
		<dto:geneSynonym>KCNO1</dto:geneSynonym>
		<dto:geneSynonym>TWIK1</dto:geneSynonym>
		<dto:geneSynonym>HOHO1</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes one of the members of the superfamily of potassium channel proteins containing two pore-forming P domains. The product of this gene has not been shown to be a functional channel, however, it may require other non-pore-forming proteins for activity. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200214 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200214">
		<rdfs:label rdf:datatype="&xsd;string">KCNK2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>3776</dto:entrez_xref>
		<dto:geneSymbol>KCNK2</dto:geneSymbol>
		<dto:geneSynonym>TREK1</dto:geneSynonym>
		<dto:geneSynonym>TREK</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes one of the members of the two-pore-domain background potassium channel protein family. This type of potassium channel is formed by two homodimers that create a channel that leaks potassium out of the cell to control resting membrane potential. The channel can be opened, however, by certain anesthetics, membrane stretching, intracellular acidosis, and heat. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200215 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200215">
		<rdfs:label rdf:datatype="&xsd;string">KCNK3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>3777</dto:entrez_xref>
		<dto:geneSymbol>KCNK3</dto:geneSymbol>
		<dto:geneSynonym>TASK1</dto:geneSynonym>
		<dto:geneSynonym>TASK</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the superfamily of potassium channel proteins that contain two pore-forming P domains. The encoded protein is an outwardly rectifying channel that is sensitive to changes in extracellular pH and is inhibited by extracellular acidification. Also referred to as an acid-sensitive potassium channel, it is activated by the anesthetics halothane and isoflurane. Although three transcripts are detected in northern blots, there is currently no sequence available to confirm transcript variants for this gene. [provided by RefSeq, Aug 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200216 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200216">
		<rdfs:label rdf:datatype="&xsd;string">KCNK4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>50801</dto:entrez_xref>
		<dto:geneSymbol>KCNK4</dto:geneSymbol>
		<dto:geneSynonym>TRAAK</dto:geneSynonym>
		<obo:IAO_0000115>Potassium channels play a role in many cellular processes including maintenance of the action potential, muscle contraction, hormone secretion, osmotic regulation, and ion flow. This gene encodes one of the members of the superfamily of potassium channel proteins containing two pore-forming P domains. The encoded protein homodimerizes and functions as an outwardly rectifying channel. It is expressed primarily in neural tissues and is stimulated by membrane stretch and polyunsaturated fatty acids. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200217 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200217">
		<rdfs:label rdf:datatype="&xsd;string">KCNK5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>8645</dto:entrez_xref>
		<dto:geneSymbol>KCNK5</dto:geneSymbol>
		<dto:geneSynonym>TASK2</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes one of the members of the superfamily of potassium channel proteins containing two pore-forming P domains. The message for this gene is mainly expressed in the cortical distal tubules and collecting ducts of the kidney. The protein is highly sensitive to external pH and this, in combination with its expression pattern, suggests it may play an important role in renal potassium transport. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200218 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200218">
		<rdfs:label rdf:datatype="&xsd;string">KCNK6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>9424</dto:entrez_xref>
		<dto:geneSymbol>KCNK6</dto:geneSymbol>
		<dto:geneSynonym>TWIK2</dto:geneSynonym>
		<dto:geneSynonym>TOSS</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes one of the members of the superfamily of potassium channel proteins containing two pore-forming P domains. This channel protein, considered an open rectifier, is widely expressed. It is stimulated by arachidonic acid, and inhibited by internal acidification and volatile anaesthetics. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200219 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200219">
		<rdfs:label rdf:datatype="&xsd;string">KCNK7 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>10089</dto:entrez_xref>
		<dto:geneSymbol>KCNK7</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the superfamily of potassium channel proteins containing two pore-forming P domains. The product of this gene has not been shown to be a functional channel; however, it may require other non-pore-forming proteins for activity. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200220 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200220">
		<rdfs:label rdf:datatype="&xsd;string">KCNK9 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>51305</dto:entrez_xref>
		<dto:geneSymbol>KCNK9</dto:geneSymbol>
		<dto:geneSynonym>TASK3</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a protein that contains multiple transmembrane regions and two pore-forming P domains and functions as a pH-dependent potassium channel. Amplification and overexpression of this gene have been observed in several types of human carcinomas. This gene is imprinted in the brain, with preferential expression from the maternal allele. A mutation in this gene was associated with Birk-Barel mental retardation dysmorphism syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200221 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200221">
		<rdfs:label rdf:datatype="&xsd;string">KCNK10 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>54207</dto:entrez_xref>
		<dto:geneSymbol>KCNK10</dto:geneSymbol>
		<dto:geneSynonym>TREK2</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene belongs to the family of potassium channel proteins containing two pore-forming P domains. This channel is an open rectifier which primarily passes outward current under physiological K+ concentrations, and is stimulated strongly by arachidonic acid and to a lesser degree by membrane stretching, intracellular acidification, and general anaesthetics. Several alternatively spliced transcript variants encoding different isoforms have been identified for this gene. [provided by RefSeq, Sep 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200222 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200222">
		<rdfs:label rdf:datatype="&xsd;string">KCNK12 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>56660</dto:entrez_xref>
		<dto:geneSymbol>KCNK12</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes one of the members of the superfamily of potassium channel proteins containing two pore-forming P domains. The product of this gene has not been shown to be a functional channel, however, it may require other non-pore-forming proteins for activity. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200223 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200223">
		<rdfs:label rdf:datatype="&xsd;string">KCNK13 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>56659</dto:entrez_xref>
		<dto:geneSymbol>KCNK13</dto:geneSymbol>
		<obo:IAO_0000115>Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a potassium channel containing two pore-forming domains. This protein is an open channel that can be stimulated by arachidonic acid and inhibited by the anesthetic halothane. [provided by RefSeq, Jul 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200224 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200224">
		<rdfs:label rdf:datatype="&xsd;string">KCNK15 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>60598</dto:entrez_xref>
		<dto:geneSymbol>KCNK15</dto:geneSymbol>
		<dto:geneSynonym>TASK5</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes one of the members of the superfamily of potassium channel proteins containing two pore-forming P domains. The product of this gene has not been shown to be a functional channel, however, it may require other non-pore-forming proteins for activity. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200225 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200225">
		<rdfs:label rdf:datatype="&xsd;string">KCNK16 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>83795</dto:entrez_xref>
		<dto:geneSymbol>KCNK16</dto:geneSymbol>
		<dto:geneSynonym>TALK1</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene belongs to the family of potassium channel proteins containing two pore-forming P domains. This channel is an open rectifier which primarily passes outward current under physiological K+ concentrations. This gene is expressed predominantly in the pancreas and is activated at alkaline pH. Several alternatively spliced transcript variants encoding different isoforms have been identified for this gene. [provided by RefSeq, Sep 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200226 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200226">
		<rdfs:label rdf:datatype="&xsd;string">KCNK17 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>89822</dto:entrez_xref>
		<dto:geneSymbol>KCNK17</dto:geneSymbol>
		<dto:geneSynonym>TASK4</dto:geneSynonym>
		<dto:geneSynonym>TALK2</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene belongs to the family of potassium channel proteins containing two pore-forming P domains. This channel is an open rectifier which primarily passes outward current under physiological K+ concentrations. This gene is activated at alkaline pH. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200227 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200227">
		<rdfs:label rdf:datatype="&xsd;string">KCNK18 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400359"/>
		<dto:entrez_xref>338567</dto:entrez_xref>
		<dto:geneSymbol>KCNK18</dto:geneSymbol>
		<dto:geneSynonym>TRIK</dto:geneSynonym>
		<dto:geneSynonym>TRESK</dto:geneSynonym>
		<obo:IAO_0000115>Potassium channels play a role in many cellular processes including maintenance of the action potential, muscle contraction, hormone secretion, osmotic regulation, and ion flow. This gene encodes a member of the superfamily of potassium channel proteins containing two pore-forming P domains and the encoded protein functions as an outward rectifying potassium channel. A mutation in this gene has been found to be associated with migraine with aura.[provided by RefSeq, Jan 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200228 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200228">
		<rdfs:label rdf:datatype="&xsd;string">KCNN1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400437"/>
		<dto:entrez_xref>3780</dto:entrez_xref>
		<dto:geneSymbol>KCNN1</dto:geneSymbol>
		<dto:geneSynonym>SK</dto:geneSynonym>
		<obo:IAO_0000115>Action potentials in vertebrate neurons are followed by an afterhyperpolarization (AHP) that may persist for several seconds and may have profound consequences for the firing pattern of the neuron. Each component of the AHP is kinetically distinct and is mediated by different calcium-activated potassium channels. The protein encoded by this gene is activated before membrane hyperpolarization and is thought to regulate neuronal excitability by contributing to the slow component of synaptic AHP. The encoded protein is an integral membrane protein that forms a voltage-independent calcium-activated channel with three other calmodulin-binding subunits. This gene is a member of the KCNN family of potassium channel genes. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200229 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200229">
		<rdfs:label rdf:datatype="&xsd;string">KCNN2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400437"/>
		<dto:entrez_xref>3781</dto:entrez_xref>
		<dto:geneSymbol>KCNN2</dto:geneSymbol>
		<obo:IAO_0000115>Action potentials in vertebrate neurons are followed by an afterhyperpolarization (AHP) that may persist for several seconds and may have profound consequences for the firing pattern of the neuron. Each component of the AHP is kinetically distinct and is mediated by different calcium-activated potassium channels. The protein encoded by this gene is activated before membrane hyperpolarization and is thought to regulate neuronal excitability by contributing to the slow component of synaptic AHP. This gene is a member of the KCNN family of potassium channel genes. The encoded protein is an integral membrane protein that forms a voltage-independent calcium-activated channel with three other calmodulin-binding subunits. Alternate splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200230 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200230">
		<rdfs:label rdf:datatype="&xsd;string">KCNN3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400437"/>
		<dto:entrez_xref>3782</dto:entrez_xref>
		<dto:geneSymbol>KCNN3</dto:geneSymbol>
		<dto:geneSynonym>K3</dto:geneSynonym>
		<obo:IAO_0000115>Action potentials in vertebrate neurons are followed by an afterhyperpolarization (AHP) that may persist for several seconds and may have profound consequences for the firing pattern of the neuron. Each component of the AHP is kinetically distinct and is mediated by different calcium-activated potassium channels. This gene belongs to the KCNN family of potassium channels. It encodes an integral membrane protein that forms a voltage-independent calcium-activated channel, which is thought to regulate neuronal excitability by contributing to the slow component of synaptic AHP. This gene contains two CAG repeat regions in the coding sequence. It was thought that expansion of one or both of these repeats could lead to an increased susceptibility to schizophrenia or bipolar disorder, but studies indicate that this is probably not the case. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200231 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200231">
		<rdfs:label rdf:datatype="&xsd;string">KCNN4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400437"/>
		<dto:entrez_xref>3783</dto:entrez_xref>
		<dto:geneSymbol>KCNN4</dto:geneSymbol>
		<dto:geneSynonym>IKCA1</dto:geneSynonym>
		<dto:geneSynonym>KCA4</dto:geneSynonym>
		<dto:geneSynonym>IK1</dto:geneSynonym>
		<dto:geneSynonym>SK4</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene is part of a potentially heterotetrameric voltage-independent potassium channel that is activated by intracellular calcium. Activation is followed by membrane hyperpolarization, which promotes calcium influx. The encoded protein may be part of the predominant calcium-activated potassium channel in T-lymphocytes. This gene is similar to other KCNN family potassium channel genes, but it differs enough to possibly be considered as part of a new subfamily. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200232 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200232">
		<rdfs:label rdf:datatype="&xsd;string">KCNQ1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400561"/>
		<dto:entrez_xref>3784</dto:entrez_xref>
		<dto:geneSymbol>KCNQ1</dto:geneSymbol>
		<dto:geneSynonym>KCNA9</dto:geneSynonym>
		<dto:geneSynonym>KVLQT1</dto:geneSynonym>
		<dto:geneSynonym>KCNA8</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a voltage-gated potassium channel required for repolarization phase of the cardiac action potential. This protein can form heteromultimers with two other potassium channel proteins, KCNE1 and KCNE3. Mutations in this gene are associated with hereditary long QT syndrome 1 (also known as Romano-Ward syndrome), Jervell and Lange-Nielsen syndrome, and familial atrial fibrillation. This gene exhibits tissue-specific imprinting, with preferential expression from the maternal allele in some tissues, and biallelic expression in others. This gene is located in a region of chromosome 11 amongst other imprinted genes that are associated with Beckwith-Wiedemann syndrome (BWS), and itself has been shown to be disrupted by chromosomal rearrangements in patients with BWS. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Aug 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200233 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200233">
		<rdfs:label rdf:datatype="&xsd;string">KCNQ2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400562"/>
		<dto:entrez_xref>3785</dto:entrez_xref>
		<dto:geneSymbol>KCNQ2</dto:geneSymbol>
		<obo:IAO_0000115>The M channel is a slowly activating and deactivating potassium channel that plays a critical role in the regulation of neuronal excitability.  The M channel is formed by the association of the protein encoded by this gene and a related protein encoded by the KCNQ3 gene, both integral membrane proteins. M channel currents are inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 1 (BFNC), also known as epilepsy, benign neonatal type 1 (EBN1). At least five transcript variants encoding five different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200234 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200234">
		<rdfs:label rdf:datatype="&xsd;string">KCNQ3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400563"/>
		<dto:entrez_xref>3786</dto:entrez_xref>
		<dto:geneSymbol>KCNQ3</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a protein that functions in the regulation of neuronal excitability. The encoded protein forms an M-channel by associating with the products of the related KCNQ2 or KCNQ5 genes, which both encode integral membrane proteins. M-channel currents are inhibited by M1 muscarinic acetylcholine receptors and are activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 2 (BFNC2), also known as epilepsy, benign neonatal type 2 (EBN2). Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200235 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200235">
		<rdfs:label rdf:datatype="&xsd;string">KCNQ4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400564"/>
		<dto:entrez_xref>9132</dto:entrez_xref>
		<dto:geneSymbol>KCNQ4</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded by this gene forms a potassium channel that is thought to play a critical role in the regulation of neuronal excitability, particularly in sensory cells of the cochlea. The current generated by this channel is inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. The encoded protein can form a homomultimeric potassium channel or possibly a heteromultimeric channel in association with the protein encoded by the KCNQ3 gene. Defects in this gene are a cause of nonsyndromic sensorineural deafness type 2 (DFNA2), an autosomal dominant form of progressive hearing loss. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200236 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200236">
		<rdfs:label rdf:datatype="&xsd;string">KCNQ5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400565"/>
		<dto:entrez_xref>56479</dto:entrez_xref>
		<dto:geneSymbol>KCNQ5</dto:geneSymbol>
		<obo:IAO_0000115>This gene is a member of the KCNQ potassium channel gene family that is differentially expressed in subregions of the brain and in skeletal muscle. The protein encoded by this gene yields currents that activate slowly with depolarization and can form heteromeric channels with the protein encoded by the KCNQ3 gene. Currents expressed from this protein have voltage dependences and inhibitor sensitivities in common with M-currents. They are also inhibited by M1 muscarinic receptor activation. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200237 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200237">
		<rdfs:label rdf:datatype="&xsd;string">KCNS1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400566"/>
		<dto:entrez_xref>3787</dto:entrez_xref>
		<dto:geneSymbol>KCNS1</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium channels form the largest and most diversified class of ion channels and are present in both excitable and nonexcitable cells. Their main functions are associated with the regulation of the resting membrane potential and the control of the shape and frequency of action potentials. The alpha subunits are of 2 types: those that are functional by themselves and those that are electrically silent but capable of modulating the activity of specific functional alpha subunits. The protein encoded by this gene is not functional by itself but can form heteromultimers with member 1 and with member 2 (and possibly other members) of the Shab-related subfamily of potassium voltage-gated channel proteins. This gene belongs to the S subfamily of the potassium channel family. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200238 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200238">
		<rdfs:label rdf:datatype="&xsd;string">KCNS2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400567"/>
		<dto:entrez_xref>3788</dto:entrez_xref>
		<dto:geneSymbol>KCNS2</dto:geneSymbol>
		<dto:geneSynonym>KIAA1144</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200239 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200239">
		<rdfs:label rdf:datatype="&xsd;string">KCNS3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400568"/>
		<dto:entrez_xref>3790</dto:entrez_xref>
		<dto:geneSymbol>KCNS3</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium channels form the largest and most diversified class of ion channels and are present in both excitable and nonexcitable cells. Their main functions are associated with the regulation of the resting membrane potential and the control of the shape and frequency of action potentials. The alpha subunits are of 2 types: those that are functional by themselves and those that are electrically silent but capable of modulating the activity of specific functional alpha subunits. The protein encoded by this gene is not functional by itself but can form heteromultimers with member 1 and with member 2 (and possibly other members) of the Shab-related subfamily of potassium voltage-gated channel proteins. This gene belongs to the S subfamily of the potassium channel family. Alternatively spliced transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Sep 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200240 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200240">
		<rdfs:label rdf:datatype="&xsd;string">KCNT1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400569"/>
		<dto:entrez_xref>57582</dto:entrez_xref>
		<dto:geneSymbol>KCNT1</dto:geneSymbol>
		<dto:geneSynonym>KIAA1422</dto:geneSynonym>
		<obo:IAO_0000115>Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a sodium-activated potassium channel subunit which is thought to function in ion conductance and developmental signaling pathways. Mutations in this gene cause the early-onset epileptic disorders, malignant migrating partial seizures of infancy and autosomal dominant nocturnal frontal lobe epilepsy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200241 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200241">
		<rdfs:label rdf:datatype="&xsd;string">KCNT2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400570"/>
		<dto:entrez_xref>343450</dto:entrez_xref>
		<dto:geneSymbol>KCNT2</dto:geneSymbol>
		<dto:geneSynonym>SLICK</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200242 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200242">
		<rdfs:label rdf:datatype="&xsd;string">KCNU1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400571"/>
		<dto:entrez_xref>157855</dto:entrez_xref>
		<dto:geneSymbol>KCNU1</dto:geneSymbol>
		<dto:geneSynonym>KCNMC1</dto:geneSynonym>
		<dto:geneSynonym>SLO3</dto:geneSynonym>
		<dto:geneSynonym>KCNMA3</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200243 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200243">
		<rdfs:label rdf:datatype="&xsd;string">KCNV1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400572"/>
		<dto:entrez_xref>27012</dto:entrez_xref>
		<dto:geneSymbol>KCNV1</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium voltage-gated channel subfamily V. This protein is essentially present in the brain, and its role might be to inhibit the function of a particular class of outward rectifier potassium channel types. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200244 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200244">
		<rdfs:label rdf:datatype="&xsd;string">KCNV2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400573"/>
		<dto:entrez_xref>169522</dto:entrez_xref>
		<dto:geneSymbol>KCNV2</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium voltage-gated channel subfamily V. This member is identified as a &apos;silent subunit&apos;, and it does not form homomultimers, but forms heteromultimers with several other subfamily members. Through obligatory heteromerization, it exerts a function-altering effect on other potassium channel subunits. This protein is strongly expressed in pancreas and has a weaker expression in several other tissues. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200245 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200245">
		<rdfs:label rdf:datatype="&xsd;string">LRRC26 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
		<dto:geneSymbol>LRRC26</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200246 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200246">
		<rdfs:label rdf:datatype="&xsd;string">LRRC38 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
		<dto:geneSymbol>LRRC38</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200247 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200247">
		<rdfs:label rdf:datatype="&xsd;string">LRRC52 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
		<dto:geneSymbol>LRRC52</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200248 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200248">
		<rdfs:label rdf:datatype="&xsd;string">LRRC55 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
		<dto:geneSymbol>LRRC55</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200249 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200249">
		<rdfs:label rdf:datatype="&xsd;string">MCOLN1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400574"/>
		<dto:entrez_xref>57192</dto:entrez_xref>
		<dto:geneSymbol>MCOLN1</dto:geneSymbol>
		<dto:geneSynonym>ML4</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a memberof the transient receptor potential (TRP) cation channel gene family. The transmembrane protein localizes to intracellular vesicular membranes including lysosomes, and functions in the late endocytic pathway and in the regulation of lysosomal exocytosis. The channel is permeable to Ca(2+), Fe(2+), Na(+), K(+), and H(+), and is modulated by changes in Ca(2+) concentration. Mutations in this gene result in mucolipidosis type IV. [provided by RefSeq, Oct 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200250 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200250">
		<rdfs:label rdf:datatype="&xsd;string">MCOLN2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400575"/>
		<dto:entrez_xref>255231</dto:entrez_xref>
		<dto:geneSymbol>MCOLN2</dto:geneSymbol>
		<obo:IAO_0000115>Mucolipins constitute a family of cation channel proteins with homology to the transient receptor potential superfamily. In mammals, the mucolipin family includes 3 members, MCOLN1 (MIM 605248), MCOLN2, and MCOLN3 (MIM 607400), that exhibit a common 6-membrane-spanning topology. Homologs of mammalian mucolipins exist in Drosophila and C. elegans. Mutations in the human MCOLN1 gene cause mucolipodosis IV (MIM 262650) (Karacsonyi et al., 2007 [PubMed 17662026]).[supplied by OMIM, Sep 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200251 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200251">
		<rdfs:label rdf:datatype="&xsd;string">MCOLN3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400576"/>
		<dto:entrez_xref>55283</dto:entrez_xref>
		<dto:geneSymbol>MCOLN3</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes one of members of the mucolipin cation channel proteins. Mutation studies of the highly similar protein in mice have shown that the protein is found in cochlea hair cells, and mutant mice show early-onset hearing loss and balance problems. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200252 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200252">
		<rdfs:label rdf:datatype="&xsd;string">MCU gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400361"/>
		<dto:entrez_xref>90550</dto:entrez_xref>
		<dto:geneSymbol>MCU</dto:geneSymbol>
		<dto:geneSynonym>CCDC109A</dto:geneSynonym>
		<dto:geneSynonym>C10orf42</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a calcium transporter that localizes to the mitochondrial inner membrane. The encoded protein interacts with mitochondrial calcium uptake 1. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200253 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200253">
		<rdfs:label rdf:datatype="&xsd;string">MLC1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400362"/>
		<dto:entrez_xref>23209</dto:entrez_xref>
		<dto:geneSymbol>MLC1</dto:geneSymbol>
		<dto:geneSynonym>WKL1</dto:geneSynonym>
		<dto:geneSynonym>KIAA0027</dto:geneSynonym>
		<obo:IAO_0000115>The function of this gene product is unknown; however, homology to other proteins suggests that it may be an integral membrane transporter. Mutations in this gene have been associated with megalencephalic leukoencephalopathy with subcortical cysts, an autosomal recessive neurological disorder. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200254 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200254">
		<rdfs:label rdf:datatype="&xsd;string">NALCN gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400363"/>
		<dto:entrez_xref>259232</dto:entrez_xref>
		<dto:geneSymbol>NALCN</dto:geneSymbol>
		<dto:geneSynonym>VGCNL1</dto:geneSynonym>
		<obo:IAO_0000115>NALCN forms a voltage-independent, nonselective, noninactivating cation channel permeable to Na+, K+, and Ca(2+). It is responsible for the neuronal background sodium leak conductance (Lu et al., 2007 [PubMed 17448995]).[supplied by OMIM, Mar 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200255 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200255">
		<rdfs:label rdf:datatype="&xsd;string">GRIN3A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400453"/>
		<dto:entrez_xref>116443</dto:entrez_xref>
		<dto:geneSymbol>GRIN3A</dto:geneSymbol>
		<dto:geneSynonym>KIAA1973</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a subunit of the N-methyl-D-aspartate (NMDA) receptors, which belong to the superfamily of glutamate-regulated ion channels, and function in physiological and pathological processes in the central nervous system. This subunit shows greater than 90% identity to the corresponding subunit in rat. Studies in the knockout mouse deficient in this subunit suggest that this gene may be involved in the development of synaptic elements by modulating NMDA receptor activity. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200256 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200256">
		<rdfs:label rdf:datatype="&xsd;string">GRIN3B gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400454"/>
		<dto:entrez_xref>116444</dto:entrez_xref>
		<dto:geneSymbol>GRIN3B</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200257 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200257">
		<rdfs:label rdf:datatype="&xsd;string">GRIN2A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400455"/>
		<dto:entrez_xref>2903</dto:entrez_xref>
		<dto:geneSymbol>GRIN2A</dto:geneSymbol>
		<dto:geneSynonym>NMDAR2A</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the glutamate-gated ion channel protein family. The encoded protein is an N-methyl-D-aspartate (NMDA) receptor subunit. NMDA receptors are both ligand-gated and voltage-dependent, and are involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. These receptors are permeable to calcium ions, and activation results in a calcium influx into post-synaptic cells, which results in the activation of several signaling cascades. Disruption of this gene is associated with focal epilepsy and speech disorder with or without mental retardation. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200258 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200258">
		<rdfs:label rdf:datatype="&xsd;string">GRIN2B gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400456"/>
		<dto:entrez_xref>2904</dto:entrez_xref>
		<dto:geneSymbol>GRIN2B</dto:geneSymbol>
		<dto:geneSynonym>NMDAR2B</dto:geneSynonym>
		<obo:IAO_0000115>N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate receptors. NMDA receptor channel has been shown to be involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. NMDA receptor channels are heteromers composed of three different subunits: NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The NR2 subunit acts as the agonist binding site for glutamate. This receptor is the predominant excitatory neurotransmitter receptor in the mammalian brain. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200259 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200259">
		<rdfs:label rdf:datatype="&xsd;string">GRIN2C gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400457"/>
		<dto:entrez_xref>2905</dto:entrez_xref>
		<dto:geneSymbol>GRIN2C</dto:geneSymbol>
		<dto:geneSynonym>NMDAR2C</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a subunit of the N-methyl-D-aspartate (NMDA) receptor, which is a subtype of ionotropic glutamate receptor. NMDA receptors are found in the central nervous system, are permeable to cations and have an important role in physiological processes such as learning, memory, and synaptic development. The receptor is a tetramer of different subunits (typically heterodimer of subunit 1 with one or more of subunits 2A-D), forming a channel that is permeable to calcium, potassium, and sodium, and whose properties are determined by subunit composition. Alterations in the subunit composition of the receptor are associated with pathophysiological conditions such as Parkinson&apos;s disease, Alzheimer&apos;s disease, depression, and schizophrenia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jun 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200260 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200260">
		<rdfs:label rdf:datatype="&xsd;string">GRIN2D gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400458"/>
		<dto:entrez_xref>2906</dto:entrez_xref>
		<dto:geneSymbol>GRIN2D</dto:geneSymbol>
		<dto:geneSynonym>NMDAR2D</dto:geneSynonym>
		<dto:geneSynonym>GluN2D</dto:geneSynonym>
		<obo:IAO_0000115>N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate receptors. NMDA channel has been shown to be involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. NMDA receptor channels are heteromers composed of the key receptor subunit NMDAR1 (GRIN1) and 1 or more of the 4 NMDAR2 subunits: NMDAR2A (GRIN2A), NMDAR2B (GRIN2B), NMDAR2C (GRIN2C), and NMDAR2D (GRIN2D). [provided by RefSeq, Mar 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200261 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200261">
		<rdfs:label rdf:datatype="&xsd;string">GRIN1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400459"/>
		<dto:entrez_xref>2902</dto:entrez_xref>
		<dto:geneSymbol>GRIN1</dto:geneSymbol>
		<dto:geneSynonym>NMDAR1</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene is a critical subunit of N-methyl-D-aspartate receptors, members of the glutamate receptor channel superfamily which are heteromeric protein complexes with multiple subunits arranged to form a ligand-gated ion channel. These subunits play a key role in the plasticity of synapses, which is believed to underlie memory and learning. Cell-specific factors are thought to control expression of different isoforms, possibly contributing to the functional diversity of the subunits. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200262 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200262">
		<rdfs:label rdf:datatype="&xsd;string">NOX1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400346"/>
		<dto:entrez_xref>27035</dto:entrez_xref>
		<dto:geneSymbol>NOX1</dto:geneSymbol>
		<dto:geneSynonym>NOH1</dto:geneSynonym>
		<dto:geneSynonym>MOX1</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the NADPH oxidase family of enzymes responsible for the catalytic one-electron transfer of oxygen to generate superoxide or hydrogen peroxide. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Nov 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200263 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200263">
		<rdfs:label rdf:datatype="&xsd;string">NOX5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400346"/>
		<dto:entrez_xref>79400</dto:entrez_xref>
		<dto:geneSymbol>NOX5</dto:geneSymbol>
		<obo:IAO_0000115>This gene is predominantly expressed in the testis and lymphocyte-rich areas of spleen and lymph nodes. It encodes a calcium-dependen NADPH oxidase that generates superoxide, and functions as a calcium-dependent proton channel that may regulate redox-dependent processes in lymphocytes and spermatozoa. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Oct 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200264 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200264">
		<rdfs:label rdf:datatype="&xsd;string">P2RX1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400364"/>
		<dto:entrez_xref>5023</dto:entrez_xref>
		<dto:geneSymbol>P2RX1</dto:geneSymbol>
		<dto:geneSynonym>P2X1</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene belongs to the P2X family of G-protein-coupled receptors. These proteins can form homo-and heterotimers and function as ATP-gated ion channels and mediate rapid and selective permeability to cations. This protein is primarily localized to smooth muscle where binds ATP and mediates synaptic transmission between neurons and from neurons to smooth muscle and may being responsible for sympathetic vasoconstriction in small arteries, arterioles and vas deferens. Mouse studies suggest that this receptor is essential for normal male reproductive function. This protein may also be involved in promoting apoptosis. [provided by RefSeq, Jun 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200265 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200265">
		<rdfs:label rdf:datatype="&xsd;string">P2RX2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400364"/>
		<dto:entrez_xref>22953</dto:entrez_xref>
		<dto:geneSymbol>P2RX2</dto:geneSymbol>
		<dto:geneSynonym>P2X2</dto:geneSynonym>
		<obo:IAO_0000115>The product of this gene belongs to the family of purinoceptors for ATP. This receptor functions as a ligand-gated ion channel. Binding to ATP mediates synaptic transmission between neurons and from neurons to smooth muscle. Multiple transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Aug 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200266 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200266">
		<rdfs:label rdf:datatype="&xsd;string">P2RX3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400364"/>
		<dto:entrez_xref>5024</dto:entrez_xref>
		<dto:geneSymbol>P2RX3</dto:geneSymbol>
		<obo:IAO_0000115>The product of this gene belongs to the family of purinoceptors for ATP. This receptor functions as a ligand-gated ion channel and may transduce ATP-evoked nociceptor activation. Mouse studies suggest that this receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes. It is possible that the development of selective antagonists for this receptor may have a therapeutic potential in pain relief and in the treatment of disorders of urine storage. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200267 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200267">
		<rdfs:label rdf:datatype="&xsd;string">P2RX4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400364"/>
		<dto:entrez_xref>5025</dto:entrez_xref>
		<dto:geneSymbol>P2RX4</dto:geneSymbol>
		<obo:IAO_0000115>The product of this gene belongs to the family of purinoceptors for ATP. This receptor functions as a ligand-gated ion channel with high calcium permeability. The main pharmacological distinction between the members of the purinoceptor family is the relative sensitivity to the antagonists suramin and PPADS. The product of this gene has the lowest sensitivity for these antagonists. Multiple alternatively spliced transcript variants, some protein-coding and some not protein-coding, have been found for this gene. [provided by RefSeq, Feb 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200268 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200268">
		<rdfs:label rdf:datatype="&xsd;string">P2RX5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400364"/>
		<dto:entrez_xref>5026</dto:entrez_xref>
		<dto:geneSymbol>P2RX5</dto:geneSymbol>
		<dto:geneSynonym>P2X5</dto:geneSynonym>
		<obo:IAO_0000115>The product of this gene belongs to the family of purinoceptors for ATP. This receptor functions as a ligand-gated ion channel. Alternative splicing results in multiple transcript variants. Read-through transcription also exists between this gene and the neighboring downstream gene, TAX1BP3 (Tax1 binding protein 3). [provided by RefSeq, Mar 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200269 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200269">
		<rdfs:label rdf:datatype="&xsd;string">P2RX6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400364"/>
		<dto:entrez_xref>9127</dto:entrez_xref>
		<dto:geneSymbol>P2RX6</dto:geneSymbol>
		<dto:geneSynonym>P2X6</dto:geneSynonym>
		<dto:geneSynonym>P2RXL1</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene belongs to the family of P2X receptors, which are ATP-gated ion channels and mediate rapid and selective permeability to cations. This gene is predominantly expressed in skeletal muscle, and regulated by p53. The encoded protein is associated with VE-cadherin at the adherens junctions of human umbilical vein endothelial cells. Alternative splicing results in multiple transcript variants. A related pseudogene, which is also located on chromosome 22, has been identified. [provided by RefSeq, Apr 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200270 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200270">
		<rdfs:label rdf:datatype="&xsd;string">P2RX7 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400364"/>
		<dto:entrez_xref>5027</dto:entrez_xref>
		<dto:geneSymbol>P2RX7</dto:geneSymbol>
		<obo:IAO_0000115>The product of this gene belongs to the family of purinoceptors for ATP. This receptor functions as a ligand-gated ion channel and is responsible for ATP-dependent lysis of macrophages through the formation of membrane pores permeable to large molecules. Activation of this nuclear receptor by ATP in the cytoplasm may be a mechanism by which cellular activity can be coupled to changes in gene expression. Multiple alternatively spliced variants have been identified, most of which fit nonsense-mediated decay (NMD) criteria. [provided by RefSeq, Jul 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200271 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200271">
		<rdfs:label rdf:datatype="&xsd;string">PANX1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400365"/>
		<dto:entrez_xref>24145</dto:entrez_xref>
		<dto:geneSymbol>PANX1</dto:geneSymbol>
		<dto:geneSynonym>MRS1</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene belongs to the innexin family. Innexin family members are the structural components of gap junctions. This protein and pannexin 2 are abundantly expressed in central nerve system (CNS) and are coexpressed in various neuronal populations. Studies in Xenopus oocytes suggest that this protein alone and in combination with pannexin 2 may form cell type-specific gap junctions with distinct properties. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200272 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200272">
		<rdfs:label rdf:datatype="&xsd;string">PANX2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400365"/>
		<dto:entrez_xref>56666</dto:entrez_xref>
		<dto:geneSymbol>PANX2</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded by this gene belongs to the innexin family. Innexin family members are the structural components of gap junctions. This protein and pannexin 1 are abundantly expressed in central nervous system (CNS) and are coexpressed in various neuronal populations. Studies in Xenopus oocytes suggest that this protein alone and in combination with pannexin 1 may form cell type-specific gap junctions with distinct properties. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200273 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200273">
		<rdfs:label rdf:datatype="&xsd;string">PANX3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400365"/>
		<dto:entrez_xref>116337</dto:entrez_xref>
		<dto:geneSymbol>PANX3</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded by this gene belongs to the innexin family. Innexin family members are known to be the structural components of gap junctions. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200274 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200274">
		<rdfs:label rdf:datatype="&xsd;string">PIEZO1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400366"/>
		<dto:entrez_xref>9780</dto:entrez_xref>
		<dto:geneSymbol>PIEZO1</dto:geneSymbol>
		<dto:geneSynonym>KIAA0233</dto:geneSynonym>
		<dto:geneSynonym>FAM38A</dto:geneSynonym>
		<obo:IAO_0000115>Piezos are large transmembrane proteins conserved among various species, all having between 24 and 36 predicted transmembrane domains. &apos;Piezo&apos; comes from the Greek &apos;piesi,&apos; meaning &apos;pressure.&apos; The FAM38A gene encodes PIEZO1, a protein that induces mechanically activated (MA) currents in various cell types (Coste et al., 2010 [PubMed 20813920]).[supplied by OMIM, Nov 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200275 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200275">
		<rdfs:label rdf:datatype="&xsd;string">PIEZO2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400366"/>
		<dto:entrez_xref>63895</dto:entrez_xref>
		<dto:geneSymbol>PIEZO2</dto:geneSymbol>
		<dto:geneSynonym>C18orf58</dto:geneSynonym>
		<dto:geneSynonym>FAM38B</dto:geneSynonym>
		<dto:geneSynonym>C18orf30</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene contains more than thirty transmembrane domains and likely functions as part of mechanically-activated (MA) cation channels. These channels serve to connect mechanical forces to biological signals. The encoded protein quickly adapts MA currents in somatosensory neurons. Defects in this gene are a cause of type 5 distal arthrogryposis. Several alternatively spliced transcript variants of this gene have been described, but their full-length nature is not known. [provided by RefSeq, Feb 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200276 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200276">
		<rdfs:label rdf:datatype="&xsd;string">PKD1L2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400367"/>
		<dto:entrez_xref>114780</dto:entrez_xref>
		<dto:geneSymbol>PKD1L2</dto:geneSymbol>
		<dto:geneSynonym>PC1L2</dto:geneSynonym>
		<dto:geneSynonym>KIAA1879</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the polycystin protein family. The encoded protein contains 11 transmembrane domains, a latrophilin/CL-1-like GPCR proteolytic site (GPS) domain, and a polycystin-1, lipoxygenase, alpha-toxin (PLAT) domain. This protein may function as a component of cation channel pores. This gene appears to be a polymorphic pseudogene in humans, where some individuals contain a non-functional allele. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200277 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200277">
		<rdfs:label rdf:datatype="&xsd;string">PKD1L3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400367"/>
		<dto:entrez_xref>342372</dto:entrez_xref>
		<dto:geneSymbol>PKD1L3</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the polycystin protein family. The encoded protein contains 11 transmembrane domains, a latrophilin/CL-1-like GPCR proteolytic site (GPS) domain, and a polycystin-1, lipoxygenase, alpha-toxin (PLAT) domain. This protein may function as a component of cation channel pores.[provided by RefSeq, Apr 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200278 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200278">
		<rdfs:label rdf:datatype="&xsd;string">PKD2L1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400367"/>
		<dto:entrez_xref>9033</dto:entrez_xref>
		<dto:geneSymbol>PKD2L1</dto:geneSymbol>
		<dto:geneSynonym>PKDL</dto:geneSynonym>
		<dto:geneSynonym>TRPP3</dto:geneSynonym>
		<dto:geneSynonym>PKD2L</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the polycystin protein family. The encoded protein contains multiple transmembrane domains, and cytoplasmic N- and C-termini. The protein may be an integral membrane protein involved in cell-cell/matrix interactions. This protein functions as a calcium-regulated nonselective cation channel. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200279 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200279">
		<rdfs:label rdf:datatype="&xsd;string">PKD2L2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400367"/>
		<dto:entrez_xref>27039</dto:entrez_xref>
		<dto:geneSymbol>PKD2L2</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200280 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200280">
		<rdfs:label rdf:datatype="&xsd;string">PKD2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400367"/>
		<dto:entrez_xref>5311</dto:entrez_xref>
		<dto:geneSymbol>PKD2</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the polycystin protein family. The encoded protein is a multi-pass membrane protein that functions as a calcium permeable cation channel, and is involved in calcium transport and calcium signaling in renal epithelial cells. This protein interacts with polycystin 1, and they may be partners in a common signaling cascade involved in tubular morphogenesis. Mutations in this gene are associated with autosomal dominant polycystic kidney disease type 2. [provided by RefSeq, Mar 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200281 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200281">
		<rdfs:label rdf:datatype="&xsd;string">PKDREJ gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400367"/>
		<dto:entrez_xref>10343</dto:entrez_xref>
		<dto:geneSymbol>PKDREJ</dto:geneSymbol>
		<obo:IAO_0000115>This intronless gene encodes a member of the polycystin protein family. The encoded protein contains 11 transmembrane domains, a receptor for egg jelly (REJ) domain, a G-protein-coupled receptor proteolytic site (GPS) domain, and a polycystin-1, lipoxygenase, alpha-toxin (PLAT) domain. This protein may play a role in human reproduction. Alternative splice variants have been described but their biological natures have not been determined. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200282 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200282">
		<rdfs:label rdf:datatype="&xsd;string">PLLP gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
		<dto:geneSymbol>PLLP</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200283 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200283">
		<rdfs:label rdf:datatype="&xsd;string">FXYD1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400348"/>
		<dto:entrez_xref>5348</dto:entrez_xref>
		<dto:geneSymbol>FXYD1</dto:geneSymbol>
		<dto:geneSynonym>PLM</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Mouse FXYD5 has been termed RIC (Related to Ion Channel). FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. The protein encoded by this gene is a plasma membrane substrate for several kinases, including protein kinase A, protein kinase C, NIMA kinase, and myotonic dystrophy kinase. It is thought to form an ion channel or regulate ion channel activity. Transcript variants with different 5&apos; UTR sequences have been described in the literature. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200284 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200284">
		<rdfs:label rdf:datatype="&xsd;string">RYR1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400460"/>
		<dto:entrez_xref>6261</dto:entrez_xref>
		<dto:geneSymbol>RYR1</dto:geneSymbol>
		<dto:geneSynonym>RYDR</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a ryanodine receptor found in skeletal muscle. The encoded protein functions as a calcium release channel in the sarcoplasmic reticulum but also serves to connect the sarcoplasmic reticulum and transverse tubule. Mutations in this gene are associated with malignant hyperthermia susceptibility, central core disease, and minicore myopathy with external ophthalmoplegia. Alternatively spliced transcripts encoding different isoforms have been described. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200285 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200285">
		<rdfs:label rdf:datatype="&xsd;string">RYR2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400461"/>
		<dto:entrez_xref>6262</dto:entrez_xref>
		<dto:geneSymbol>RYR2</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a ryanodine receptor found in cardiac muscle sarcoplasmic reticulum. The encoded protein is one of the components of a calcium channel, composed of a tetramer of the ryanodine receptor proteins and a tetramer of FK506 binding protein 1B proteins, that supplies calcium to cardiac muscle. Mutations in this gene are associated with stress-induced polymorphic ventricular tachycardia and arrhythmogenic right ventricular dysplasia. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200286 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200286">
		<rdfs:label rdf:datatype="&xsd;string">RYR3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400462"/>
		<dto:entrez_xref>6263</dto:entrez_xref>
		<dto:geneSymbol>RYR3</dto:geneSymbol>
		<dto:geneSynonym>HBRR</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene is a ryanodine receptor, which functions to release calcium from intracellular storage for use in many cellular processes. For example, the encoded protein is involved in skeletal muscle contraction by releasing calcium from the sarcoplasmic reticulum followed by depolarization of T-tubules. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200287 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200287">
		<rdfs:label rdf:datatype="&xsd;string">SLC26A1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400368"/>
		<dto:entrez_xref>10861</dto:entrez_xref>
		<dto:geneSymbol>SLC26A1</dto:geneSymbol>
		<dto:geneSynonym>SAT1</dto:geneSynonym>
		<obo:IAO_0000115>This gene is a member of a family of sulfate/anion transporter genes. Family members are well conserved in their genomic (number and size of exons) and protein (aa length among species) structures, but have markedly different tissue expression patterns. This gene is primarily expressed in the liver, pancreas, and brain. Three splice variants that encode different isoforms have been identified. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200288 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200288">
		<rdfs:label rdf:datatype="&xsd;string">SLC26A6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400368"/>
		<dto:entrez_xref>65010</dto:entrez_xref>
		<dto:geneSymbol>SLC26A6</dto:geneSymbol>
		<obo:IAO_0000115>This gene belongs to the solute carrier 26 family, whose members encode anion transporter proteins. This particular family member encodes a protein involved in transporting chloride, oxalate, sulfate and bicarbonate. Alternatively spliced transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Aug 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200289 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200289">
		<rdfs:label rdf:datatype="&xsd;string">SCN1A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400463"/>
		<dto:entrez_xref>6323</dto:entrez_xref>
		<dto:geneSymbol>SCN1A</dto:geneSymbol>
		<dto:geneSynonym>SCN1</dto:geneSynonym>
		<dto:geneSynonym>NAC1</dto:geneSynonym>
		<obo:IAO_0000115>The vertebrate sodium channel is a voltage-gated ion channel essential for the generation and propagation of action potentials, mainly in nerve and muscle. Voltage-sensitive sodium channels are heteromeric complexes consisting of a large central pore-forming glycosylated alpha subunit, and two smaller auxiliary beta subunits. This gene encodes the large alpha subunit, and mutations in this gene have been associated with several epilepsy, convulsion and migraine disorders. Alternative splicing results in multiple transcript variants. The RefSeq Project has decided to create four representative RefSeq records. Three of the transcript variants are supported by experimental evidence and the fourth contains alternate 5&apos; untranslated exons, the exact combination of which have not been experimentally confirmed for the full-length transcript.[provided by RefSeq, Jan 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200290 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200290">
		<rdfs:label rdf:datatype="&xsd;string">SCN1B gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400464"/>
		<dto:entrez_xref>6324</dto:entrez_xref>
		<dto:geneSymbol>SCN1B</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated sodium channels are heteromeric proteins that function in the generation and propagation of action potentials in muscle and neuronal cells. They are composed of one alpha and two beta subunits, where the alpha subunit provides channel activity and the beta-1 subunit modulates the kinetics of channel inactivation. This gene encodes a sodium channel beta-1 subunit. Mutations in this gene result in generalized epilepsy with febrile seizures plus, Brugada syndrome 5, and defects in cardiac conduction. Multiple transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Oct 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200291 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200291">
		<rdfs:label rdf:datatype="&xsd;string">SCN2A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400465"/>
		<dto:entrez_xref>6326</dto:entrez_xref>
		<dto:geneSymbol>SCN2A</dto:geneSymbol>
		<dto:geneSynonym>SCN2A1</dto:geneSynonym>
		<dto:geneSynonym>SCN2A2</dto:geneSynonym>
		<dto:geneSynonym>NAC2</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-gated sodium channels are transmembrane glycoprotein complexes composed of a large alpha subunit with 24 transmembrane domains and one or more regulatory beta subunits. They are responsible for the generation and propagation of action potentials in neurons and muscle. This gene encodes one member of the sodium channel alpha subunit gene family. It is heterogeneously expressed in the brain, and mutations in this gene have been linked to several seizure disorders. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been determined. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200292 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200292">
		<rdfs:label rdf:datatype="&xsd;string">SCN2B gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400466"/>
		<dto:entrez_xref>6327</dto:entrez_xref>
		<dto:geneSymbol>SCN2B</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200293 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200293">
		<rdfs:label rdf:datatype="&xsd;string">SCN3A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400467"/>
		<dto:entrez_xref>6328</dto:entrez_xref>
		<dto:geneSymbol>SCN3A</dto:geneSymbol>
		<dto:geneSynonym>NAC3</dto:geneSynonym>
		<dto:geneSynonym>KIAA1356</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-gated sodium channels are transmembrane glycoprotein complexes composed of a large alpha subunit with 24 transmembrane domains and one or more regulatory beta subunits. They are responsible for the generation and propagation of action potentials in neurons and muscle. This gene encodes one member of the sodium channel alpha subunit gene family, and is found in a cluster of five alpha subunit genes on chromosome 2. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200294 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200294">
		<rdfs:label rdf:datatype="&xsd;string">SCN3B gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400468"/>
		<dto:entrez_xref>55800</dto:entrez_xref>
		<dto:geneSymbol>SCN3B</dto:geneSymbol>
		<dto:geneSynonym>KIAA1158</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-gated sodium channels are transmembrane glycoprotein complexes composed of a large alpha subunit and one or more regulatory beta subunits. They are responsible for the generation and propagation of action potentials in neurons and muscle. This gene encodes one member of the sodium channel beta subunit gene family, and influences the inactivation kinetics of the sodium channel. Two alternatively spliced variants, encoding the same protein, have been identified. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200295 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200295">
		<rdfs:label rdf:datatype="&xsd;string">SCN4A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400469"/>
		<dto:entrez_xref>6329</dto:entrez_xref>
		<dto:geneSymbol>SCN4A</dto:geneSymbol>
		<obo:IAO_0000115>Voltage-gated sodium channels are transmembrane glycoprotein complexes composed of a large alpha subunit with 24 transmembrane domains and one or more regulatory beta subunits. They are responsible for the generation and propagation of action potentials in neurons and muscle. This gene encodes one member of the sodium channel alpha subunit gene family. It is expressed in skeletal muscle, and mutations in this gene have been linked to several myotonia and periodic paralysis disorders. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200296 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200296">
		<rdfs:label rdf:datatype="&xsd;string">SCN4B gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400470"/>
		<dto:entrez_xref>6330</dto:entrez_xref>
		<dto:geneSymbol>SCN4B</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded by this gene is one of several sodium channel beta subunits. These subunits interact with voltage-gated alpha subunits to change sodium channel kinetics. The encoded transmembrane protein forms interchain disulfide bonds with SCN2A. Defects in this gene are a cause of long QT syndrome type 10 (LQT10). Three protein-coding and one non-coding transcript variant have been found for this gene.[provided by RefSeq, Mar 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200297 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200297">
		<rdfs:label rdf:datatype="&xsd;string">SCN5A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400471"/>
		<dto:entrez_xref>6331</dto:entrez_xref>
		<dto:geneSymbol>SCN5A</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded by this gene is an integral membrane protein and tetrodotoxin-resistant voltage-gated sodium channel subunit. This protein is found primarily in cardiac muscle and is responsible for the initial upstroke of the action potential in an electrocardiogram. Defects in this gene are a cause of long QT syndrome type 3 (LQT3), an autosomal dominant cardiac disease. Alternative splicing results in several transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200298 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200298">
		<rdfs:label rdf:datatype="&xsd;string">SCN7A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400472"/>
		<dto:entrez_xref>6332</dto:entrez_xref>
		<dto:geneSymbol>SCN7A</dto:geneSymbol>
		<dto:geneSynonym>SCN6A</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes one of the many voltage-gated sodium channel proteins. For proper functioning of neurons and muscles during action potentials, voltage-gated sodium channels direct sodium ion diffusion for membrane depolarization. This sodium channel protein has some atypical characteristics; the similarity between the human and mouse proteins is lower compared to other orthologous sodium channel pairs. Also, the S4 segments, which sense voltage changes, have fewer positive charged residues that in other sodium channels; domain 4 has fewer arginine and lysine residues compared to other sodium channel proteins. Several alternatively spliced transcript variants exist, but the full-length natures of all of them remain unknown. [provided by RefSeq, Dec 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200299 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200299">
		<rdfs:label rdf:datatype="&xsd;string">SCN8A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400473"/>
		<dto:entrez_xref>6334</dto:entrez_xref>
		<dto:geneSymbol>SCN8A</dto:geneSymbol>
		<dto:geneSynonym>MED</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the sodium channel alpha subunit gene family. The encoded protein forms the ion pore region of the voltage-gated sodium channel. This protein is essential for the rapid membrane depolarization that occurs during the formation of the action potential in excitable neurons. Mutations in this gene are associated with mental retardation, pancerebellar atrophy and ataxia. Alternate splicing results in multiple transcript variants.[provided by RefSeq, May 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200300 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200300">
		<rdfs:label rdf:datatype="&xsd;string">SCN9A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400474"/>
		<dto:entrez_xref>6335</dto:entrez_xref>
		<dto:geneSymbol>SCN9A</dto:geneSymbol>
		<dto:geneSynonym>NENA</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a voltage-gated sodium channel which plays a significant role in nociception signaling. Mutations in this gene have been associated with primary erythermalgia, channelopathy-associated insensitivity to pain, and paroxysmal extreme pain disorder. [provided by RefSeq, Aug 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200301 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200301">
		<rdfs:label rdf:datatype="&xsd;string">SCN10A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400475"/>
		<dto:entrez_xref>6336</dto:entrez_xref>
		<dto:geneSymbol>SCN10A</dto:geneSymbol>
		<obo:IAO_0000115>The protein encoded by this gene is a tetrodotoxin-resistant voltage-gated sodium channel alpha subunit. The properties of the channel formed by the encoded transmembrane protein can be altered by interaction with different beta subunits. This protein may be involved in the onset of pain associated with peripheral neuropathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jun 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200302 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200302">
		<rdfs:label rdf:datatype="&xsd;string">SCN11A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400476"/>
		<dto:entrez_xref>11280</dto:entrez_xref>
		<dto:geneSymbol>SCN11A</dto:geneSymbol>
		<dto:geneSynonym>SNS2</dto:geneSynonym>
		<dto:geneSynonym>SCN12A</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-gated sodium channels are membrane protein complexes that play a fundamental role in the rising phase of the action potential in most excitable cells. Alpha subunits, such as SCN11A, mediate voltage-dependent gating and conductance, while auxiliary beta subunits regulate the kinetic properties of the channel and facilitate membrane localization of the complex. Aberrant expression patterns or mutations of alpha subunits underlie a number of disorders. Each alpha subunit consists of 4 domains connected by 3 intracellular loops; each domain consists of 6 transmembrane segments and intra- and extracellular linkers.[supplied by OMIM, Apr 2004]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200303 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200303">
		<rdfs:label rdf:datatype="&xsd;string">SCNN1A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400477"/>
		<dto:entrez_xref>6337</dto:entrez_xref>
		<dto:geneSymbol>SCNN1A</dto:geneSymbol>
		<dto:geneSynonym>SCNN1</dto:geneSynonym>
		<obo:IAO_0000115>Nonvoltage-gated, amiloride-sensitive, sodium channels control fluid and electrolyte transport across epithelia in many organs. These channels are heteromeric complexes consisting of 3 subunits: alpha, beta, and gamma. This gene encodes the alpha subunit, and mutations in this gene have been associated with pseudohypoaldosteronism type 1 (PHA1), a rare salt wasting disease resulting from target organ unresponsiveness to mineralocorticoids. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Apr 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200304 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200304">
		<rdfs:label rdf:datatype="&xsd;string">SCNN1B gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400478"/>
		<dto:entrez_xref>6338</dto:entrez_xref>
		<dto:geneSymbol>SCNN1B</dto:geneSymbol>
		<obo:IAO_0000115>Nonvoltage-gated, amiloride-sensitive, sodium channels control fluid and electrolyte transport across epithelia in many organs. These channels are heteromeric complexes consisting of 3 subunits: alpha, beta, and gamma. This gene encodes the beta subunit, and mutations in this gene have been associated with pseudohypoaldosteronism type 1 (PHA1), and Liddle syndrome. [provided by RefSeq, Apr 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200305 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200305">
		<rdfs:label rdf:datatype="&xsd;string">SCNN1D gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400479"/>
		<dto:entrez_xref>6339</dto:entrez_xref>
		<dto:geneSymbol>SCNN1D</dto:geneSymbol>
		<dto:geneSynonym>DNACH</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200306 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200306">
		<rdfs:label rdf:datatype="&xsd;string">SCNN1G gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400480"/>
		<dto:entrez_xref>6340</dto:entrez_xref>
		<dto:geneSymbol>SCNN1G</dto:geneSymbol>
		<obo:IAO_0000115>Nonvoltage-gated, amiloride-sensitive, sodium channels control fluid and electrolyte transport across epithelia in many organs. These channels are heteromeric complexes consisting of 3 subunits: alpha, beta, and gamma. This gene encodes the gamma subunit, and mutations in this gene have been associated with Liddle syndrome. [provided by RefSeq, Apr 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200307 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200307">
		<rdfs:label rdf:datatype="&xsd;string">TMEM38A gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400371"/>
		<dto:entrez_xref>79041</dto:entrez_xref>
		<dto:geneSymbol>TMEM38A</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200308 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200308">
		<rdfs:label rdf:datatype="&xsd;string">TMEM38B gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400371"/>
		<dto:entrez_xref>55151</dto:entrez_xref>
		<dto:geneSymbol>TMEM38B</dto:geneSymbol>
		<dto:geneSynonym>C9orf87</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes an intracellular monovalent cation channel that functions in maintenance of intracellular calcium release. Mutations in this gene may be associated with autosomal recessive osteogenesis. [provided by RefSeq, Oct 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200309 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200309">
		<rdfs:label rdf:datatype="&xsd;string">TMC1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400372"/>
		<dto:entrez_xref>117531</dto:entrez_xref>
		<dto:geneSymbol>TMC1</dto:geneSymbol>
		<obo:IAO_0000115>This gene is considered a member of a gene family predicted to encode transmembrane proteins. The specific function of this gene is unknown; however, it is known to be required for normal function of cochlear hair cells. Mutations in this gene have been associated with progressive postlingual hearing loss and profound prelingual deafness. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200310 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200310">
		<rdfs:label rdf:datatype="&xsd;string">TMC2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400372"/>
		<dto:entrez_xref>117532</dto:entrez_xref>
		<dto:geneSymbol>TMC2</dto:geneSymbol>
		<dto:geneSynonym>C20orf145</dto:geneSynonym>
		<obo:IAO_0000115>This gene is considered a member of a gene family predicted to encode transmembrane proteins. The specific function of this gene is unknown; however, expression in the inner ear suggests that it may be crucial for normal auditory function. Mutations in this gene may underlie hereditary disorders of balance and hearing. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200311 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200311">
		<rdfs:label rdf:datatype="&xsd;string">TMC3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400372"/>
		<dto:entrez_xref>342125</dto:entrez_xref>
		<dto:geneSymbol>TMC3</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200312 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200312">
		<rdfs:label rdf:datatype="&xsd;string">TMC4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400372"/>
		<dto:entrez_xref>147798</dto:entrez_xref>
		<dto:geneSymbol>TMC4</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200313 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200313">
		<rdfs:label rdf:datatype="&xsd;string">TMC5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400372"/>
		<dto:entrez_xref>79838</dto:entrez_xref>
		<dto:geneSymbol>TMC5</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200314 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200314">
		<rdfs:label rdf:datatype="&xsd;string">TMC6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400329"/>
		<dto:entrez_xref>11322</dto:entrez_xref>
		<dto:geneSymbol>TMC6</dto:geneSymbol>
		<dto:geneSynonym>EVIN1</dto:geneSynonym>
		<dto:geneSynonym>EVER1</dto:geneSynonym>
		<obo:IAO_0000115>Epidermodysplasia verruciformis (EV) is an autosomal recessive dermatosis characterized by abnormal susceptibility to human papillomaviruses (HPVs) and a high rate of progression to squamous cell carcinoma on sun-exposed skin. EV is caused by mutations in either of two adjacent genes located on chromosome 17q25.3. Both of these genes encode integral membrane proteins that localize to the endoplasmic reticulum and are predicted to form transmembrane channels. This gene encodes a transmembrane channel-like protein with 10 transmembrane domains and 2 leucine zipper motifs. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200315 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200315">
		<rdfs:label rdf:datatype="&xsd;string">TMC7 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400372"/>
		<dto:entrez_xref>79905</dto:entrez_xref>
		<dto:geneSymbol>TMC7</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200316 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200316">
		<rdfs:label rdf:datatype="&xsd;string">TMC8 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400329"/>
		<dto:entrez_xref>147138</dto:entrez_xref>
		<dto:geneSymbol>TMC8</dto:geneSymbol>
		<dto:geneSynonym>EVIN2</dto:geneSynonym>
		<dto:geneSynonym>EVER2</dto:geneSynonym>
		<obo:IAO_0000115>Epidermodysplasia verruciformis (EV) is an autosomal recessive dermatosis characterized by abnormal susceptibility to human papillomaviruses (HPVs) and a high rate of progression to squamous cell carcinoma on sun-exposed skin. EV is caused by mutations in either of two adjacent genes located on chromosome 17q25.3. Both of these genes encode integral membrane proteins that localize to the endoplasmic reticulum and are predicted to form transmembrane channels. This gene encodes a transmembrane channel-like protein with 8 predicted transmembrane domains and 3 leucine zipper motifs. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200317 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200317">
		<rdfs:label rdf:datatype="&xsd;string">TPCN1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400481"/>
		<dto:entrez_xref>53373</dto:entrez_xref>
		<dto:geneSymbol>TPCN1</dto:geneSymbol>
		<dto:geneSynonym>TPC1</dto:geneSynonym>
		<dto:geneSynonym>KIAA1169</dto:geneSynonym>
		<obo:IAO_0000115>Voltage-gated Ca(2+) and Na+ channels have 4 homologous domains, each containing 6 transmembrane segments, S1 to S6. TPCN1 is similar to these channels, but it has only 2 domains containing S1 to S6 (Ishibashi et al., 2000 [PubMed 10753632]).[supplied by OMIM, Mar 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200318 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200318">
		<rdfs:label rdf:datatype="&xsd;string">TPCN2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400481"/>
		<dto:entrez_xref>219931</dto:entrez_xref>
		<dto:geneSymbol>TPCN2</dto:geneSymbol>
		<dto:geneSynonym>TPC2</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a putative cation-selective ion channel with two repeats of a six-transmembrane-domain. The protein localizes to lysosomal membranes and enables nicotinic acid adenine dinucleotide phosphate (NAADP) -induced calcium ion release from lysosome-related stores. This ubiquitously expressed gene has elevated expression in liver and kidney. Two common nonsynonymous SNPs in this gene strongly associate with blond versus brown hair pigmentation.[provided by RefSeq, Dec 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200319 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200319">
		<rdfs:label rdf:datatype="&xsd;string">TRPA1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400360"/>
		<dto:entrez_xref>8989</dto:entrez_xref>
		<dto:geneSymbol>TRPA1</dto:geneSymbol>
		<dto:geneSynonym>ANKTM1</dto:geneSynonym>
		<obo:IAO_0000115>The structure of the protein encoded by this gene is highly related to both the protein ankyrin and transmembrane proteins.  The specific function of this protein has not yet been determined; however, studies indicate the function may involve a role in signal transduction and growth control. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200320 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200320">
		<rdfs:label rdf:datatype="&xsd;string">TRPC1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400577"/>
		<dto:entrez_xref>7220</dto:entrez_xref>
		<dto:geneSymbol>TRPC1</dto:geneSymbol>
		<dto:geneSynonym>TRP1</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene is a membrane protein that can form a non-selective channel permeable to calcium and other cations. The encoded protein appears to be induced to form channels by a receptor tyrosine kinase-activated phosphatidylinositol second messenger system and also by depletion of intracellular calcium stores. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200321 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200321">
		<rdfs:label rdf:datatype="&xsd;string">TRPC3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400578"/>
		<dto:entrez_xref>7222</dto:entrez_xref>
		<dto:geneSymbol>TRPC3</dto:geneSymbol>
		<dto:geneSynonym>TRP3</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene is a membrane protein that can form a non-selective channel permeable to calcium and other cations. The encoded protein appears to be induced to form channels by a receptor tyrosine kinase-activated phosphatidylinositol second messenger system and also by depletion of intracellular calcium stores. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200322 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200322">
		<rdfs:label rdf:datatype="&xsd;string">TRPC4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400579"/>
		<dto:entrez_xref>7223</dto:entrez_xref>
		<dto:geneSymbol>TRPC4</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the canonical subfamily of transient receptor potential cation channels. The encoded protein forms a non-selective calcium-permeable cation channel that is activated by Gq-coupled receptors and tyrosine kinases, and plays a role in multiple processes including endothelial permeability, vasodilation, neurotransmitter release and cell proliferation. Single nucleotide polymorphisms in this gene may be associated with generalized epilepsy with photosensitivity. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Aug 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200323 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200323">
		<rdfs:label rdf:datatype="&xsd;string">TRPC5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400580"/>
		<dto:entrez_xref>7224</dto:entrez_xref>
		<dto:geneSymbol>TRPC5</dto:geneSymbol>
		<dto:geneSynonym>TRP5</dto:geneSynonym>
		<obo:IAO_0000115>This gene belongs to the transient receptor family. It encodes one of the seven mammalian TRPC (transient receptor potential channel) proteins. The encoded protein is a multi-pass membrane protein and is thought to form a receptor-activated non-selective calcium permeant cation channel. The protein is active alone or as a heteromultimeric assembly with TRPC1, TRPC3, and TRPC4. It also interacts with multiple proteins including calmodulin, CABP1, enkurin, Na(+)-H+ exchange regulatory factor (NHERF ), interferon-induced GTP-binding protein (MX1), ring finger protein 24 (RNF24), and SEC14 domain and spectrin repeat-containing protein 1 (SESTD1). [provided by RefSeq, May 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200324 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200324">
		<rdfs:label rdf:datatype="&xsd;string">TRPC6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400581"/>
		<dto:entrez_xref>7225</dto:entrez_xref>
		<dto:geneSymbol>TRPC6</dto:geneSymbol>
		<dto:geneSynonym>TRP6</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene forms a receptor-activated calcium channel in the cell membrane. The channel is activated by diacylglycerol and is thought to be under the control of a phosphatidylinositol second messenger system. Activation of this channel occurs independently of protein kinase C and is not triggered by low levels of intracellular calcium. Defects in this gene are a cause of focal segmental glomerulosclerosis 2 (FSGS2). [provided by RefSeq, Mar 2009]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200325 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200325">
		<rdfs:label rdf:datatype="&xsd;string">TRPC7 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400582"/>
		<dto:entrez_xref>57113</dto:entrez_xref>
		<dto:geneSymbol>TRPC7</dto:geneSymbol>
		<dto:geneSynonym>TRP7</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200326 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200326">
		<rdfs:label rdf:datatype="&xsd;string">TRPM1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400583"/>
		<dto:entrez_xref>4308</dto:entrez_xref>
		<dto:geneSymbol>TRPM1</dto:geneSymbol>
		<dto:geneSynonym>MLSN</dto:geneSynonym>
		<dto:geneSynonym>MLSN1</dto:geneSynonym>
		<dto:geneSynonym>LTRPC1</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the transient receptor potential melastatin subfamily of transient receptor potential ion channels. The encoded protein is a calcium permeable cation channel that is expressed in melanocytes and may play a role in melanin synthesis. Specific mutations in this gene are the cause autosomal recessive complete congenital stationary night blindness-1C. The expression of this protein is inversely correlated with melanoma aggressiveness and as such it is used as a prognostic marker for melanoma metastasis. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Oct 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200327 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200327">
		<rdfs:label rdf:datatype="&xsd;string">TRPM2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400584"/>
		<dto:entrez_xref>7226</dto:entrez_xref>
		<dto:geneSymbol>TRPM2</dto:geneSymbol>
		<dto:geneSynonym>KNP3</dto:geneSynonym>
		<dto:geneSynonym>LTRPC2</dto:geneSynonym>
		<dto:geneSynonym>EREG1</dto:geneSynonym>
		<dto:geneSynonym>TRPC7</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene is a calcium-permeable cation channel that is regulated by free intracellular ADP-ribose. The encoded protein is activated by oxidative stress and confers susceptibility to cell death. Several alternatively spliced transcript variants of this gene have been described, but their full-length nature is not known. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200328 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200328">
		<rdfs:label rdf:datatype="&xsd;string">TRPM3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400585"/>
		<dto:entrez_xref>80036</dto:entrez_xref>
		<dto:geneSymbol>TRPM3</dto:geneSymbol>
		<dto:geneSynonym>LTRPC3</dto:geneSynonym>
		<dto:geneSynonym>KIAA1616</dto:geneSynonym>
		<obo:IAO_0000115>The product of this gene belongs to the family of transient receptor potential (TRP) channels. TRP channels are cation-selective channels important for cellular calcium signaling and homeostasis. The protein encoded by this gene mediates calcium entry, and this entry is potentiated by calcium store depletion. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200329 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200329">
		<rdfs:label rdf:datatype="&xsd;string">TRPM4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400586"/>
		<dto:entrez_xref>54795</dto:entrez_xref>
		<dto:geneSymbol>TRPM4</dto:geneSymbol>
		<dto:geneSynonym>LTRPC4</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene is a calcium-activated nonselective ion channel that mediates transport of monovalent cations across membranes, thereby depolarizing the membrane. The activity of the encoded protein increases with increasing intracellular calcium concentration, but this channel does not transport calcium. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200330 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200330">
		<rdfs:label rdf:datatype="&xsd;string">TRPM5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400587"/>
		<dto:entrez_xref>29850</dto:entrez_xref>
		<dto:geneSymbol>TRPM5</dto:geneSymbol>
		<dto:geneSynonym>MTR1</dto:geneSynonym>
		<dto:geneSynonym>LTRPC5</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the transient receptor potential (TRP) protein family, which is a diverse group of proteins with structural features typical of ion channels. This protein plays an important role in taste transduction, and has characteristics of a calcium-activated, non-selective cation channel that carries Na+, K+, and Cs+ ions equally well, but not Ca(2+) ions. It is activated by lower concentrations of intracellular Ca(2+), and inhibited by higher concentrations. It is also a highly temperature-sensitive, heat activated channel showing a steep increase of inward currents at temperatures between 15 and 35 degrees Celsius. This gene is located within the Beckwith-Wiedemann syndrome critical region-1 on chromosome 11p15.5, and has been shown to be imprinted, with exclusive expression from the paternal allele. [provided by RefSeq, Oct 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200331 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200331">
		<rdfs:label rdf:datatype="&xsd;string">TRPM7 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400588"/>
		<dto:entrez_xref>54822</dto:entrez_xref>
		<dto:geneSymbol>TRPM7</dto:geneSymbol>
		<dto:geneSynonym>LTRPC7</dto:geneSynonym>
		<dto:geneSynonym>CHAK1</dto:geneSynonym>
		<obo:IAO_0000115>The protein encoded by this gene is both an ion channel and a serine/threonine protein kinase. The kinase activity is essential for the ion channel function, which serves to increase intracellular calcium levels and to help regulate magnesium ion homeostasis. Defects in this gene are a cause of amyotrophic lateral sclerosis-parkinsonism/dementia complex of Guam. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Jul 2014]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200332 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200332">
		<rdfs:label rdf:datatype="&xsd;string">TRPM8 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400589"/>
		<dto:entrez_xref>79054</dto:entrez_xref>
		<dto:geneSymbol>TRPM8</dto:geneSymbol>
		<dto:geneSynonym>TRPP8</dto:geneSynonym>
		<dto:geneSynonym>LTRPC6</dto:geneSynonym>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200333 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200333">
		<rdfs:label rdf:datatype="&xsd;string">TRPV1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400590"/>
		<dto:entrez_xref>7442</dto:entrez_xref>
		<dto:geneSymbol>TRPV1</dto:geneSymbol>
		<dto:geneSynonym>VR1</dto:geneSynonym>
		<obo:IAO_0000115>Capsaicin, the main pungent ingredient in hot chili peppers, elicits a sensation of burning pain by selectively activating sensory neurons that convey information about noxious stimuli to the central nervous system. The protein encoded by this gene is a receptor for capsaicin and is a non-selective cation channel that is structurally related to members of the TRP family of ion channels. This receptor is also activated by increases in temperature in the noxious range, suggesting that it functions as a transducer of painful thermal stimuli in vivo. Four transcript variants encoding the same protein, but with different 5&apos; UTR sequence, have been described for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200334 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200334">
		<rdfs:label rdf:datatype="&xsd;string">TRPV2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400591"/>
		<dto:entrez_xref>51393</dto:entrez_xref>
		<dto:geneSymbol>TRPV2</dto:geneSymbol>
		<dto:geneSynonym>VRL</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes an ion channel that is activated by high temperatures above 52 degrees Celsius. The protein may be involved in transduction of high-temperature heat responses in sensory ganglia. It is thought that in other tissues the channel may be activated by stimuli other than heat. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200335 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200335">
		<rdfs:label rdf:datatype="&xsd;string">TRPV3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400592"/>
		<dto:entrez_xref>162514</dto:entrez_xref>
		<dto:geneSymbol>TRPV3</dto:geneSymbol>
		<obo:IAO_0000115>This gene product belongs to a family of nonselective cation channels that function in a variety of processes, including temperature sensation and vasoregulation. The thermosensitive members of this family are expressed in subsets of sensory neurons that terminate in the skin, and are activated at distinct physiological temperatures. This channel is activated at temperatures between 22 and 40 degrees C. This gene lies in close proximity to another family member gene on chromosome 17, and the two encoded proteins are thought to associate with each other to form heteromeric channels. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200336 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200336">
		<rdfs:label rdf:datatype="&xsd;string">TRPV4 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400593"/>
		<dto:entrez_xref>59341</dto:entrez_xref>
		<dto:geneSymbol>TRPV4</dto:geneSymbol>
		<dto:geneSynonym>VROAC</dto:geneSynonym>
		<dto:geneSynonym>VRL2</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the OSM9-like transient receptor potential channel (OTRPC) subfamily in the transient receptor potential (TRP) superfamily of ion channels. The encoded protein is a Ca2+-permeable, nonselective cation channel that is thought to be involved in the regulation of systemic osmotic pressure. Mutations in this gene are the cause of spondylometaphyseal and metatropic dysplasia and hereditary motor and sensory neuropathy type IIC. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2010]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200337 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200337">
		<rdfs:label rdf:datatype="&xsd;string">TRPV5 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400594"/>
		<dto:entrez_xref>56302</dto:entrez_xref>
		<dto:geneSymbol>TRPV5</dto:geneSymbol>
		<dto:geneSynonym>ECAC1</dto:geneSynonym>
		<obo:IAO_0000115>This gene is a member of the transient receptor family and the TrpV subfamily. The calcium-selective channel encoded by this gene has 6 transmembrane-spanning domains, multiple potential phosphorylation sites, an N-linked glycosylation site, and 5 ANK repeats. This protein forms homotetramers or heterotetramers and is activated by a low internal calcium level. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200338 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200338">
		<rdfs:label rdf:datatype="&xsd;string">TRPV6 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400595"/>
		<dto:entrez_xref>55503</dto:entrez_xref>
		<dto:geneSymbol>TRPV6</dto:geneSymbol>
		<dto:geneSynonym>ECAC2</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of a family of multipass membrane proteins that functions as calcium channels. The encoded protein contains N-terminal ankyrin repeats, which are required for channel assembly and regulation. This gene is situated next to a closely related gene for transient receptor potential cation channel subfamily V member 5 (TRPV5). This locus has experienced positive selection in non-African populations, resulting in several non-synonymous codon differences among individuals of different genetic backgrounds. [provided by RefSeq, Jul 2013]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200339 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200339">
		<rdfs:label rdf:datatype="&xsd;string">TTYH1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400373"/>
		<dto:entrez_xref>57348</dto:entrez_xref>
		<dto:geneSymbol>TTYH1</dto:geneSymbol>
		<obo:IAO_0000115>This gene encodes a member of the tweety family of proteins. Members of this family function as chloride anion channels. The encoded protein functions as a calcium(2+)-independent, volume-sensitive large conductance chloride(-) channel. Three transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jan 2011]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200340 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200340">
		<rdfs:label rdf:datatype="&xsd;string">TTYH2 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400373"/>
		<dto:entrez_xref>94015</dto:entrez_xref>
		<dto:geneSymbol>TTYH2</dto:geneSymbol>
		<dto:geneSynonym>C17orf29</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the tweety family of proteins. Members of this family function as chloride anion channels. The encoded protein functions as a calcium(2+)-activated large conductance chloride(-) channel, and may play a role in kidney tumorigenesis. Two transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200341 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200341">
		<rdfs:label rdf:datatype="&xsd;string">TTYH3 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400373"/>
		<dto:entrez_xref>80727</dto:entrez_xref>
		<dto:geneSymbol>TTYH3</dto:geneSymbol>
		<dto:geneSynonym>KIAA1691</dto:geneSynonym>
		<obo:IAO_0000115>This gene encodes a member of the tweety family of proteins. Members of this family function as chloride anion channels. The encoded protein functions as a calcium(2+)-activated large conductance chloride(-) channel. [provided by RefSeq, Jul 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200342 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200342">
		<rdfs:label rdf:datatype="&xsd;string">ZACN gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400328"/>
		<dto:entrez_xref>353174</dto:entrez_xref>
		<dto:geneSymbol>ZACN</dto:geneSymbol>
		<dto:geneSynonym>LGICZ</dto:geneSynonym>
		<dto:geneSynonym>LGICZ1</dto:geneSynonym>
		<dto:geneSynonym>L2</dto:geneSynonym>
		<dto:geneSynonym>ZAC</dto:geneSynonym>
		<obo:IAO_0000115>LGICZ1 is a zinc-activated ligand-gated ion channel that defines a new subgroup of the cysteine-loop superfamily of ligand-gated ion channels (Davies et al., 2003 [PubMed 12381728]).[supplied by OMIM, Mar 2008]</obo:IAO_0000115>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01200343 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01200343">
		<rdfs:label rdf:datatype="&xsd;string">PKD1L1 gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
		<dto:geneSymbol>PKD1L1</dto:geneSymbol>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400327 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400327">
		<rdfs:label rdf:datatype="&xsd;string">Ion channel gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_00200000"/>
		<obo:IAO_0000115>Ion channels are pore-forming membrane proteins whose functions include establishing a resting membrane potential, shaping action potentials and other electrical signals by gating the flow of ions across the cell membrane, controlling the flow of ions across secretory and epithelial cells, and regulating cell volume. Ion channels are present in the membranes of all cells.</obo:IAO_0000115>
		<rdfs:isDefinedBy>https://en.wikipedia.org/wiki/Ion_channel</rdfs:isDefinedBy>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400328 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400328">
		<rdfs:label rdf:datatype="&xsd;string">Neurotransmitter receptor, cys loop, ligand-gated ion channel (lic) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400329 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400329">
		<rdfs:label rdf:datatype="&xsd;string">Calcium-dependent chloride channel (ca-clc) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400330 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400330">
		<rdfs:label rdf:datatype="&xsd;string">Amiloride-sensitive sodium channel family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400331 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400331">
		<rdfs:label rdf:datatype="&xsd;string">Anion channel-forming bestrophin (bestrophin) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400332 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400332">
		<rdfs:label rdf:datatype="&xsd;string">Calcium channel auxiliary subunit 2 types 1-4 (cca-2) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400333 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400333">
		<rdfs:label rdf:datatype="&xsd;string">Calcium channel alpha-1 subunit family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400334 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400334">
		<rdfs:label rdf:datatype="&xsd;string">Calcium channel auxiliary subunit types 1-4 (cca-) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400335 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400335">
		<rdfs:label rdf:datatype="&xsd;string">Calcium homeostasis modulator calcium channel (calhm-c) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400336 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400336">
		<rdfs:label rdf:datatype="&xsd;string">Calcium channel auxiliary subunit 1-8 (cca) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400337 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400337">
		<rdfs:label rdf:datatype="&xsd;string">PMP-22/EMP/MP20 family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400338 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400338">
		<rdfs:label rdf:datatype="&xsd;string">ABCC family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400339 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400339">
		<rdfs:label rdf:datatype="&xsd;string">Epithelial chloride channel (e-clc) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400340 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400340">
		<rdfs:label rdf:datatype="&xsd;string">Intracellular chloride channel (icc) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400341 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400341">
		<rdfs:label rdf:datatype="&xsd;string">Chloride channel family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400342 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400342">
		<rdfs:label rdf:datatype="&xsd;string">Intracellular chloride channel (clic) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400343 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400343">
		<rdfs:label rdf:datatype="&xsd;string">Cyclic nucleotide-gated cation channel family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400344 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400344">
		<rdfs:label rdf:datatype="&xsd;string">Calcium release-activated calcium (crac) channel (crac-c) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400345 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400345">
		<rdfs:label rdf:datatype="&xsd;string">Cation channel sperm-associated family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400346 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400346">
		<rdfs:label rdf:datatype="&xsd;string">Phagocyte (gp91(phox)) nadph oxidase family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400347 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400347">
		<rdfs:label rdf:datatype="&xsd;string">FAM26 family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400348 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400348">
		<rdfs:label rdf:datatype="&xsd;string">Fxyd family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400349 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400349">
		<rdfs:label rdf:datatype="&xsd;string">Phospholemman (plm) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400350 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400350">
		<rdfs:label rdf:datatype="&xsd;string">Golgi pH regulator family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400351 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400351">
		<rdfs:label rdf:datatype="&xsd;string">Glutamate-gated ion channel  (GIC) Family of Neurotransmitter Receptors gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400352 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400352">
		<rdfs:label rdf:datatype="&xsd;string">Voltage-gated proton channel (vpc) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400353 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400353">
		<rdfs:label rdf:datatype="&xsd;string">Inward rectifier-type potassium channel family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400354 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400354">
		<rdfs:label rdf:datatype="&xsd;string">Ryanodine-inositol 1,4,5-triphosphate receptor calcium channel (rir-cac) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400355 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400355">
		<rdfs:label rdf:datatype="&xsd;string">Potassium channel family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400356 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400356">
		<rdfs:label rdf:datatype="&xsd;string">Voltage-gated potassium channel -subunit (kv) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400357 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400357">
		<rdfs:label rdf:datatype="&xsd;string">The phagocyte (gp91(phox)) nadph oxidase family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400358 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400358">
		<rdfs:label rdf:datatype="&xsd;string">Calcium-activated potassium channel auxiliary subunit slowpoke- (slo) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400359 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400359">
		<rdfs:label rdf:datatype="&xsd;string">Two pore domain potassium channel family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400360 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400360">
		<rdfs:label rdf:datatype="&xsd;string">Transient receptor potential calcium channel (TRP-CC) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400361 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400361">
		<rdfs:label rdf:datatype="&xsd;string">MCU family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400362 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400362">
		<rdfs:label rdf:datatype="&xsd;string">Membrane protein mlc1 family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400363 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400363">
		<rdfs:label rdf:datatype="&xsd;string">Cation-nonselective channel family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400364 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400364">
		<rdfs:label rdf:datatype="&xsd;string">Atp-gated p2x receptor cation channel (p2x receptor) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400365 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400365">
		<rdfs:label rdf:datatype="&xsd;string">Gap junction-forming innexin (innexin) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400366 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400366">
		<rdfs:label rdf:datatype="&xsd;string">Mechanical nociceptor, piezo (piezo) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400367 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400367">
		<rdfs:label rdf:datatype="&xsd;string">Polycystin cation channel (pcc) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400368 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400368">
		<rdfs:label rdf:datatype="&xsd;string">SLC26A/SulP transporter family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400369 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400369">
		<rdfs:label rdf:datatype="&xsd;string">Sodium channel family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400370 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400370">
		<rdfs:label rdf:datatype="&xsd;string">Sodium channel auxiliary subunit 1-4 (sca-) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400371 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400371">
		<rdfs:label rdf:datatype="&xsd;string">Tmem38 family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400372 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400372">
		<rdfs:label rdf:datatype="&xsd;string">Transmembrane channel (TMC) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400373 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400373">
		<rdfs:label rdf:datatype="&xsd;string">Anion channel tweety (tweety) family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400327"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400374 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400374">
		<rdfs:label rdf:datatype="&xsd;string">5-hydroxytryptamine receptor subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400328"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400375 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400375">
		<rdfs:label rdf:datatype="&xsd;string">Acetylcholine receptor subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400328"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400376 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400376">
		<rdfs:label rdf:datatype="&xsd;string">Acid-sensing ion channel 1 (ASIC1) subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400330"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400377 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400377">
		<rdfs:label rdf:datatype="&xsd;string">Acid-sensing ion channel 2 (ASIC2) subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400330"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400378 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400378">
		<rdfs:label rdf:datatype="&xsd;string">Acid-sensing ion channel 3 (ASIC3) subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400330"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400379 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400379">
		<rdfs:label rdf:datatype="&xsd;string">Acid-sensing ion channel 4 (ASIC4) subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400330"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400380 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400380">
		<rdfs:label rdf:datatype="&xsd;string">Acid-sensing ion channel 5 (ASIC5) subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400330"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400381 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400381">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1A subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400333"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400382 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400382">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1B subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400333"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400383 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400383">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1C subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400333"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400384 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400384">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1D subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400333"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400385 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400385">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1E subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400333"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400386 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400386">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1F subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400333"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400387 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400387">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1G subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400333"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400388 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400388">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1H subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400333"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400389 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400389">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1I subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400333"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400390 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400390">
		<rdfs:label rdf:datatype="&xsd;string">CACNA1S subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400333"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400391 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400391">
		<rdfs:label rdf:datatype="&xsd;string">CACNG subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400337"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400392 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400392">
		<rdfs:label rdf:datatype="&xsd;string">CFTR transporter subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400338"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400393 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400393">
		<rdfs:label rdf:datatype="&xsd;string">CLCNKA subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400341"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400394 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400394">
		<rdfs:label rdf:datatype="&xsd;string">CLCNKB subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400341"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400395 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400395">
		<rdfs:label rdf:datatype="&xsd;string">ClC-1/CLCN1 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400341"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400396 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400396">
		<rdfs:label rdf:datatype="&xsd;string">ClC-2/CLCN2 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400341"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400397 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400397">
		<rdfs:label rdf:datatype="&xsd;string">ClC-3/CLCN3 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400341"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400398 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400398">
		<rdfs:label rdf:datatype="&xsd;string">ClC-4/CLCN4 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400341"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400399 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400399">
		<rdfs:label rdf:datatype="&xsd;string">ClC-5/CLCN5 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400341"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400400 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400400">
		<rdfs:label rdf:datatype="&xsd;string">ClC-6/CLCN6 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400341"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400401 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400401">
		<rdfs:label rdf:datatype="&xsd;string">ClC-7/CLCN7 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400341"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400402 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400402">
		<rdfs:label rdf:datatype="&xsd;string">CNGA1 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400343"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400403 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400403">
		<rdfs:label rdf:datatype="&xsd;string">CNGA2 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400343"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400404 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400404">
		<rdfs:label rdf:datatype="&xsd;string">CNGA3 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400343"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400405 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400405">
		<rdfs:label rdf:datatype="&xsd;string">CNGA4 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400343"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400406 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400406">
		<rdfs:label rdf:datatype="&xsd;string">CNGB1 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400343"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400407 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400407">
		<rdfs:label rdf:datatype="&xsd;string">CNGB3 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400343"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400408 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400408">
		<rdfs:label rdf:datatype="&xsd;string">Gamma-aminobutyric acid receptor subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400328"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400409 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400409">
		<rdfs:label rdf:datatype="&xsd;string">Glycine receptor subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400328"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400410 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400410">
		<rdfs:label rdf:datatype="&xsd;string">GRIA1 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400411 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400411">
		<rdfs:label rdf:datatype="&xsd;string">GRIA2 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400412 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400412">
		<rdfs:label rdf:datatype="&xsd;string">GRIA3 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400413 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400413">
		<rdfs:label rdf:datatype="&xsd;string">GRIA4 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400414 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400414">
		<rdfs:label rdf:datatype="&xsd;string">GRID1 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400415 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400415">
		<rdfs:label rdf:datatype="&xsd;string">GRID2 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400416 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400416">
		<rdfs:label rdf:datatype="&xsd;string">GRIK1 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400417 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400417">
		<rdfs:label rdf:datatype="&xsd;string">GRIK2 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400418 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400418">
		<rdfs:label rdf:datatype="&xsd;string">GRIK3 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400419 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400419">
		<rdfs:label rdf:datatype="&xsd;string">GRIK4 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400420 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400420">
		<rdfs:label rdf:datatype="&xsd;string">GRIK5 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400421 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400421">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ10 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400422 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400422">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ11 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400423 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400423">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ12 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400424 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400424">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ13 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400425 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400425">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ14 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400426 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400426">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ15 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400427 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400427">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ16 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400428 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400428">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ1 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400429 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400429">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ2 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400430 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400430">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ3 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400431 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400431">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ4 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400432 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400432">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ5 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400433 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400433">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ6 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400434 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400434">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ8 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400435 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400435">
		<rdfs:label rdf:datatype="&xsd;string">KCNJ9 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400353"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400436 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400436">
		<rdfs:label rdf:datatype="&xsd;string">A (Shaker) subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400355"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400437 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400437">
		<rdfs:label rdf:datatype="&xsd;string">Calcium-activated subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400355"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400438 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400438">
		<rdfs:label rdf:datatype="&xsd;string">KCNMB/KCNMB1 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400358"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400439 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400439">
		<rdfs:label rdf:datatype="&xsd;string">KCNMB/KCNMB2 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400358"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400440 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400440">
		<rdfs:label rdf:datatype="&xsd;string">KCNMB/KCNMB3 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400358"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400441 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400441">
		<rdfs:label rdf:datatype="&xsd;string">KCNMB/KCNMB4 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400358"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400442 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400442">
		<rdfs:label rdf:datatype="&xsd;string">B (Shab) subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400355"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400443 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400443">
		<rdfs:label rdf:datatype="&xsd;string">C (Shaw) subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400355"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400444 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400444">
		<rdfs:label rdf:datatype="&xsd;string">D (Shal) subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400355"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400445 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400445">
		<rdfs:label rdf:datatype="&xsd;string">KCNE subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400355"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400446 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400446">
		<rdfs:label rdf:datatype="&xsd;string">F subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400355"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400447 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400447">
		<rdfs:label rdf:datatype="&xsd;string">G subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400355"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400448 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400448">
		<rdfs:label rdf:datatype="&xsd;string">H (Eag) subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400355"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400449 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400449">
		<rdfs:label rdf:datatype="&xsd;string">KQT subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400355"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400450 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400450">
		<rdfs:label rdf:datatype="&xsd;string">S subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400355"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400451 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400451">
		<rdfs:label rdf:datatype="&xsd;string">V subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400355"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400452 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400452">
		<rdfs:label rdf:datatype="&xsd;string">Polycystin subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400360"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400453 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400453">
		<rdfs:label rdf:datatype="&xsd;string">NR3A/GRIN3A subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400454 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400454">
		<rdfs:label rdf:datatype="&xsd;string">NR3B/GRIN3B subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400455 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400455">
		<rdfs:label rdf:datatype="&xsd;string">NR2A/GRIN2A subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400456 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400456">
		<rdfs:label rdf:datatype="&xsd;string">NR2B/GRIN2B subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400457 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400457">
		<rdfs:label rdf:datatype="&xsd;string">NR2C/GRIN2C subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400458 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400458">
		<rdfs:label rdf:datatype="&xsd;string">NR2D/GRIN2D subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400459 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400459">
		<rdfs:label rdf:datatype="&xsd;string">NR1/GRIN1 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400351"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400460 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400460">
		<rdfs:label rdf:datatype="&xsd;string">RYR1 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400354"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400461 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400461">
		<rdfs:label rdf:datatype="&xsd;string">RYR2 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400354"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400462 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400462">
		<rdfs:label rdf:datatype="&xsd;string">RYR3 subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400354"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400463 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400463">
		<rdfs:label rdf:datatype="&xsd;string">Nav1.1/SCN1A subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400369"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400464 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400464">
		<rdfs:label rdf:datatype="&xsd;string">SCN1B family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400370"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400465 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400465">
		<rdfs:label rdf:datatype="&xsd;string">Nav1.2/SCN2A subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400369"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400466 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400466">
		<rdfs:label rdf:datatype="&xsd;string">SCN2B family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400370"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400467 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400467">
		<rdfs:label rdf:datatype="&xsd;string">Nav1.3/SCN3A subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400369"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400468 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400468">
		<rdfs:label rdf:datatype="&xsd;string">SCN3B family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400370"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400469 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400469">
		<rdfs:label rdf:datatype="&xsd;string">Nav1.4/SCN4A subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400369"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400470 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400470">
		<rdfs:label rdf:datatype="&xsd;string">SCN4B family gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400370"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400471 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400471">
		<rdfs:label rdf:datatype="&xsd;string">Nav1.5/SCN5A subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400369"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400472 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400472">
		<rdfs:label rdf:datatype="&xsd;string">SCN7A subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400369"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400473 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400473">
		<rdfs:label rdf:datatype="&xsd;string">Nav1.6/SCN8A subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400369"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400474 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400474">
		<rdfs:label rdf:datatype="&xsd;string">Nav1.7/SCN9A subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400369"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400475 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400475">
		<rdfs:label rdf:datatype="&xsd;string">Nav1.8/SCN10A subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400369"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400476 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400476">
		<rdfs:label rdf:datatype="&xsd;string">Nav1.9/SCN11A subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400369"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400477 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400477">
		<rdfs:label rdf:datatype="&xsd;string">SCNN1A subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400330"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400478 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400478">
		<rdfs:label rdf:datatype="&xsd;string">SCNN1B subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400330"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400479 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400479">
		<rdfs:label rdf:datatype="&xsd;string">SCNN1D subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400330"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400480 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400480">
		<rdfs:label rdf:datatype="&xsd;string">SCNN1G subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400330"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400481 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400481">
		<rdfs:label rdf:datatype="&xsd;string">Two pore calcium channel subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400333"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400482 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400482">
		<rdfs:label rdf:datatype="&xsd;string">STrpC subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400360"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400483 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400483">
		<rdfs:label rdf:datatype="&xsd;string">LTrpC subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400360"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400484 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400484">
		<rdfs:label rdf:datatype="&xsd;string">TrpV subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400360"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400490 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400490">
		<rdfs:label rdf:datatype="&xsd;string">Alpha-10/CHRNA10 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400491 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400491">
		<rdfs:label rdf:datatype="&xsd;string">Alpha-2/CHRNA2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400492 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400492">
		<rdfs:label rdf:datatype="&xsd;string">Alpha-3/CHRNA3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400493 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400493">
		<rdfs:label rdf:datatype="&xsd;string">Alpha-4/CHRNA4 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400494 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400494">
		<rdfs:label rdf:datatype="&xsd;string">Alpha-5/CHRNA5 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400495 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400495">
		<rdfs:label rdf:datatype="&xsd;string">Alpha-6/CHRNA6 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400496 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400496">
		<rdfs:label rdf:datatype="&xsd;string">Alpha-7/CHRNA7 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400497 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400497">
		<rdfs:label rdf:datatype="&xsd;string">Alpha-9/CHRNA9 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400498 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400498">
		<rdfs:label rdf:datatype="&xsd;string">Alpha-1/CHRNA1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400499 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400499">
		<rdfs:label rdf:datatype="&xsd;string">Beta-2/CHRNB2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400500 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400500">
		<rdfs:label rdf:datatype="&xsd;string">Beta-3/CHRNB3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400501 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400501">
		<rdfs:label rdf:datatype="&xsd;string">Beta-4/CHRNB4 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400502 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400502">
		<rdfs:label rdf:datatype="&xsd;string">Beta-1/CHRNB1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400503 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400503">
		<rdfs:label rdf:datatype="&xsd;string">Delta/CHRND sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400504 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400504">
		<rdfs:label rdf:datatype="&xsd;string">Epsilon/CHRNE sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400505 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400505">
		<rdfs:label rdf:datatype="&xsd;string">Gamma/CHRNG sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400375"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400506 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400506">
		<rdfs:label rdf:datatype="&xsd;string">GABRA1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400507 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400507">
		<rdfs:label rdf:datatype="&xsd;string">GABRA2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400508 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400508">
		<rdfs:label rdf:datatype="&xsd;string">GABRA3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400509 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400509">
		<rdfs:label rdf:datatype="&xsd;string">GABRA4 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400510 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400510">
		<rdfs:label rdf:datatype="&xsd;string">GABRA5 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400511 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400511">
		<rdfs:label rdf:datatype="&xsd;string">GABRA6 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400512 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400512">
		<rdfs:label rdf:datatype="&xsd;string">GABRB1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400513 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400513">
		<rdfs:label rdf:datatype="&xsd;string">GABRB2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400514 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400514">
		<rdfs:label rdf:datatype="&xsd;string">GABRB3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400515 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400515">
		<rdfs:label rdf:datatype="&xsd;string">GABRD sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400516 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400516">
		<rdfs:label rdf:datatype="&xsd;string">GABRE sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400517 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400517">
		<rdfs:label rdf:datatype="&xsd;string">GABRG1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400518 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400518">
		<rdfs:label rdf:datatype="&xsd;string">GABRG2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400519 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400519">
		<rdfs:label rdf:datatype="&xsd;string">GABRG3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400520 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400520">
		<rdfs:label rdf:datatype="&xsd;string">GABRP sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400521 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400521">
		<rdfs:label rdf:datatype="&xsd;string">GABRR1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400522 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400522">
		<rdfs:label rdf:datatype="&xsd;string">GABRR2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400523 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400523">
		<rdfs:label rdf:datatype="&xsd;string">GABRR3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400524 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400524">
		<rdfs:label rdf:datatype="&xsd;string">GABRQ sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400408"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400525 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400525">
		<rdfs:label rdf:datatype="&xsd;string">GLRA1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400409"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400526 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400526">
		<rdfs:label rdf:datatype="&xsd;string">GLRA2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400409"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400527 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400527">
		<rdfs:label rdf:datatype="&xsd;string">GLRA3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400409"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400528 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400528">
		<rdfs:label rdf:datatype="&xsd;string">GLRA4 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400409"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400529 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400529">
		<rdfs:label rdf:datatype="&xsd;string">GLRB sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400409"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400530 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400530">
		<rdfs:label rdf:datatype="&xsd;string">Kv1.8/KCNA10 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400436"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400531 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400531">
		<rdfs:label rdf:datatype="&xsd;string">KCa1.1/KCNMA1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400437"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400532 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400532">
		<rdfs:label rdf:datatype="&xsd;string">Kv1.1/KCNA1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400436"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400533 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400533">
		<rdfs:label rdf:datatype="&xsd;string">Kv1.2/KCNA2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400436"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400534 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400534">
		<rdfs:label rdf:datatype="&xsd;string">Kv1.3/KCNA3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400436"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400535 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400535">
		<rdfs:label rdf:datatype="&xsd;string">Kv1.4/KCNA4 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400436"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400536 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400536">
		<rdfs:label rdf:datatype="&xsd;string">Kv1.5/KCNA5 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400436"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400537 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400537">
		<rdfs:label rdf:datatype="&xsd;string">Kv1.6/KCNA6 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400436"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400538 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400538">
		<rdfs:label rdf:datatype="&xsd;string">Kv1.7/KCNA7 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400436"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400539 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400539">
		<rdfs:label rdf:datatype="&xsd;string">Kv2.1/KCNB1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400442"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400540 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400540">
		<rdfs:label rdf:datatype="&xsd;string">Kv2.2/KCNB2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400442"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400541 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400541">
		<rdfs:label rdf:datatype="&xsd;string">Kv3.1/KCNC1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400443"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400542 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400542">
		<rdfs:label rdf:datatype="&xsd;string">Kv3.2/KCNC2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400443"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400543 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400543">
		<rdfs:label rdf:datatype="&xsd;string">Kv3.3/KCNC3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400443"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400544 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400544">
		<rdfs:label rdf:datatype="&xsd;string">Kv3.4/KCNC4 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400443"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400545 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400545">
		<rdfs:label rdf:datatype="&xsd;string">Kv4.1/KCND1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400444"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400546 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400546">
		<rdfs:label rdf:datatype="&xsd;string">Kv4.2/KCND2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400444"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400547 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400547">
		<rdfs:label rdf:datatype="&xsd;string">Kv4.3/KCND3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400444"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400548 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400548">
		<rdfs:label rdf:datatype="&xsd;string">Kv5.1/KCNF1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400446"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400549 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400549">
		<rdfs:label rdf:datatype="&xsd;string">Kv6.1/KCNG1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400447"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400550 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400550">
		<rdfs:label rdf:datatype="&xsd;string">Kv6.2/KCNG2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400447"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400551 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400551">
		<rdfs:label rdf:datatype="&xsd;string">Kv6.3/KCNG3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400447"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400552 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400552">
		<rdfs:label rdf:datatype="&xsd;string">Kv6.4/KCNG4 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400447"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400553 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400553">
		<rdfs:label rdf:datatype="&xsd;string">Kv10.1/KCNH1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400448"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400554 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400554">
		<rdfs:label rdf:datatype="&xsd;string">Kv11.1/KCNH2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400448"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400555 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400555">
		<rdfs:label rdf:datatype="&xsd;string">Kv12.2/KCNH3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400448"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400556 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400556">
		<rdfs:label rdf:datatype="&xsd;string">Kv12.3/KCNH4 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400448"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400557 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400557">
		<rdfs:label rdf:datatype="&xsd;string">Kv10.2/KCNH5 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400448"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400558 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400558">
		<rdfs:label rdf:datatype="&xsd;string">Kv11.2/KCNH6 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400448"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400559 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400559">
		<rdfs:label rdf:datatype="&xsd;string">Kv11.3/KCNH7 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400448"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400560 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400560">
		<rdfs:label rdf:datatype="&xsd;string">Kv12.1/KCNH8 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400448"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400561 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400561">
		<rdfs:label rdf:datatype="&xsd;string">Kv7.1/KCNQ1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400449"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400562 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400562">
		<rdfs:label rdf:datatype="&xsd;string">Kv7.2/KCNQ2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400449"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400563 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400563">
		<rdfs:label rdf:datatype="&xsd;string">Kv7.3/KCNQ3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400449"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400564 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400564">
		<rdfs:label rdf:datatype="&xsd;string">Kv7.4/KCNQ4 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400449"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400565 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400565">
		<rdfs:label rdf:datatype="&xsd;string">Kv7.5/KCNQ5 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400449"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400566 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400566">
		<rdfs:label rdf:datatype="&xsd;string">Kv9.1/KCNS1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400450"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400567 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400567">
		<rdfs:label rdf:datatype="&xsd;string">Kv9.2/KCNS2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400450"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400568 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400568">
		<rdfs:label rdf:datatype="&xsd;string">Kv9.3/KCNS3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400450"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400569 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400569">
		<rdfs:label rdf:datatype="&xsd;string">KCa4.1/KCNT1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400437"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400570 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400570">
		<rdfs:label rdf:datatype="&xsd;string">KCa4.2/KCNT2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400437"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400571 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400571">
		<rdfs:label rdf:datatype="&xsd;string">KCa5.1/KCNU1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400437"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400572 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400572">
		<rdfs:label rdf:datatype="&xsd;string">Kv8.1/KCNV1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400451"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400573 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400573">
		<rdfs:label rdf:datatype="&xsd;string">Kv8.2/KCNV2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400451"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400574 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400574">
		<rdfs:label rdf:datatype="&xsd;string">MCOLN1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400452"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400575 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400575">
		<rdfs:label rdf:datatype="&xsd;string">MCOLN2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400452"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400576 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400576">
		<rdfs:label rdf:datatype="&xsd;string">MCOLN3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400452"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400577 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400577">
		<rdfs:label rdf:datatype="&xsd;string">TRPC1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400482"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400578 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400578">
		<rdfs:label rdf:datatype="&xsd;string">TRPC3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400482"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400579 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400579">
		<rdfs:label rdf:datatype="&xsd;string">TRPC4 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400482"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400580 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400580">
		<rdfs:label rdf:datatype="&xsd;string">TRPC5 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400482"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400581 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400581">
		<rdfs:label rdf:datatype="&xsd;string">TRPC6 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400482"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400582 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400582">
		<rdfs:label rdf:datatype="&xsd;string">TRPC7 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400482"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400583 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400583">
		<rdfs:label rdf:datatype="&xsd;string">TRPM1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400483"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400584 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400584">
		<rdfs:label rdf:datatype="&xsd;string">TRPM2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400483"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400585 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400585">
		<rdfs:label rdf:datatype="&xsd;string">TRPM3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400483"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400586 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400586">
		<rdfs:label rdf:datatype="&xsd;string">TRPM4 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400483"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400587 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400587">
		<rdfs:label rdf:datatype="&xsd;string">TRPM5 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400483"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400588 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400588">
		<rdfs:label rdf:datatype="&xsd;string">TRPM7 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400483"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400589 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400589">
		<rdfs:label rdf:datatype="&xsd;string">TRPM8 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400483"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400590 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400590">
		<rdfs:label rdf:datatype="&xsd;string">TRPV1 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400484"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400591 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400591">
		<rdfs:label rdf:datatype="&xsd;string">TRPV2 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400484"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400592 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400592">
		<rdfs:label rdf:datatype="&xsd;string">TRPV3 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400484"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400593 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400593">
		<rdfs:label rdf:datatype="&xsd;string">TRPV4 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400484"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400594 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400594">
		<rdfs:label rdf:datatype="&xsd;string">TRPV5 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400484"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01400595 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01400595">
		<rdfs:label rdf:datatype="&xsd;string">TRPV6 sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400484"/>
	</owl:Class>

	<!-- http://www.drugtargetontology.org/dto/DTO_01409932 -->

	<owl:Class rdf:about="http://www.drugtargetontology.org/dto/DTO_01409932">
		<rdfs:label rdf:datatype="&xsd;string">5-HT3 receptor sub-subfamily gene</rdfs:label>
		<rdfs:subClassOf rdf:resource="http://www.drugtargetontology.org/dto/DTO_01400374"/>
	</owl:Class>

</rdf:RDF>